

1 Eve H. Karasik  
California Bar No. 155356  
2 LEVENE, NEALE, BENDER, YOO & GOLUBCHIK L.L.P.  
2818 La Cienega Avenue  
3 Los Angeles, CA 90034  
4 Phone | Telephone: (310) 229-1234  
Facsimile: (310) 229-1244  
5 Email: [EHK@lnbyg.com](mailto:EHK@lnbyg.com)

6 Bankruptcy Counsel for the J.T. Thorpe Settlement Trust

7 UNITED STATES BANKRUPTCY COURT

8 CENTRAL DISTRICT OF CALIFORNIA

9 LOS ANGELES DIVISION

10 In re

11 J.T. THORPE, INC, a California  
12 Corporation; J.T. THORPE, INC., a  
13 dissolved California Corporation,

14 Debtors,

Chapter Number: 11

Case Nos. LA-02-14216-BB & LA-04-35876-  
BB

(Jointly Administrated Under Case No. LA-02-  
14216-BB)

**NINETEENTH ANNUAL REPORT AND  
ACCOUNTING, AUDITED FINANCIAL  
STATEMENTS, AND CLAIM REPORT**

**HEARING:**

**HEARING DATE:  
HEARING TIME: 10:00 A.M.  
PLACE: COURTROOM 1539 OR  
ZOOMGOV**

**Roybal Federal Building  
255 E. Temple Street  
Los Angeles, CA 90012**

23  
24  
25  
26  
27  
28

1 **TO THE HONORABLE UNITED STATES BANKRUPTCY JUDGE AND OTHER**  
2 **PARTIES IN INTEREST:**

3 The Trustees of the J.T. Thorpe Settlement Trust by and through their counsel, Levene,  
4 Neale, Bender, Yoo & Golubchik, L.L.P. hereby file the Nineteenth Annual Report and  
5 Accounting, Audited Financial Statements, and Claim Report.

6 DATED: April 29, 2025

7 Respectfully submitted,

8  
9 By: /s/ Eve H. Karasik

10 EVE H. KARASIK  
11 LEVENE, NEALE, BENDER,  
12 YOO & GOLUBCHIK L.L.P.

13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
Bankruptcy Counsel for the  
J.T. Thorpe Settlement Trust

**NINETEENTH ANNUAL REPORT AND ACCOUNTING  
OF J.T. THORPE SETTLEMENT TRUST**

The Trustees of the J.T. Thorpe Settlement Trust (“Trust”) hereby submit this Nineteenth Annual Report and Accounting (“Annual Report”) covering Trust activities that occurred during the period from January 1, 2024 to and including December 31, 2024 (“Accounting Period”), and certain activities of the Trust that took place outside of the Accounting Period. This Annual Report is submitted to the U.S. Bankruptcy Court for the Central District of California, Los Angeles Division (“Bankruptcy Court”), *In re J.T. Thorpe, Inc. a California corporation; J.T. Thorpe, a dissolved California corporation; Thorpe Holding Company, a California corporation; and Thorpe Technologies, Inc. a California corporation*, Case Nos. LA 02-14216-BB; LA 04-35876-BB; LA 04-35877-BB; LA 04-35847-BB, Jointly Administered Under Case No. LA 02-14216-BB, in accordance with the *First Amended Joint Plan of Reorganization* Docket No. 472 (“Plan”); *Order Confirming First Amended Joint Plan of Reorganization Dated August 5, 2005, and Granting Related Relief* Docket No. 1455 (“Confirmation Order”); Fifteenth Amendment to and Complete Restatement of J.T. Thorpe Settlement Trust Agreement (“Trust Agreement”); Fourth Amendment to and Complete Restatement of J.T. Thorpe Settlement Trust Bylaws (“Bylaws”); J.T. Thorpe, Inc. a California Corporation/J.T. Thorpe, Inc., a dissolved California Corporation/Thorpe Holding Company, Inc., a California Corporation/Thorpe Technologies, Inc., a California Corporation Asbestos Personal Injury Settlement Fifth Amendment to and Complete Restatement of Trust Distribution Procedures (“TDP”); and Third Amendment to and Complete Restatement of J.T. Thorpe Case Valuation Matrix (“Matrix”),<sup>1</sup> established pursuant to the Plan,<sup>2</sup>

---

<sup>1</sup> True and correct copies of each of the current governing documents consisting of the Trust Agreement, the Bylaws, the TDP and the Matrix, are attached hereto as Exhibits A, B, C and D, respectively.

<sup>2</sup> The Appendix to Tenth Annual Report and Accounting of J.T. Thorpe Settlement Trust Docket Nos. 1755-2 through 1755-4 includes the Plan; Confirmation Order; certain other controlling documents approved by the Bankruptcy Court; and other documents as indicated.

1 and pursuant to the laws of the State of Nevada, where the Trust is organized and where it resides.  
2 Section 7.11 of the Trust Agreement states that the Trust is governed by Nevada law. Section  
3 164.015 of the Nevada Revised Statutes allows the Trust to render an accounting and seek  
4 approval for its past actions. The factual statements in this Annual Report are supported by the  
5 *Declaration of Laura M. Paul, Executive Director, in Support of Motion to Approve and Settle*  
6 *J.T. Thorpe Settlement Trust's Nineteenth Annual Report and Accounting, the Audited Financial*  
7 *Statements and Claim Report*, as described in paragraphs 7, 8, and 9, *infra*. Capitalized terms not  
8 defined herein are as defined in the Glossary of Terms for the Plan Documents, which may be  
9 found in Exhibit 1 to the Plan.

10 1. Effective Date: In compliance with Sections 4.1 and 7.2 of the Plan, and the  
11 Glossary of Terms for the Plan Documents, the Effective Date of the Trust is June 29, 2006.

12 2. Trustees: John F. Luikart and Sandra R. Hernandez, M.D. currently serve as  
13 Trustees of the Trusts. Mr. Luikart also serves as the Managing Trustee of the Trust.

14 3. Trust Advisory Committee (the "TAC"): Alan R. Brayton, Steven Kazan, and  
15 Patrick A. DeBlase currently serve as members of the TAC.

16 4. Futures Representative: The Honorable David F. Levi currently serves as the  
17 Futures Representative to the Trust.

18 5. Trust Management Update: As part of the Trust's ongoing efforts to streamline  
19 operations and increase efficiency, the Trustees merged the positions of Chief Operating Officer  
20 and Executive Director. As a result, the employment of Steven L. Bray, who served as the  
21 Executive Director since January, 2020, ended effective April 18, 2025 and Laura Paul, the  
22 previous Chief Operating Officer, was appointed the Trust's Executive Director by the Trustees  
23 on April 18, 2025.

24 6. Fiscal Year and Tax Obligations: The Trust is required by the Internal Revenue  
25 Code to account for and report on its activities for tax purposes on a calendar-year basis.

1 Therefore, the Trust's fiscal year is the calendar year. Except where otherwise stated, all reports  
2 attached to this Annual Report cover the Accounting Period. Section 2.2(b) of the Trust  
3 Agreement requires the Trustees to file income tax, other returns, and statements in a timely  
4 manner, and comply with all withholding obligations as legally required, including fulfilling  
5 requirements to maintain the Trust's status as a Qualified Settlement Fund. The 2023 federal  
6 tax return was filed by its extended due date of September 15, 2024 and the 2024 federal tax  
7 return will be filed by its extended due date of September 15, 2025. The Trust resides in  
8 Nevada, and Nevada has no state income tax. Although the Trust is not subject to tax in  
9 California, the Trustees file a tax return in California each year, attaching a copy of the Trust's  
10 federal tax return, but showing no California taxable income or state tax liability.

11 7. Annual Report: Section 2.2(c)(i) of the Trust Agreement provides in pertinent part:

12 The Trustees shall cause to be prepared and filed with the Bankruptcy Court, as  
13 soon as available, and in any event within 120 days following the end of each fiscal  
14 year, an annual report containing financial statements of the Trust (including,  
15 without limitation, a statement of the net claimants' equity of the Trust as of the  
16 end of such fiscal year and a statement of changes in net claimants' equity for such  
17 fiscal year) audited by a firm of independent certified public accountants selected  
18 by the Trustees and accompanied by an opinion of such firm as to the fairness of  
19 the financial statements' presentation of the equity presently available to current  
20 and future claimants and as to the conformity of the financial statements with the  
21 following special-purpose accounting methods...

18 The Trust's financial statements are prepared using special-purpose accounting methods  
19 that depart from Generally Accepted Accounting Principles (GAAP) in certain respects in order  
20 to better disclose the amount and changes in net claimants' equity.

21 8. Audited Financial Statements: In accordance with the requirements of Section  
22 2.2(c)(i) of the Trust Agreement, the Trustees have caused the Trust's financial statements to be  
23 audited by Eide Bailly LLP, the independent certified public accountants retained by the Trust to  
24 perform the annual audit of its financial statements. The Trust's audited financial statements for  
25

1 the year ended December 31, 2024 (“Audited Financial Statements”) are attached hereto as  
2 Exhibit “E” and include a Statement of Net Claimants’ Equity, a Statement of Changes in Net  
3 Claimants’ Equity, a Statement of Cash Flows and Explanatory Notes. The Statement of Net  
4 Claimants’ Equity, which is the equivalent of a corporate balance sheet, reflects total assets of the  
5 Trust at market value and on the other comprehensive basis of accounting utilized by the Trust.  
6 These Audited Financial Statements show, among other things, that as of December 31, 2024,  
7 total Trust assets were \$126,282,490, total liabilities were \$11,691,146, and Net Claimants’  
8 Equity was \$114,591,344.

9       9.     Claim Report: Section 2.2(c)(ii) of the Trust Agreement provides that along with  
10 the Audited Financial Statements, the Trustees shall file with the Bankruptcy Court a report  
11 containing a summary regarding the number and type of claims disposed of during the period  
12 covered by the financial statements. The J.T. Thorpe Settlement Trust Claim Report as of  
13 December 31, 2024 (“Claim Report”) is attached hereto as Exhibit “F”.

14       Section 5.4 of the TDP provides that, “as soon as practicable after the Effective Date, the  
15 Trust shall pay all Trust Claims that were liquidated by (i) a written settlement agreement entered  
16 into prior to the Petition Date for the particular claim, or (ii) the pre-confirmation claims  
17 liquidation process.” The vast majority of the 1,474 claims identified in the Bankruptcy Court’s  
18 January 27, 2006, Order Liquidated Asbestos Related Claims (hereafter “PCLP Claims”) were  
19 paid in 2006. The Trust has not yet received proper release documents for thirteen (13)  
20 outstanding PCLP Claims in the total amount of \$38,594. The representative law firms continue  
21 to search for the remaining claimants and beneficiaries.

22       10.    Public Inspection: In compliance with Section 2.2(c) of the Trust Agreement, the  
23 Annual Report, including the Audited Financial Statements and Claim Report, have been  
24 provided to the Futures Representative, the TAC, the Debtors, and the Office of the United States  
25 Trustee with Responsibility for the Central District of California. The Trust has filed the Annual  
26

1 Report, including the Audited Financial Statements and Claim Report with the Bankruptcy Court.  
2 Accordingly, the Annual Report and related documents have been made available for inspection  
3 by the public in accordance with established procedures.

4 11. Trustees' Meetings: Article II, Section 4 of the Bylaws provides that the Trustees  
5 shall meet in Nevada, or a state other than California, at least four times a year, as close as  
6 practicable on a quarterly basis. The Trustees held four (4) regular meetings during the  
7 Accounting Period (February 16, 2024, April 11, 2024, September 20, 2024, and November 8,  
8 2024).

9 12. Payment Percentage: Section 4.2 of the TDP provides that commencing on the  
10 first day of January after the Plan has been consummated, and no less frequently than once every  
11 three years or at any time if requested to do so by the TAC or Futures Representative, the Trustees  
12 shall reconsider the Payment Percentage to assure that it is based on accurate current information  
13 and may, after such reconsideration, change the Payment Percentage if necessary, with the  
14 consent of the TAC and Futures Representative. The Trust fiduciaries have evaluated and, based  
15 on such evaluations, modified the Payment Percentage at times over the years. The Payment  
16 Percentage was reviewed on February 21, 2025, and the Payment Percentage remains at 50%.

17 13. Maximum Annual Payment: Section 2.4 of the TDP requires that the Trust  
18 calculate an annual payment limit for claims ("Maximum Annual Payment") based upon a model  
19 of the amount of cash flow anticipated to be necessary over the entire life of the Trust to ensure  
20 that funds will be available to treat all present and future claimants as similarly as possible.  
21 Effective September 1, 2020, Section 2.5 of the TDP was amended, suspending the claims  
22 payment ratio, or "collar", related to claims made by disease category (non-malignant vs.  
23 malignant). At the November 8, 2024 meeting, the Maximum Annual Payment for 2025 was set  
24 at \$6,698,960.

1 14. Adjustments for Inflation: The original Payment Percentage approved by the  
2 Bankruptcy Court was based upon projections of future claim payments adjusted annually for  
3 inflation. Beginning in 2008, all claim payments made during a calendar year include a cost of  
4 living adjustment based upon the Federal Bureau of Labor Statistics' *Consumer Price Index for*  
5 *Urban Wage Earners and Clerical Workers* (CPI-W) announced in January each year. At the  
6 November 8, 2024 meeting, the CPI-W to be published in January 2025 was approved for use by  
7 the Trust in making the cost of living adjustment for claim payments made in 2025. The CPI-W  
8 of 2.8% was issued on January 15, 2025 and all inflation adjustments are cumulative.  
9 Consequently, all claim payments made during the 2025 calendar year will have a cumulative  
10 inflation rate of 56.82% added to the payment amount.

11 The Trust began indexing the base case values for Economic Loss, Medical Loss, and  
12 Assumed Future Medical Loss and Funeral Expenses in 2018. For claims paid in 2025, the base  
13 case value for Economic Loss is \$313,645, for Medical Loss is \$322,677, and for Assumed Future  
14 Medical Loss and Funeral Expenses is \$121,004.

15 15. Budget and Cash Flow Projections: Prior to the commencement of each fiscal year,  
16 Section 2.2(d) of the Trust Agreement requires the Trust to prepare a budget covering such fiscal  
17 year, and cash flow projections covering the succeeding four fiscal years. The 2025 budget and  
18 four-year cash flow projections were prepared in November 2024. The Trustees reviewed the  
19 2025 budget on November 8, 2024. The Trustees reviewed the four-year cash flow projections  
20 on November 8, 2024. These were provided to the Futures Representative and TAC pursuant to  
21 Section 2.2(d) of the Trust Agreement. The budget for operating expenses in 2025 totals  
22 \$945,780<sup>3</sup>.

---

23  
24  
25 <sup>3</sup> This figure excludes claimant payments budgeted for \$6,698,960, extraordinary legal fees budgeted for \$150,000,  
income tax payments budgeted for \$800,000, and investment fees budgeted for \$281,600.



1           16.     Trust Facilities and Services Sharing Agreement with Western Asbestos  
2 Settlement Trust: As described in the Trust’s prior Annual Report, the Trust and the Western  
3 Asbestos Settlement Trust (“Western Trust”) entered into a Trust Facilities and Services Sharing  
4 Agreement. The Trust agreed to pay negotiated monthly amounts that were approved by the  
5 Bankruptcy Court. Pursuant to the annual reconciliation of fees presented on February 16, 2024,  
6 the Trust and the Western Trust agreed that the advance payments would be \$24,200 per month  
7 for 2024. The total amount paid by the Trust to the Western Trust, after accounts were reconciled  
8 for 2024, was \$310,902. Pursuant to the annual reconciliation of fees presented on February 21,  
9 2025, the Trust and the Western Trust agreed that the advance payments shall be \$26,900 per  
10 month for 2025.

11           17.     Indemnity Fund (Self-Insured Retention): Section 4.6 of the Trust Agreement  
12 provides that the Trust shall indemnify the Trustees, Trust officers and employees, Futures  
13 Representative, TAC and each of their respective agents. The Trustees, Futures Representative,  
14 TAC and their respective agents have a first priority lien upon the Trust’s assets to secure the  
15 payment of any amounts payable to them pursuant to Section 4.7 of the Trust Agreement. In  
16 addition to the first priority lien on the Trust’s assets, in 2006, the Trust established an indemnity  
17 fund in the amount of \$5,000,000 to provide liability coverage for the Trustees, Futures  
18 Representative and TAC, and their agents to pay the expenses, costs and fees (including attorneys’  
19 fees and costs) associated with defending any judicial, administrative, or arbitative action, suit  
20 or proceeding, as described in all the Trust’s Annual Reports. Northern Trust became the  
21 custodian of the fund on January 4, 2021. All interest earned by the fund is returned to the Trust  
22 quarterly.

23           The Trust also maintains a Directors and Officers/Errors and Omissions policy and a  
24 Directors and Officers/Errors and Omissions Excess DIC policy.

1           18.     Settlement Fund Control Account and Security Interest Documents: On December  
2 18, 2020, the Trustees, the TAC and the Futures Representative executed an Account Control  
3 Agreement between the parties and Northern Trust to perfect the security interest in the assets  
4 maintained at Northern Trust, including the Indemnity Fund, accounts, securities, financial assets,  
5 investment property and security entitlements, among other things. Northern Trust subsequently  
6 executed the Account Control Agreement, which supersedes any previous Agreements.

7           19.     Amendments to the Trust Documents: During the Accounting Period and,  
8 additionally, from January 1, 2024 to and including April 18, 2025, no revisions were made to  
9 certain Trust controlling documents.

10          20.     Notifications to Beneficiaries: During the Accounting Period and, additionally,  
11 from January 1, 2024 to and including April 18, 2025, the following notifications were placed on  
12 the Trust's Website:

- 13           a.     Notice of Timing of Requests for Consideration at Trustees' Meetings (posted  
14                    January 2, 2024);
- 15           b.     Notice of Physician Request (posted January 23, 2024);
- 16           c.     Notice of Indexed Base Case Values for Economic and Medical Loss (posted  
17                    January 23, 2024);
- 18           d.     Notice of Annual Report (posted April 30, 2024);
- 19           e.     Notice of Timing of Requests for Consideration at Trustees' Meeting (posted  
20                    January 3, 2025);
- 21           f.     Notice of Indexed Base Case Values for Economic and Medical Loss (posted  
22                    January 15, 2025); and
- 23           g.     Notice of J.T. Thorpe Payment Percentage Review (posted February 21, 2025).

1 21. Filing Fee: Pursuant to Section 6.5 of the TDP, the filing fee was reviewed at the  
2 November 8, 2024 meeting and there were no recommended changes to the existing \$250 filing  
3 fee during the Accounting Period or as of the date hereof.

4 22. Trustees' Compensation: Section 4.5(c) of the Trust Agreement requires the Trust  
5 to report the amounts paid to the Trustees for compensation and expenses. For services during  
6 the Accounting Period, Mr. Luikart and Dr. Hernandez each earned per annum stipends in the  
7 amount of \$19,071. The total paid to all Trustees in addition to the annual stipends for hourly  
8 compensation and for reimbursement of expenses was \$29,069 and \$2,013, respectively.

9 23. Significant Vendors: Although the Trust has many vendors, those who were paid  
10 more than \$100,000 for services during the Accounting Period are listed below:

11 a. Aon Risk Insurance Services West, Inc.: Insurance broker for Directors and  
12 Officers/Errors and Omissions policy and a Directors and Officers/Errors and  
13 Omissions Excess DIC policy;

14 b. Western Asbestos Settlement Trust for shared services pursuant to the Trust  
15 Facilities and Services Sharing Agreement, as described in paragraph 16, *supra*.

16 24. Trust Investment Management: Article 3 of the Trust Agreement authorizes the  
17 Trust to administer the investment of funds in the manner in which individuals of ordinary  
18 prudence, discretion and judgment would act in the management of their own affairs, subject to  
19 certain limitations. The Trust closely monitors any market volatility with its investment advisors  
20 and continues to comply with its Investment Policy Statement. In light of increased yield  
21 available in the fixed income markets at reduced relative investment risk, the Trust has adjusted  
22 its long-term asset allocation targets from 65 to 70% fixed income and from 35 to 30% equities.  
23 The Trust has also extended duration for part of its fixed income portfolio and, when appropriate,  
24 has adopted benchmark indices of longer duration. The Trust has further diversified its equity  
25 portfolio, which now includes large cap, small/mid cap, value and international strategies.

1 Accordingly, the Trust's Investment Policy Statement was amended on April 12, 2024  
2 and February 21, 2025, a copy of which is attached hereto as Exhibit "G".

3 Callan, LLC continued to assist the Trust during the Accounting Period as its investment  
4 consultant. Harding Loevner, LP, Insight Investments Corporation, Jennison Associates LLC,  
5 Segall Bryant & Hamill, and State Street Global Advisors act as investment managers to the Trust.

6 The Trust's investment portfolio is diversified across a combination of asset classes with  
7 the objective to achieve, over the long run, a positive return after the payment of taxes, fees, and  
8 the impact of inflation.

9 During the Accounting Period and thereafter, the United States and Global markets  
10 experienced significant volatility negatively impacted by world-wide supply and inflationary  
11 pressures due to geopolitical and international economic and trade uncertainty and the changing  
12 expectations of the Federal Reserve's monetary policies. Overall performance during the  
13 Accounting Period was positive, however, with material declines at times during the Accounting  
14 Period, significantly offset by strong gains at times during the Accounting Period.

15 The Trust is closely monitoring its investment portfolio, its liquidity, and is actively  
16 working to minimize the impact of this volatility.

17 It has always been the Trust's focus with regard to asset management to maintain principal  
18 in order to ensure the Trust's claimants a fair and reasonable inflation-adjusted settlement in the  
19 future.

20 \*\*\*

21 The Trustees submit that the Annual Report and attached exhibits demonstrate the Trust  
22 acted prudently and expeditiously in executing its legal obligations during the Accounting Period,  
23 and up to and including the date hereof. The Trust conscientiously worked to execute equitable  
24 claim procedures and process Trust Claims with due diligence during the Accounting Period, and  
25 up to and including the date hereof. Moreover, the Trust worked with its accountants and financial

1 advisors to preserve and grow Trust assets in order to fulfill the purpose of the Trust established  
2 pursuant to section 524(g) of the Bankruptcy Code-to efficiently, promptly, and fairly compensate  
3 victims and their families who have legitimate claims against the companies. In so doing, the  
4 Trust has carefully complied with the Plan, all Plan documents, and orders of the Bankruptcy  
5 Court.

# **EXHIBIT “A”**

**FIFTEENTH AMENDMENT TO AND COMPLETE RESTATEMENT OF  
J.T. THORPE SETTLEMENT TRUST AGREEMENT**

This Fifteenth Amendment to and Complete Restatement of J.T. Thorpe Settlement Trust Agreement (this “**Trust Agreement**”), originally dated June 29, 2006, and revised July 10, 2006, as amended September 20, 2006, February 22, 2007, September 20, 2007, April 21, 2010, November 18, 2010, April 21, 2011, November 18, 2011, November 20, 2014, April 19, 2018, September 13, 2018, November 15, 2018, May 24, 2019, and July 18, 2019 is among J.T. Thorpe, Inc., a California corporation (“**Thorpe**”), J.T. Thorpe, Inc., a dissolved California corporation (“**Dissolved Thorpe**”), Thorpe Technologies, Inc., a California corporation (“**Technologies**”), Thorpe Holding Company, Inc., a California corporation (“**Holdings**”), which, collectively, are the debtors and debtors-in-possession in the Reorganization Cases (collectively, the “**Debtors**”), the Futures Representative, the trustees identified herein and appointed by order of court pursuant to the First Amended Joint Plan of Reorganization, dated August 5, 2005, as amended, modified or supplemented from time to time (the “**Plan**”). This Fifteenth Amendment to and Complete Restatement of the J.T. Thorpe Settlement Trust Agreement amends and completely restates the

J.T. Thorpe Settlement Trust Agreement executed June 29, 2006 (the “Effective Date”). All capitalized terms not otherwise defined herein shall have their respective meanings as set forth in the Glossary of Terms for the Plan Documents, attached as Exhibit 1 to the Plan, and such definitions are incorporated herein by reference. All capitalized terms not defined herein or defined in the Glossary, but defined in the Bankruptcy Code or Rules, shall have the meanings ascribed to them by the Bankruptcy Code and Rules, and such definitions are incorporated herein by reference.

WHEREAS, at the time of the entry of the order for relief in the Reorganization Cases, each of the Debtors was named as a defendant in personal injury and wrongful death actions seeking recovery for damages allegedly caused by the presence of, or exposure to, asbestos or asbestos-containing products; and

WHEREAS, the Debtors have reorganized under the provisions of Chapter 11 of the Bankruptcy Code in a case pending in the United States Bankruptcy Court for the Central District of California, styled as *In re J.T. Thorpe, Inc., a California corporation, J.T. Thorpe, Inc., a dissolved California corporation, Thorpe Technologies, Inc., a California corporation, and Thorpe Holding Company, Inc., a California corporation*, Chapter 11 Case Nos. LA 02-14216BB, 04-35876BB, 04-35847BB and 04-35877BB (jointly administered under Case No. LA 02-14216BB); and

WHEREAS, the Plan, filed by the Debtors, the Futures Representative and the Committee, as Plan Proponents, has been confirmed (and issued or affirmed) by the applicable Bankruptcy Court; and

WHEREAS, the Plan Documents provide, *inter alia*, for the creation of the J.T. Thorpe Settlement Trust; and

WHEREAS, pursuant to the Plan, the Trust is to use the Trust Assets to pay the Asbestos Related Claims not otherwise enjoined; and

WHEREAS, pursuant to the Plan, the Trust is intended to qualify as a “qualified settlement fund” within the meaning of section 1.468B-1, *et seq.*, of the Treasury Regulations promulgated under section 468B of the IRC; and

WHEREAS, it is the intent of the Debtors, the Trustee, the TAC, the Futures Representative and the other parties that the Trust be administered, maintained, and operated at all times as a qualified settlement fund through mechanisms that provide reasonable assurance that the Trust will value, and be in a financial position to pay, all Asbestos Related Claims and Demands that involve similar claims in substantially the same manner, in strict compliance with the terms of this Trust Agreement; and

WHEREAS, the Plan provides, among other things, for the complete treatment of all liabilities and obligations of the Debtors with respect to Asbestos Related Claims; and

WHEREAS, the Bankruptcy Court has determined that the Trust and the Plan satisfy all the prerequisites for the Injunctions, including the injunctions pursuant to section 524(g) of the Bankruptcy Code, and such Injunctions have been entered in connection with the Confirmation Order.

WHEREAS, Section 2.4 has been made part of this Trust Agreement pursuant to a certain letter agreement dated June 29, 2006, among the Debtors, the Trustees, the Futures Representative, and the TAC.

NOW, THEREFORE, it is hereby agreed as follows:

## ARTICLE 1

### AGREEMENT OF TRUST

**1.1 Creation and Name.** The Debtors hereby create a trust known as the “J.T. Thorpe Settlement Trust,” which is the Trust provided for and referred to in the Plan.

**1.2 Purpose.** The purpose of the Trust is to assume the liabilities of each Debtor, and each of its respective successors in interest and their Affiliates, arising from or relating to Asbestos Related Claims and to use the Trust’s assets and income to pay holders of Allowed Asbestos Related Claims in accordance with the Trust Agreement and in such a way that all holders of similar Allowed Asbestos Related Claims are treated in a substantially equivalent manner and to otherwise comply in all respects with the requirements of a trust set forth in section 524(g)(2)(B)(i) of the Bankruptcy Code.

**1.3 Transfer of Assets.** Pursuant to the Plan Documents, the Debtors have transferred and assigned the Trust Assets to the Trust, free and clear of any liens or other interests of the Debtors or any creditor, shareholder or other entity. The Debtors shall execute and deliver such documents as the Trustee reasonably requests to transfer and assign any such Trust Assets.



**1.4 Acceptance of Assets and Assumption of Liabilities.**

(a) In furtherance of the purposes of the Trust, the Trustees, on behalf of the Trust, hereby expressly accept the transfer and assignment to the Trust of the Trust Assets in the time and manner as contemplated in the Plan Documents.

(b) In furtherance of the purposes of the Trust, the Trustees, on behalf of the Trust, hereby expressly assume all liability for all Asbestos Related Claims not enjoined. Except as otherwise provided in the TDP, the Trust shall have all defenses, cross-claims, offsets and recoupments, as well as rights of indemnification, contribution, subrogation, and similar rights, regarding Asbestos Related Claims that the Debtors or any of the reorganized Thorpe, Dissolved Thorpe, Technologies or Holdings have or would have had under applicable law.

(c) In furtherance of the purpose of the Trust, commencing on the Effective Date, the Trustees, on behalf of the Trust, hereby agree to pay, as Trust Expenses, all remaining obligations of any of the Debtors to their present and former attorneys and consultants, Zevnick Horton LLP (“ZIH”), Morgan, Lewis & Bockius LLP (“ML&B”), Rutter, Hobbs & Davidoff LLP (“RH&D”) and Global Risk Strategies LLC (“G-Risk”), related to or arising from the Coverage Litigation, whether such obligations shall be then due or thereafter due, owing and payable, as more specifically set forth in the engagement letter between Thorpe and ZH dated November 12, 2002 and the engagement letter between Thorpe and G-Risk dated November 12, 2002, copies of which engagement letters are attached as Exhibit A and Exhibit B. respectively, of that certain “Notice Of Motion And Motion For: Order Approving Employment Of: (I) Zevnik Horton LLP As Special Insurance Counsel; (II) Rutter Hobbs & Davidoff Incorporated As Co-Counsel; And (110 Global Risk As Insurance Consultant; And For Reconsideration Of Order Authorizing Use Of Insurance Recovery Proceeds For General Administrative And Litigation Expenses.”

(d) In furtherance of the purposes of the Trust, the Trustees, on behalf of the Trust, hereby indemnify the Debtors, and each of their respective successors in interest and Affiliates from any expenses, costs and fees (including attorneys’ fees and costs, but excluding any such expenses, costs and fees incurred prior to the Effective Date), judgments, settlements or other liabilities arising from or incurred in connection with, any action related to an Asbestos Related Claim not enjoined, including, but not limited to, indemnification or contribution for Asbestos Related Claims prosecuted against any of the Debtors.

(e) Nothing in this Trust Agreement shall be construed in any way to limit the scope, enforceability or effectiveness of the Injunctions issued and affirmed in connection with the Plan or the Trust’s assumption of all liability with respect to Asbestos Related Claims.

**ARTICLE 2**

**POWERS AND TRUST ADMINISTRATION,**

**2.1 Powers.**

(a) Trustees are and shall act as fiduciaries to the Trust in accordance with the provisions of this Trust Agreement and the Plan. The Trustees shall, at all times, administer the Trust and the Trust Assets in accordance with Section 1.2 of this Trust Agreement. Subject to

the limitations set forth in this Trust Agreement, the Trustees shall have the power to take any and all actions that, in the judgment of the Trustees, are necessary or proper to fulfill the purposes of the Trust, including, without limitation, each power expressly granted in this Section 2.1, any power reasonably incidental thereto, and any trust power now or hereafter permitted under the laws of the State of Nevada. Within the first thirty days after the formation of this Trust, the Trustees shall adopt internal control procedures covering, among other things, procedures for the following: receipt of payments and the handling of checks, wire transfers and claims processing fees; disbursement of funds, including disbursement of funds to vendors, agents and employees of the Trust, payment of business credit cards, and payment of expense report reimbursements; disbursements to claimants; accounting and account reconciliation; investments; and, retention of special documents (“Internal Control Procedures”). Within such thirty day period the Trustees shall submit the Internal Control Procedures to the TAC and the Futures Representative for their consent. If the consent of the Futures Representative and TAC is obtained, they shall be deemed the “Approved Internal Control Procedures.” If the consent of the TAC and/or the Futures Representative is not obtained within thirty days after the Internal Control Procedures are submitted to the TAC and the Futures Representative, the matter shall be resolved as set forth in paragraph 5.7 and/or 6.8 of this Trust Agreement, and the Internal Control Procedures approved under those paragraphs shall be deemed the “Approved Internal Control Procedures.” All actions of the Trustees and their designees shall comply with the Approved Internal Control Procedures. The non-managing Trustees, with the consent of the TAC and the Futures Representative, hereby delegate authority to the Managing Trustee to approve any changes to the Approved Internal Control Procedures, as necessary from time to time.

(b) as otherwise specified herein, the Trustees need not obtain the order or approval of any court in the exercise of any power or discretion conferred hereunder.

(c) limiting the generality of Subsection 2.1(a) above, and except as limited below, the Trustees shall have the power to:

(i) and hold the Trust Assets, and exercise all rights with respect to (including sale of) any or all such assets;

(ii) time to time by the Trust;

(iii) transfer or exchange any or all of the Trust Assets at such prices and upon such terms as he or she may consider proper, consistent with the other terms of this Trust Agreement;

(iv) all rights granted under the Holdings Pledge Agreement with respect to the shares of common stock of Holdings pledged pursuant thereto, as and to the extent provided therein, and exercise all rights with respect to the Holdings Note, subject to any restrictions set forth therein;

(v) agreements with third parties to the extent such agreements are reasonably necessary to permit the Trust to operate;

(vi) and expenses of the Trust, including, but not limited to, Trust Expenses;

(vii) such funds, reserves and accounts within the Trust estate, as deemed by the Trustee to be useful in carrying out the purposes of the Trust;

(viii) be sued and participate, as a party or otherwise, in any judicial, administrative, arbitratative or other proceeding;

(ix) the Trust Bylaws in accordance with the terms thereof; a copy of which is annexed hereto as Annex A;

(x) supervise and administer the Trust in accordance with the TDP and the Matrix and administer, amend, supplement or modify the TDP and the Matrix in accordance with the terms thereof a copy of which is annexed hereto as Annex B;

(xi) such officers and hire such employees and engage such legal, financial, accounting, investment, auditing and forecasting and other consultants or alternative dispute resolution panelists and agents as the business of the Trust requires, and to delegate to such persons such powers and authorities as the fiduciary duties of the Trustees permit and as the Trustees, in their discretion, deem advisable or necessary in order to carry out the terms of this Trust;

(xii) employees, legal, financial, accounting, investment, auditing and forecasting, and other consultants, advisors and agents reasonable compensation, including without limitation, compensation at rates approved by the Trustees for services rendered prior to the execution hereof;

(xiii) the Trustees, the members of the TAC, the Futures Representative and their respective Agents and reimburse to them all reasonable out-of-pocket costs and expenses incurred by such persons in connection with the performance of their duties hereunder, including without limitation, costs and expenses incurred prior to the execution hereof,

(xiv) and deliver such instruments as the Trustees consider proper in administering the Trust;

(xv) r into such other arrangements with third parties as are deemed by the Trustees to be useful in carrying out the purposes of the Trust, provided such arrangements do not conflict with any other provision of this Trust Agreement;

(xvi) nce with Section 4.6, indemnify (and purchase insurance indemnifying) the Trustees, the Futures Representative, the TAC, and each of the Debtors, and the respective Agents of the Trust, the Futures Representative, the TAC, and each of the Debtors to the fullest extent that a corporation or trust organized under the law of the Trust's sites is from time to time entitled to indemnify and/or insure such Agents;

(xvii) e any or all of the authority herein conferred with respect to the investment of all or any portion of the Trust Assets to any one or more reputable individuals or recognized institutional investment advisors or investment managers without liability for any action taken or omission made because of any such delegation, except as provided in Section 1.1;

(xviii) with the Debtors at such times and with respect to such issues relating to the conduct of the Trust as the Trustees consider desirable;

(xix) pursue (by litigation or otherwise), collect, compromise or settle, in its own name or the name of the applicable Debtor, any claim, right, action, or cause of action included in the Trust Assets, including without limitation, the Asbestos Insurance Action Recoveries and the Asbestos In-Place Insurance Coverage, before any court of competent jurisdiction; provided that settlement of any action before the Bankruptcy Court requires the approval of the Bankruptcy Court after notice to such Debtor,

(xx) the prior consent of the Approving Entities, merge or contract with other claims resolution facilities that are not specifically created by this Trust Agreement or the TDP, provided that such merger or contract shall not (a) subject the Debtors or any successor in interest to any risk of having any Asbestos Related Claim asserted against any of them, or (b) otherwise jeopardize the validity or enforceability of the Injunctions; and

(xxi) prior consent of the Approving Entities, establish binding and non-binding arbitration procedures for the purposes set forth in Section 5.9 of the TDP.

(d) Trustees shall not have the power to guarantee any debt of other Persons.

(e) Trustees shall give the Approving Entities prompt notice of any act performed or taken pursuant to Subsection 2.1(c)(i),(iii), (vii), (viii), (ix), (x), (xvi), (xix), (xx), and Subsection 2.2(f).

## **2.2 Administration.**

(a) Trustees shall act in accordance with the Trust Bylaws. To the extent not inconsistent with the terms of this Trust Agreement, the Trust Bylaws govern the affairs of the Trust. In the event of an inconsistency between the Trust Bylaws and this Trust Agreement, the Trust Agreement shall govern.

(b) Trustees shall timely file such income tax and other returns and statements and comply with all withholding obligations as required under the applicable provisions of the IRC and of any state law and the regulations promulgated thereunder, including without limitation all requirements necessary to qualify and maintain qualification as a qualified settlement fund, and shall timely pay all taxes required to be paid.

(c) The Trustees shall cause to be prepared and filed with the Bankruptcy Court, as soon as available, and in any event within 120 days following the end of each fiscal year, an annual report containing financial statements of the Trust (including, without limitation, a statement of the net claimants' equity of the Trust as of the end of such fiscal year and a statement of changes in net claimants' equity for such fiscal year) audited by a firm of independent certified public accountants selected by the Trustees and accompanied by an opinion of such firm as to the fairness of the financial statements' presentation of the equity presently available to current and future claimants and as to the conformity of the financial statements with

the following special-purpose accounting methods which differ from accounting principles generally accepted in the United States:

1. The financial statements shall be prepared using the accrual method of accounting.

2. The funding received from J.T. Thorpe, Inc., a California corporation, J.T. Thorpe, Inc., a dissolved California corporation, Thorpe Technologies, Inc., a California corporation, Thorpe Holding Company, Inc., a California corporation and their insurers shall be recorded directly to net claimants' equity. These funds shall not represent income of the Trust. Settlement offers for asbestos health claims shall be reported as deductions in net claimants' equity and shall not represent expenses of the Trust.

3. Costs of fixed assets, which shall be exhausted during the life of the Trust and will not be available for satisfying claims, shall be expensed when incurred. These costs shall include acquisition costs of computer hardware, software, software development, office furniture, and leasehold improvements.

4. Future fixed liabilities and contractual obligations entered into by the Trust shall be recorded directly against net claimants' equity. Accordingly, the future minimum rental commitments outstanding at period end for noncancelable operating leases, net of any sublease agreements, shall be recorded as deductions to net claimants' equity.

5. The liability for unpaid claims reflected in the statements of net claimants' equity shall represent settled but unpaid claims and outstanding settlement offers. A claims liability shall be recorded once a settlement offer is made to the claimant at the amount equal to the expected pro rata payment. No liability shall be recorded for future claim filings and filed claims on which no settlement offer has been made. Net claimants' equity represents funding available to pay present and future claims on which no fixed liability has been recorded.

6. Available-for-sale securities shall be recorded at market. All interest and dividend income on available-for-sale securities, net of investment expenses, shall be included in investment income on the statement of changes in net claimants' equity. Net realized and unrealized gains and losses on available-for-sale securities shall be recorded as a separate component on the statements of changes in net claimants' equity.

7. Realized gains/losses on available-for-sale securities shall be recorded based on the security's amortized cost. At the time a security is sold, all previously recorded unrealized gains/losses shall be reversed and recorded net, as a component of other unrealized gains/losses in the statement of changes in net claimants' equity.

The Trustees shall provide a copy of such report to the Approving Entities and each of the Debtors when such reports are filed with the Bankruptcy Court.

(ii) Simultaneously with delivery of each set of financial statements referred to in Subsection 2.2(c)(i) above, the Trustees shall cause to be prepared and filed with the Bankruptcy Court a report containing a summary regarding the number and type of claims

disposed of during the period covered by the financial statements. The Trustees shall provide a copy of such report to the Approving Entities and the Debtors when such report is filed.

(iii) All materials required to be filed with the Bankruptcy Court by this Subsection 2.2(c) shall be available for inspection by the public, other than materials filed under seal, in accordance with procedures established by the Bankruptcy Court and shall be filed with the Office of the United States Trustee with responsibility for the Central District of California. The Trustees shall file materials under seal which they determine should remain confidential, provided, however, such materials shall be available to the TAC and Futures Representative.

(d) Trustees shall cause to be prepared, as soon as practicable prior to the commencement of each fiscal year, a budget and cash flow projections covering such fiscal year and the succeeding four fiscal years. The Trustees shall provide a copy of the budget and cash flow to the Approving Entities.

(e) Trustees shall consult with the TAC and the Futures Representative (i) on the implementation and administration of the TDP and the Matrix, and (ii) on the implementation and administration of the Trust.

(f) Trustees shall be required to obtain the consent of the Approving Entities in addition to those instances elsewhere enumerated, in order:

(i) to add to or change the schedule of Asbestos-Related Disease Categories or criteria, or to increase the Allowed Liquidated Values pursuant to the TDP; or

(ii) to merge or participate in the handling of bodily injury claims with any claims resolution facility that was not specifically created under this Trust Agreement or the TDP; or

(iii) to amend any provision of the Trust Agreement; Article I, Article II, Article III Section 4, or Article IV of the Trust Bylaws; or, where required by the TDP, the TDP; or

(iv) to terminate the Trust pursuant to Section 7.2 herein; or

(v) [intentionally left blank]; or

(vi) to settle the liability of any insurer under any insurance policy covering Asbestos Related Claims or Demands or to settle any Asbestos Insurance Action; or

(vii) to change the compensation of the Trustees, other than cost-of-living increases;

(viii) to change the Trust claim form used by the Trust to evaluate claims; or

(ix) to amend, supplement or modify the provisions of the Case Valuation Matrix.

(g) the consent of the Approving Entities is required pursuant to Subsection 2.2(f) above, or elsewhere in this Trust Agreement, such consent shall be deemed given if the Approving Entities are signatories to a document or the minutes of the Trustees' meeting reflect such consent was given orally and said minutes are then subsequently approved by the Trustees.

(h) Trustees, upon notice from either of the Approving Entities, shall at their next regular meeting or, if appropriate, at a specially called meeting, place on their agenda and consider issues requested by such Approving Entity.

**2.3 Administration.** The Trustees shall promptly proceed to implement the TDP.

**2.4 Asbestos Trust Transaction.** In order to employ the resources of an organization whose capabilities are uniquely suited to the claims processing and administrative work of the Trust, and to realize cost savings through two similar trusts sharing overhead, the Debtors hereby direct the Trustees to enter into a transaction with the Western Asbestos Settlement Trust to permit the Trust's use of Western Asbestos Settlement Trust employees for administrative support and the processing of claims pursuant to the TDP. Notwithstanding anything to the contrary in this Trust Agreement, and in express acknowledgment that the Trustees also serve as trustees of the Western Asbestos Settlement Trust, the Trustees, the Futures Representative and the TAC are expressly relieved of any fiduciary obligation to act solely in the best interest of the beneficiaries of the Trust only with regard to such transaction with the Western Asbestos Settlement Trust. The Trustees may disregard this direction to so transact with the Western Asbestos Settlement Trust for administrative support and claims processing services if, due to a change of circumstances, the Trustees determine, with the consent of the Futures Representative and the TAC, it is no longer reasonable to do so.

### ARTICLE 3

#### **ACCOUNTS, INVESTMENTS, AND PAYMENTS**

**3.1 Accounts.** The Trustees may, from time to time, create such accounts and reserves within the Trust estate as they may deem necessary, prudent, or useful in order to provide for the payment of expenses and valid Asbestos Related Claims and may, with respect to any such account or reserve, restrict the use of monies therein.

**3.2 Investments.** Investment of monies held in the Trust shall be administered in the manner in which individuals of ordinary prudence, discretion and judgment would act in the management of their own affairs, subject to the following limitations and provisions:

(a) The Trust shall not acquire, directly or indirectly, equity in any Person (other than the Debtors or any successor to any of the Debtors, on the terms and conditions in the Plan) or business enterprise if, immediately following such acquisition, the Trust would hold more than five percent of the equity in such Person or business enterprise. The Trust shall not hold, directly or indirectly, more than ten percent of the equity in any Person (other than the Debtors, on the terms and conditions in the Plan) or business enterprise.

(b) The Trust shall not acquire or hold any long-term debt securities unless (i) such securities are rated “Baa” or higher by Moody’s, “BBB” or higher by S&P’s or have been given an equivalent investment grade rating by another nationally recognized statistical rating agency, or (ii) have been issued or fully guaranteed as to principal and interest by the United States of America or any agency or instrumentality thereof, or (iii) with respect to no more than ten percent (10%) of the total assets of the Trust, such securities are included in a diversified and managed portfolio or portfolios.

(c) The Trust shall not acquire or hold for longer than 90 days any commercial paper unless such commercial paper is rated “Prime-1” or higher by Moody’s or “A-1” or higher by S&P’s or has been given an equivalent rating by another nationally recognized statistical rating agency.

(d) Excluding any securities issued by the Debtors, the Trust shall not acquire or hold any common or preferred stock or convertible securities, REITS, MLPs and Royalty Trusts (“Stocks”) unless such Stock is included in a diversified and managed portfolio or portfolios. The Trust shall not acquire, directly or indirectly, more than forty percent (40%) of the Trust’s total assets in such Stock Portfolios, or hold, directly or indirectly, more than forty-five (45%) of the Trust’s total assets in such Stock Portfolios.

(e) Except as provided in Section 3.2(d) above, the Trust shall not acquire any securities or other instruments issued by any person (other than debt securities or other instruments issued or fully guaranteed as to principal and interest by the United States of America or any agency or instrumentality thereof) if, following such acquisition, the aggregate market value of all securities and instruments issued by such Person held by the Trust would exceed five percent of the aggregate value of the Trust estate. The Trust shall not hold any securities or other instruments issued by any Person (other than debt securities or other instruments issued or fully guaranteed as to principal and interest by the United States of America or any agency or instrumentality thereof and other than securities or other instruments of the Debtors or any successor to any of the Debtors) to the extent that the aggregate market value of all securities and instruments issued by such Person held by the Trust would exceed five percent of the aggregate value of the Trust Estate.

(f) The Trust shall not acquire or hold any certificates of deposit unless all publicly held, long-term debt securities, if any, of the financial institution issuing the certificate of deposit and the holding company, if any, of which such financial institution is a subsidiary, meet the standards set forth in Subsection 3.2(b).

(g) The Trust shall not acquire or hold any repurchase obligations unless, in the opinion of the Trustee, they are adequately collateralized.

(h) The Trust shall not acquire or hold any options.

**3.3 Source of Payments.** All Trust Expenses and all liabilities with respect to Asbestos Related Claims shall be payable solely by the Trust out of the Trust Assets, Asbestos Insurance Settlement Agreements, Asbestos Insurance Policies, and Asbestos Insurance Action Recoveries. Neither the Debtors, their subsidiaries, any successor in interest or the present or former stockholders, directors, officers, employees or agents of the Debtors, or their subsidiaries, nor the



Trustee, the Approving Entities, or any of their officers, agents, advisors, or employees shall be liable for the payment of any Trust Expense or any other liability of the Trust.

## **ARTICLE 4**

### **TRUSTEES**

#### **4.1 Number of Trustees.**

- (a) There shall be at least two Trustees and no more than three Trustees.
- (b) The Trustees shall designate one of their number to serve as the Managing Trustee.
- (c) Trustees shall act by majority vote when there are three Trustees and by unanimous vote when there are two Trustees. When there are two Trustees and the Trustees, having exercised reasonable efforts to discuss their differing views and reach consensus, cannot agree on action that requires a vote of the Trustees the Trustees will promptly so inform the Approving Entities in writing thereby invoking the provisions of Section 4.3(a) requiring the appointment of a third Trustee.

#### **4.2 Term of Service.**

- (a) Each of the Trustees shall serve until the earlier of (i) his or her death, (ii) his or her resignation pursuant to Subsection 4.2(c), (iii) his or her removal pursuant to Subsection 4.2(d), or (iv) the termination of the Trust pursuant to Section 7.2.
- (b) Each Successor Trustee shall serve until the earlier of (i) his or her death, (ii) his or her resignation pursuant to Subsection 4.2(c), (iii) his or her removal pursuant to Subsection 4.2(d), or (iv) the termination of the Trust pursuant to Section 7.2.
- (c) Any Trustee may resign at any time by written notice to each of the remaining Trustees, the Futures Representative, and the TAC. Such notice shall specify a date when such resignation shall take effect, which shall not be fewer than 90 days after the date such notice is given, where practicable.
- (d) Any Trustee may be removed in the event that such Trustee becomes unable to discharge his or her duties hereunder due to accident or physical or mental deterioration, or for other good cause. "Good cause" includes, without limitation, any substantial failure to comply with Section 2.2, a consistent pattern of neglect and failure to perform or participate in performing the duties of the Trustees hereunder, or repeated non-attendance at scheduled meetings. If there are three Trustees, a Trustee shall be removed by unanimous decision of the two other Trustees and prompt written notification by the two other Trustees to the Trustee being removed and the Approving Entities of the removal decision specifying the basis for removal. If there are two Trustees, such removal shall be made upon prompt written notification by the removing Trustee to the Trustee being removed and to the Approving Entities of the removal decision specifying the basis for removal and invoking the process for appointment of a Trustee in accordance with the provisions of Section 4.3(a) below.

#### **4.3 Appointment of Successor Trustee.**

(a) In the event of a vacancy in the position of Trustee, the vacancy shall be filled by the unanimous vote of the remaining Trustee(s) subject to the consent of the Approving Entities. If, after a vacancy occurs, there are two remaining Trustees, the remaining Trustees may decide, subject to consent of the Approving Entities, not to fill the vacancy. Where such consent is given, thereafter any of the existing Trustees (acting individually), the TAC or the Futures Representative may deliver a written notice to the remaining Approving Entities and Trustees requiring that a third Trustee be appointed. The third Trustee shall be appointed in accordance with this Section 4.3(a). If the vacancy has not been filled within 90 days the matter shall, on application of any such persons, be submitted promptly to the Bankruptcy Court for resolution. In the event that more than one vacancy shall exist, the vacancies shall be filled by the remaining Trustee (if one should exist), subject to the consent of the Approving Entities.

(b) Immediately upon the appointment of any successor Trustee, all rights, titles, duties, powers and authority of the predecessor Trustee hereunder shall be vested in, and undertaken by, the successor Trustee without any further act. No successor Trustee shall be liable personally for any act or omission of his or her predecessor Trustee.

**4.4 Liability of Trustees, Officers and Employees.** Neither the Trustees, the Futures Representative, the TAC (or any member of the TAC), nor any of their respective Agents, shall be liable to the Trust, to any person holding an Asbestos Related Claim, or to any other Person, except for such individual's or entity's own breach of trust committed in bad faith or willful misappropriation. Neither the Trustees, the Futures Representative, the TAC (or any member of the TAC), nor any of their respective Agents, shall be liable for any act or omission of any Agent of the Trust, the Futures Representative, the TAC (or any member of the TAC), unless the Trustees, the Futures Representative, the TAC (or any member of the TAC), respectively, acted with bad faith in the selection or retention of such Agent.

#### **4.5 Compensation and Expenses of Trustees.**

(a) The Trustees shall be compensated as follows:

(1) *Hourly Compensation* Each of the Trustees shall receive compensation from the Trust for his or her services as Trustee for each hour spent at an official meeting of the Trustees, an official trip of the Trustees, or dedicated to Trust Business ("Hourly Compensation"). For the period January 1, 2019 to May 31, 2019, the rate for Hourly Compensation for individual Trustees shall remain the same as each has been paid as of January 1, 2019. As of June 1, 2019 the rate for Hourly Compensation for the remaining two Trustees including the Managing Trustee shall be \$587.73.

(2) *Annual Compensation* As of January 1, 2019, in addition to the Hourly Compensation, each Trustee shall receive compensation from the Trust for his or her services as Trustee in the amount of \$21,372 per annum paid quarterly in advance ("Annual Compensation").

(3) *Inflation Adjustment* The Hourly Compensation and the Annual Compensation shall be adjusted each year in accordance with the Federal Bureau of Labor Statistics' Consumer Price Index for Urban Wage Earners and Clerical Workers (CPI-W) published in January of each year retroactive to the beginning of that year commencing January 1, 2020.

(4) *Managing Trustee* The Trustee serving as Managing Trustee shall be compensated as established from time to time by the other Trustees, the Futures Representative and the TAC.

(5) *Review of Trustee Compensation* The structure and amounts of Hourly Compensation and the Annual Compensation payable to the Trustees shall be reviewed when requested by the Trustees, the TAC and/or the Futures Representative but no less than every three years beginning in April 2022 and appropriately adjusted with the consent of the Approving Entities.

(b) *Out of Pocket Expenses* The Trust will promptly reimburse the Trustees for all reasonable out of pocket costs and expenses incurred by the Trustees in connection with the performance of their duties hereunder.

(c) *Reporting* The Trust will include a description of the amounts paid under this Section 4.5 in the report to be filed pursuant to Subsection 2.2(c)(i) of this Trust Agreement.

#### **4.6 Indemnification of Trustee and Additional Indemnitees.**

(a) The Trust shall indemnify and defend the Trustees, the Trust's officers, and employees to the fullest extent that a corporation or trust organized under the laws of the Trust's situs is from time to time entitled to indemnify and defend its directors, trustees, officers and employees against any and all liabilities, expenses, claims, damages or losses incurred by them in the performance of their duties hereunder. Notwithstanding the foregoing, the Trustees shall not be indemnified or defended in any way for any liability, expense, claim, damage or loss for which they are ultimately liable under Section 4.4.

Additionally, the Committee, the Futures Representative, the TAC, the Debtors, and each of their respective Agents, who was or is a party, or is threatened to be made a party to any threatened or pending judicial, administrative or arbitral action, by reason of any act or omission of such Committee, the Futures Representative, the TAC, the Debtors, and their respective Agents, with respect to (i) the Reorganization Case and any act or omission undertaken by them prior to the commencement thereof, (ii) the liquidation of any Asbestos Related Claims, (iii) the administration of the Trust and the implementation of the TDP, or (iv) any and all activities in connection with the Trust Agreement, shall be indemnified and defended by the Trust, to the fullest extent that a corporation or trust organized under the laws of the Trust's situs is from time to time entitled to indemnify and defend its officers, directors, trustees and employees, against reasonable expenses, costs and fees (including attorneys' fees and costs), judgments, awards, amounts paid in settlement and liabilities of all kinds incurred by the Committee, the Futures Representative, the TAC, the Debtors, and their respective members, professionals, officers, and directors, in connection with or resulting from such action, suit or proceeding, if he or she acted in good faith and in a manner such Committee, the Futures Representative, the TAC, the Debtors, and their respective members, professionals, officers and directors reasonably believed to be in, or not opposed to, the best interests of the holders of Asbestos Related Claims whom the Committee, the Futures Representative, the TAC, the Debtors, and their respective members, professionals, officers, and directors represent.

(b) Reasonable expenses, costs and fees (including attorneys' fees and costs) incurred by or on behalf of a Trustee, the Committee, the Futures Representative, the TAC, the

Debtors, and their respective Agents in connection with any action, suit or proceeding, whether civil, administrative or arbitral, from which they are indemnified by the Trust pursuant to Subsection 4.6(a), shall be paid by the Trust in advance of the final disposition thereof upon receipt of an undertaking, by or on behalf of such Trustee the Committee, the Futures Representative, the TAC, the Debtors and their respective Agents, to repay such amount in the event that it shall be determined ultimately by Final Order that such Trustee or the Committee, the Futures Representative, the TAC, the Debtors and their respective professionals, officers and directors is not entitled to be indemnified by the Trust.

(c) The Trustees shall have the power, generally or in specific cases, to cause the Trust to indemnify the Agents of the Trust to the same extent as provided in this Section 4.6 with respect to the Trustees.

(d) Any indemnification under Subsection 4.6(c) of this Trust Agreement shall be made by the Trust upon a determination by the Trustees that indemnification of such Person is proper in the circumstances.

(e) The Trustees may purchase and maintain reasonable amounts and types of insurance on behalf of an individual who is or was a Trustee, an Agent of the Trust, the Committee, the Futures Representative, the TAC, the Debtors, and their respective Agents against liability asserted against or incurred by such individual in that capacity or arising from his or her status as such.

(f) For avoidance of doubt, former Trustees, Trust officers and employees, members of the Committee, Futures Representatives, members of the TAC, and each of their respective Agents entitled to indemnification under this section continue to be so entitled to the same extent with respect to their conduct or status during their past tenure as Trustees, Trust officers and employees, members of the Committee, Futures Representatives, members of the TAC, or Agents.

**4.7 Trustees' Lien.** The Trustees, the Committee, the Futures Representative, the TAC, the Debtors, and their respective Agents shall have a first priority lien upon the Trust Assets to secure the payment of any amounts payable to them pursuant to Sections 4.5, 4.6, 4.7, 5.5, 6.5 or 6.6.

**4.8 Trustees' Employment of Experts.** The Trustees may, but shall not be required to, retain or consult with counsel, accountants, appraisers, auditors and forecasters, and other parties deemed by the Trustees to be qualified as experts on the matters submitted to them and the opinion of any such parties on any matters submitted to them by the Trustees shall be full and complete authorization and protection in respect of any action taken or not taken by the Trustees hereunder in good faith and in accordance with the written opinion of any such party.

**4.9 Trustees' Independence.** No Trustee shall, during the term of his or her service, hold a financial interest in, act as attorney or agent for, or serve as any other professional for any of the Debtors. Notwithstanding the foregoing, the Trustees may serve as officers or directors of

any of the Debtors. No Trustee shall act as an attorney for any person who holds an Asbestos Related Claim.

**4.10 Bond.** The Trustees shall not be required to post any bond or other form of surety or security unless otherwise ordered by the Bankruptcy Court.

## ARTICLE 5

### **THE FUTURES REPRESENTATIVE**

**5.1 Duties.** The Futures Representative shall be Charles B. Renfrew. He shall serve in a fiduciary capacity, representing the interests of the Future Asbestos Claimants, for the purpose of protecting the rights of persons who might subsequently assert Demands. The Trustee must consult with the Futures Representative on matters identified in Subsection 2.2(e), must obtain the consent of the Futures Representative on matters identified in Subsection 2.2(f), and may consult with the Futures Representative on any matter affecting the Trust Where provided in this Trust Agreement, the TDP or the Matrix, certain actions of the Trustee are subject to the consent of the Futures Representative.

### **5.2 Term of Office.**

(a) The Futures Representative shall serve until the earlier of (i) his or her death, (ii) his or her resignation pursuant to Subsection 5.2(b), (iii) his or her removal or (iv) the termination of the Trust pursuant to Section 7.2.

(b) The Futures Representative may resign at any time by written notice to the Trustee and the TAC. Such notice shall specify a date when such resignation shall take effect, which shall not be fewer than 90 days after the date such notice is given, where practicable.

(c) The Futures Representative may be removed in the event he or she becomes unable to discharge his or her duties hereunder due to accident, physical deterioration, mental incompetence, or a consistent pattern of neglect and failure to perform or to participate in performing the duties hereunder, such as repeated non-attendance at scheduled meetings. Such removal shall be made by the decision of the Trustees and the consent of the TAC.

**5.3 Appointment of Successor.** A vacancy caused by resignation shall be filled with an individual nominated by the Futures Representative. A vacancy for any other reason, or in the absence of a nomination by the Futures Representative, shall be filled with an individual selected by the Trustees. The successor Futures Representative shall, in either case, be subject to Bankruptcy Court approval.

**5.4 Futures Representative's Employment of Professionals.** The Futures Representative may retain or consult with counsel, accountants, appraisers, auditors, forecasters, asbestos experts and other parties deemed by the Futures Representative to be qualified as experts on matters submitted to them, and the opinion of any such parties on any matters submitted to them shall be full and complete authorization and protection in support of any action taken or not taken by the Futures Representative hereunder in good faith and in accordance with the written opinion of any such party, and in the absence of gross negligence. The Futures Representative and his or

her experts shall at all times have complete access to the Trust's Agents retained by the Trust, as well as all information generated by them or otherwise available to the Trust or Trustees.

**5.5 Compensation and Expenses of the Futures Representative.**

(a) (a) As of January 1, 2019, the Futures Representative shall receive compensation from the Trust for his or her services as the Futures Representative at his or her current hourly rate, such rate being subject to an annual review and adjustment by the Trustees with the consent of the TAC. As of January 1, 2019, the Futures Representative's hourly rate is set at \$865.30 per hour spent at an official meeting of the Trust, an official trip of the Trustees, or dedicated to Trust Business. The hourly amount of compensation payable to the Futures Representative hereunder shall be adjusted each year in accordance with the Federal Bureau of Labor Statistics' Consumer Price Index for Urban Wage Earners and Clerical Workers (CPI-W) published in January of each year retroactive to the beginning of that year commencing January 1, 2020. The hourly compensation for the Futures Representative will be reviewed annually when requested by the Trustees, the TAC and/or the Futures Representative, but no less than every three (3) years beginning in April 2022.

(b) The Trust will promptly reimburse, or pay directly if so instructed, the Futures Representative for all reasonable out-of-pocket costs and expenses, including fees and costs associated with employment of professionals pursuant to Section 5.4 and the procurement and maintenance of insurance incurred by the Futures Representative in connection with the performance of his or her duties hereunder and his or her duties in connection with the formulation, negotiation, and Confirmation of the Plan and Plan Documents. Such reimbursement or direct payment shall be deemed a Trust Expense.

**5.6 Procedure for Obtaining Consent of the Futures Representative.**

(a) In the event the consent of the Futures Representative is required pursuant to the terms hereof or of the TDP, the Trustees shall promptly provide the Futures Representative and his or her counsel with notice and with all information regarding the matter in question.

(b) The Futures Representative must consider in good faith and in a timely fashion any request by the Trustees and may not withhold his or her consent unreasonably. If the Futures Representative does not notify the Trustees of his or her objection to such request within 30 days after receiving notice and information regarding such request, then the Future Representative shall be deemed to have objected to the request and the procedures set forth in Section 5.7 shall be followed.

**5.7 Lack of Consent of the Futures Representative.** In the event the Trustees are unable to obtain the consent of the Futures Representative to any action or decision for which consent is required after following the procedure set forth in Section 5.6 of this Trust Agreement, or if the Trustees and the Futures Representative are unable to reach agreement on any matter on which such consent is required, the matter shall be submitted promptly to alternative dispute resolution if mutually agreeable to the Trustees and the Futures Representative. If the disagreement is not resolved by alternative dispute resolution, the Trustees may apply to the

Bankruptcy Court on an expedited basis for approval of such action or decision, and only if such approval is given by the Bankruptcy Court by entry of an appropriate order, shall the Trustees have the authority to implement such action or decision without the Futures Representative's consent.

## ARTICLE 6

### **TRUST ADVISORY COMMITTEE**

**6.1 Number.** There shall be three TAC members. The initial TAC members shall be Alan R. Brayton, Steven Kazan, and David A. Rosen.

**6.2 Duties.** The TAC shall serve in a fiduciary capacity representing all holders of Asbestos Related Claims (excluding, however, Future Asbestos Claimants). The Trustees must consult with the TAC on matters identified in Subsection 2.2(e), must obtain the consent of the TAC on matters identified in Subsection 2.2(f), and may consult with the TAC on any matter affecting the Trust. Where provided in this Trust Agreement or the TDP, certain actions by the Trustees are subject to the consent of the TAC. The TAC will act on the majority vote of its members for all purposes under this Agreement, including the consents required in the Agreement and the TDP.

**6.3 Term of Office.**

(a) Each member of the TAC shall serve until the earlier of (i) his or her death, (ii) his or her resignation pursuant to Subsection 6.3(b), (iii) his or her removal pursuant to Subsection 6.3(c) or (iv) the termination of the Trust pursuant to Section 7.2.

(b) Any member of the TAC may resign at any time by written notice to the Trustees, the other members of the TAC, and the Futures Representative. Such notice shall specify a date when such resignation shall take effect, which shall not be less than 90 days after the date such notice is given, where practicable.

(c) Any member of the TAC may be removed in the event that he or she becomes unable to discharge his or her duties hereunder due to accident, physical deterioration, mental incompetence, or a consistent pattern of neglect and failure to perform or to participate in performing the duties of such member hereunder, such as repeated non-attendance at scheduled meetings. Such removal shall be made by the decision of the Trustees and the consent of the Futures Representative with notice to the other members of the TAC.

**6.4 Appointment of Successor.** A vacancy caused by resignation shall be filled with an individual nominated by the remaining members of the TAC. A vacancy for any other reason, or in the absence of a nomination by the remaining members of the TAC, shall be filled with an individual selected by the Trustees. The successor TAC member shall, in either case, be subject to Bankruptcy Court approval.

**6.5 TAC's Employment of Professionals.** The TAC may retain or consult with counsel, accountants, appraisers, auditors, forecasters, asbestos experts and other parties deemed by the TAC to be qualified as experts on matters submitted to them, and the opinion of any such parties on any matters submitted to them shall be full and complete authorization and protection

in support of any action taken or not taken by the TAC hereunder in good faith and in accordance with the written opinion of any such party, and in the absence of gross negligence. The TAC and its experts shall at all times have complete access to the Trusts officers, employees and agents, and the accountants, appraisers, auditors, forecasters, and other experts retained by the Trust as well as information generated by them or otherwise available to the Trust or Trustees.

**6.6 Reimbursement of TAC Expenses and Compensation of TAC Members.**

(a) Each of the TAC members or their representatives shall receive compensation from the Trust for each of the following tasks, which are hereinafter called the “TAC Trust Tasks”:

(i) Attendance at meetings of the Trustees;

(ii) Performance of tasks requested to be performed by the Managing Trustee that the Managing Trustee believes benefits or has benefited the Trust, as opposed to individual client or clients of the member of the TAC.

(b) As of January 1, 2019, each of the TAC members and/or their representatives shall each be compensated as a Trust Expense at the rate of \$534.30 per hour spent at an official meeting of the Trustees, or on an official trip of the Trustees, or in the performance of any other TAC Trust Task. The hourly amount of compensation payable to the TAC members and/or their representatives hereunder shall be adjusted each year in accordance with the Federal Bureau of Labor Statistics' Consumer Price Index for Urban Wage Earners and Clerical Workers (CPI-W) published in January of each year retroactive to the beginning of that year commencing January 1, 2020.

(c) The structure and amounts of compensation will be reviewed when requested by the Trustees, the TAC and/or the Futures Representative, but no less than every three (3) years beginning in April, 2022.

**6.7 Procedure for Obtaining Consent of the TAC.**

(a) In the event the consent of the TAC is required pursuant to the terms hereof or of the TDP, the Trustees shall promptly provide the TAC and its counsel with notice and with all information regarding the matter in question.

(b) The TAC must consider in good faith and in a timely fashion any request by the Trustees, and the TAC may not withhold its consent unreasonably. If the TAC does not notify the Trustees of its objection to such request within 30 days after receiving notice and information regarding such request, then the TAC's consent shall be deemed to have objected to the request and the procedures set forth in Section 6.8 shall be followed.

**6.8 Lack of Consent of the TAC.** In the event the Trustees are unable to obtain the consent of the TAC for any action or decision for which consent of the TAC is required, after following the procedure set forth in Section 6.7 of this Trust Agreement, or if the Trustees and the



TAC are unable to reach agreement on any matter on which the TAC's consent is required, then the matter shall be submitted promptly to alternative dispute resolution if mutually agreeable to the Trustees and the TAC. If the disagreement is not resolved by alternative dispute resolution, the Trustees may apply to the Bankruptcy Court on an expedited basis for approval of such action or decision, and only if such approval is given by the Bankruptcy Court by entry of an appropriate order shall the Trustees have the authority to implement such action or decision without the TAC's consent.

## ARTICLE 7

### GENERAL PROVISIONS

7.1 **Irrevocability.** The Trust is irrevocable.

7.2 **Termination.**

(a) The Trust shall automatically terminate on the date 90 days after the first to occur of the following events:

(i) the Trustees in their discretion decide to terminate the Trust because (A) they deem it unlikely that new Asbestos Related Claims will be filed or served against the Trust and (B) all Asbestos Related Claims duly filed with the Trust have been Allowed and paid to the extent provided in this Trust Agreement and the TDP or disallowed by a final, non-appealable order, to the extent possible based upon the funds available through the Plan, and twelve (12) consecutive months have elapsed during which no new Asbestos Related Claim has been filed with the Trust;

(ii) if the Trustees have procured and have in place irrevocable insurance policies and have established claims handling agreements and other necessary arrangements with suitable third parties adequate to discharge all expected remaining obligations and expenses of the Trust in a manner consistent with this Trust Agreement and the TDP, the date on which the Bankruptcy Court enters an order approving such insurance and other arrangements and such order becomes a Final Order; or

(iii) to the extent that any rule against perpetuities shall be deemed applicable to the Trust, 21 years less 91 days pass after the death of the last survivor of all of the descendants of Joseph P. Kennedy, Sr., of Massachusetts living on the date hereof.

(b) On the Termination Date, after payment of all the Trust's liabilities have been provided for, all monies remaining in the Trust estate shall be given to such organization(s) exempt from federal income tax under section 501(c)(3) of the IRC, which tax-exempt organization(s) shall be selected by the Trustees using their reasonable discretion; provided, however, that (i) if practicable, the tax-exempt organization(s) shall be related to the treatment of, research on, or the relief of suffering of individuals suffering from asbestos related lung disorders, and (ii) the tax-exempt organization(s) shall not bear any relationship to any of the Debtors within the meaning of section 468B(d)(3) of the IRC. Notwithstanding any other provision of the Plan Documents, this Subsection 7.2(b) cannot be modified or amended.

**7.3 Amendments.** The Trustees, after consultation with the Approving Entities, and subject to the consent of the Approving Entities where so provided, may modify or amend this Trust Agreement or any document annexed to it, including, without limitation, the Trust Bylaws or the TDP. Any modification or amendment made pursuant to this Section must be done in writing. Notwithstanding anything contained in this Trust Agreement to the contrary, neither this Trust Agreement, the Trust Bylaws, the TDP, nor any document annexed to the foregoing shall be modified or amended in any way that could jeopardize, impair or modify the applicability of section 524(g) of the Bankruptcy Code, the efficacy or enforceability of the Injunctions, the Trust's qualified settlement fund status.

**7.4 Meetings.** A member of the TAC shall be deemed to have attended a meeting in the event such person spends a substantial portion of the day conferring, by phone or in person, on Trust matters with the TAC, the Futures Representative or Trustees, as applicable. The Trustees or the TAC, as the case may be, shall have complete discretion to determine whether a meeting, as described herein, occurred for purposes of Sections 4.5 and 6.6.

**7.5 Severability.** Should any provision in this Trust Agent be determined to be unenforceable, such determination shall in no way limit or affect the enforceability and operative effect of any and all other provisions of this Trust Agreement.

**7.6 Notices.** Notices to persons asserting claims shall be given at the address of such person, or, where applicable, such person's Futures Representative, in each case as provided on such person's claim form submitted to the Trust with respect to his or her or its Asbestos Related Claim.

All notices, requests, demands, and other communications required or permitted hereunder shall be in writing and given by (a) personal delivery, or (b) by established express delivery service that maintains delivery records, or (c) by mail, postage prepaid, or (d) by facsimile, e-mail or other electronic methods addressed as follows, or to such other address or addresses as may hereafter be furnished by any of the Notice Recipients, the Trustees, the Approving Entities or the Debtors, to the other notice recipients in compliance with the terms hereof.

To the Trust through the Trustees: Executive Director  
J.T. Thorpe Settlement Trust  
300 East Second Street, Suite 1205  
Reno, NV 89501

With a copy to: Eve H. Karasik, Esq.  
  
Levene, Neale, Bender, Yoo & Brill, L.L.P.  
10250 Constellation Boulevard, Suite 1700  
Los Angeles, CA 90067  
ehk@lnbyb.com

To the Futures Representative: David F. Levi  
Duke Law School  
210 Science Drive  
Durham, NC 27708  
levi@law.duke.edu

With a copy to: Sander L. Esserman, Esq.  
Stutzman, Bromberg, Esserman & Plifka  
2323 Bryan Street, Suite 2200  
Dallas, TX 75201  
esserman@sbep-law.com

To the TAC: Alan R. Brayton  
Brayton Purcell LLP  
222 Rush Landing Road  
P.O. Box 6169  
Novato, CA 94948-6169  
abrayton@braytonlaw.com

With a copy to: Steven B. Sacks, Esq.  
Sheppard, Mullin, Richter & Hampton LLP  
Four Embarcadero Center, Suite 1700  
San Francisco, CA 94111  
ssacks@sheppardmullin.com

To Thorpe,  
Dissolved Thorpe,  
Technologies and Holdings: J.T. Thorpe, Inc.  
J.T. Thorpe, Inc.  
Thorpe Technologies, Inc.  
Thorpe Holding Company, Inc.  
Attention: John Allen  
9905 Painter Avenue, Suite D  
Whittier, CA 90605

With copies to: Greenberg Glusker  
Attention: Brian L. Davidoff, Esq.  
1900 Avenue of the Stars, 21<sup>st</sup> Floor  
Los Angeles, CA 90067  
bdavidoff@greenbergglusker.com

All such notices and communications if mailed shall be effective when physically delivered at the designated addresses or, if electronically transmitted, when the communication is received at the designated addresses and confirmed by the recipient by return electronic transmission.

**7.7 Successors and Assigns.** The provisions of this Trust Agreement shall be binding upon and inure to the benefit of the Debtors, the Trust, and the Trustees and their respective successors and assigns, except that neither the Debtors, nor the Trust, nor the Trustees may assign

or otherwise transfer any of its, his or her rights or obligations under this Trust Agreement except, in the case of the Trust and the Trustees, as contemplated by Section 2.1.

**7.8 Limitation on Claim Interests for Securities Laws Purposes.** Except as otherwise permitted under the Plan, Asbestos Related Claims and any interests therein: (a) shall not be assigned, conveyed, hypothecated, pledged or otherwise transferred, voluntarily or involuntarily, directly or indirectly, except by will or under the laws of descent and distribution; (b) shall not be evidenced by a certificate or other instrument; (c) shall not possess any voting rights; and (d) shall not be entitled to receive any dividends or interest provided, however, that the foregoing shall not apply to the holder of an Indirect Asbestos Related Claim not otherwise enjoined that is subrogated to an Asbestos Related Claim as a result of its satisfaction of such Asbestos Related Claim.

**7.9 Entire Agreement: No Waiver.** The entire agreement of the parties relating to the subject matter of this Trust Agreement is contained herein and in the documents referred to herein, and this Trust Agreement and such documents supersede any prior oral or written agreements concerning the subject matter hereof. No failure to exercise or delay in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any right, power or privilege hereunder preclude any further exercise thereof or of any other right, power or privilege. The rights and remedies herein provided are cumulative and are not exclusive of rights under law or in equity.

**7.10 Headings.** The headings used in this Trust Agreement are inserted for convenience only and neither constitute a portion of this Trust Agreement, nor in any manner affect the construction of the provisions of this Trust Agreement.

**7.11 Governing Law; Submission to Jurisdiction.** This Trust Agreement shall be governed by, and construed in accordance with, the laws of the State of Nevada without regard to the conflict of laws principles of that State. The Trust is subject to the continuing jurisdiction of the Bankruptcy Court.

**7.12 Dispute Resolution.** Any disputes that arise under this Trust Agreement or under the annexes hereto shall be resolved by the Bankruptcy Court pursuant to the Plan, except as otherwise provided herein or in the annexes hereto. Notwithstanding anything else herein contained, to the extent any provision of this Trust Agreement is inconsistent with any provision of the Plan, the Plan shall control.

**7.13 Enforcement and Administration.** The provisions of this Trust Agreement and the annexes hereto shall be enforced by the Bankruptcy Court pursuant to the Plan. The parties hereby further acknowledge and agree that the Bankruptcy Court shall have exclusive jurisdiction over the settlement of the accounts of the Trustees.

**7.14 Effectiveness.** This Trust Agreement shall not become effective until it has been executed and delivered by all the parties hereto.

**7.15 Counterpart Signatures.** This Trust Agreement may be executed in any number of counterparts, each of which shall constitute an original, but such counterparts shall together constitute but one and the same instrument.

IN WITNESS WHEREOF, the parties have executed this Fifteenth Amendment to and Complete Restatement of J.T. Thorpe Settlement Trust Agreement as of November 11, 2022.

TRUSTEES:




\_\_\_\_\_  
Sandra R. Hernandez, M.D.



\_\_\_\_\_  
John F. Luikart

FUTURES REPRESENTATIVE:



\_\_\_\_\_  
David F. Levi

TRUST ADVISORY COMMITTEE

By: \_\_\_\_\_

Name: Alan R. Brayton

Title: Chair

IN WITNESS WHEREOF, the parties have executed this Fifteenth Amendment to and Complete Restatement of J.T. Thorpe Settlement Trust Agreement as of November 11, 2022.

TRUSTEES:

---

Sandra R. Hernandez, M.D.

---


John F. Luikart

FUTURES REPRESENTATIVE:

---

David F. Levi

TRUST ADVISORY COMMITTEE

By:   
Steven B. Sacks, its: Counsel, as authorized by  
Alan R. Brayton, its: Chair

## **EXHIBIT “B”**

**FOURTH AMENDED AND COMPLETELY RESTATED  
J.T. THORPE SETTLEMENT TRUST BYLAWS**

**ARTICLE I - OFFICES**

**SECTION 1. Principal Office.** The initial principal office of the J.T. Thorpe Settlement Trust (the "Trust")<sup>1</sup> shall be in the County of Washoe, the State of Nevada, or at such other place as the Trustees, shall from time to time select.

**SECTION 2. Other Offices.** The Trust may have such other offices at such other places as the Trustees may from time to time determine to be necessary for the efficient and cost-effective administration of the Trust.

**ARTICLE II - TRUSTEES**

**SECTION 1. Control of Property, Business and Affairs.** The property, business and affairs of the Trust shall be managed by or under the direction of the Trustees, provided that certain decisions of the Trustees shall be subject to the consent of the Futures Representative and the TAC, as provided in the Trust Agreement to which these Bylaws are attached as Annex A.

**SECTION 2. Number, Resignation and Removal.** The number of Trustee(s) and the provisions governing the resignation and removal of a Trustee and the appointment of a successor Trustee shall be governed by the provisions of Article 4 of the Trust Agreement.

**SECTION 3. Quorum and Manner of Acting.** When there are three Trustees, a majority of the Trustees shall constitute a quorum for the transaction of business. When there are three Trustees, the vote, at a meeting at which a quorum is present, of a majority of Trustees shall be an act of the Trustees. When there are two Trustees, both must be present to constitute a quorum for the transaction of business. When there are two Trustees, at a meeting at which a quorum is present, only a unanimous vote of the Trustees shall be an act of the Trustees. In the absence of a quorum, the Trustee(s) present may adjourn the meeting from time to time until a quorum shall be present.

**SECTION 4. Regular Meetings.** Regular meetings of the Trustees with the Futures Representative and TAC may be held at such time and place as shall from time to time be determined by the Trustees ("Trust Meeting"), provided that the Trustees shall meet at least four times a year, as close as practicable on a quarterly basis, pursuant to a schedule announced year, and provided further that all meetings shall be held in the State of Nevada or such other state (other than California) as may be selected by the Trustees. After there has been such determination, and

---

<sup>1</sup> Capitalized terms used herein shall be the meanings ascribed to them in the Glossary of Terms for the Plan Documents, attached as Exhibit 1 to the Plan, and such definitions are incorporated herein by reference. All capitalized terms not defined in the Glossary, but defined in the Bankruptcy Code or Rules, shall have the meanings ascribed to them by the Bankruptcy Code or Rules, and such definitions are incorporated herein by reference.



a notice thereof has been once given to the Futures Representative and the TAC, regular Trust Meetings may be held without further notice being given.

SECTION 5. Special Meeting Notice. Special Trust Meetings shall be held whenever called by one or more of the Trustees ("Special Trust Meeting"). Notice of each such Special Trust Meeting shall be delivered by overnight courier to each Trustee, the Futures Representative and the TAC, addressed to each such party at the place designated by such party for receipt of such notice, or, failing such designation, at such party's residence or usual place of business, at least three days before the date on which the meeting is to be held, or shall be sent to such party at such place by personal delivery or by telephone or telecopy not later than two days before the day on which such meeting is to be held. Such notice shall state the place, date and hour of the Special Trust Meeting and the purposes for which it is called. In lieu of the notice to be given as set forth above, a waiver thereof in writing, signed by the Futures Representative or the TAC, entitled to receive such notice, whether before or after the Special Trust Meeting, shall be deemed equivalent thereto for purposes of this Section 5. No notice or waiver by the Futures Representative or the TAC, with respect to any Special Trust Meeting shall be required if such person or entity shall be present at said meeting. The Futures Representative and the TAC shall be entitled to attend every Special Trust Meeting of the Trustees. All Special Trust Meetings shall be held in the State of Nevada or such other state (other than California) as may be selected by the Trustees.

SECTION 6. Action without a Meeting; Meeting by Conference Call. Any action required or permitted to be taken at any meeting of the Trustees may be taken without a meeting if all Trustees, after notice to the Futures Representative and the TAC, consent thereto in writing, and the writing or writings are filed with the minutes of proceedings of the Trustees; provided that no such consents may be provided by a Trustee acting in the State of California.

The Trustees also may take action required or permitted to be taken at any meeting by means of conference telephone or similar communication equipment provided that all persons participating in the meeting can hear each other and provided that no Trustee shall participate in such a meeting from the State of California. Participation in a meeting pursuant to this paragraph shall constitute presence in person at such meeting

SECTION 7. Meeting of Trustees Only.

(a) The Trustees may meet outside the presence of the TAC and Futures Representative for the purpose of (i) formulating policies to be presented to the TAC and Futures Representative at a Regular or Special Meeting of the Trustees, TAC and Futures Representative or (ii) meeting with counsel to the Trust regarding Trust documents and the fiduciary duties of the Trustees.

(b) In addition, the Trustees may also meet outside the presence of the TAC and the Futures Representative when necessary for routine administration of the Trust, including personnel, financial, investment or claims matters arising in the course of managing the affairs of the Trust or under circumstances where the Trustees in their judgment conclude that it is a matter requiring prompt action before a regular or special meeting could be scheduled. In all such circumstances, the Trustees shall record, and make available to the TAC and Futures

Representative, the minutes of any meeting held pursuant to this Section 7(b). At the request of the TAC or Futures Representative the subject of any meeting held pursuant to Section 7(b) shall be placed on the agenda for the next regularly scheduled or special Trust meeting.

### **ARTICLE III - OFFICERS**

**SECTION 1. Principal Officers.** The principal officer of the Trust shall be the Managing Trustee, as appointed pursuant to Section 4.1 of the Trust Agreement. The Trust may also have such other officers as the Trustees may appoint after determining that such appointment will promote the efficient and cost-effective administration of the Trust.

**SECTION 2. Election and Term of Office.** The principal officers of the Trust shall be chosen by the Trustees. Each such officer shall hold office until his or her successor shall have been duly chosen and qualified or until the earlier of his or her death, resignation, retirement or removal.

**SECTION 3. Subordinate Officers.** In addition to the principal officer enumerated in Section 1 of this Article III, the Trust may have such other subordinate officers, agents and employees as the Trustees may deem necessary for the efficient and cost-effective administration of the Trust, each of whom shall hold office for such period, have such authority, and perform such duties as the Trustee may from time to time determine. The Trustees may delegate to any principal officer the power to appoint and to remove any such subordinate officers, agents or employees.

**SECTION 4. Removal.** The Managing Trustee or any other officer may be removed with or without cause, at any time, by resolution adopted by the Trustees at any regular Meeting of the Trustees or at any Special Meeting of the Trustees called for that purpose; provided, however, that the consent of the TAC and the Futures Representative shall be required for the removal of the Managing Trustee without cause.

**SECTION 5. Resignations.** Any officer may resign at any time by giving written notice to the Trustees. The resignation of any officer shall take effect upon receipt of notice thereof or at such later time as shall be specified in such notice and, unless otherwise specified therein, the acceptance of such resignation shall not be necessary to make it effective.

**SECTION 6. Powers and Duties.** The officers of the Trust shall have such powers and perform such duties as may be conferred upon or assigned to them by the Trustees.

### **ARTICLE IV - AMENDMENTS**

The Bylaws of the Trust, other than Article I, Article II, Article III Section 4, and this Article IV, and any provisions relating to the activities of the Trustees in California, may be amended by the Trustees at any Meeting of the Trustees, provided that notice of the proposed amendment is contained in the notice of such meeting. The remaining Bylaws may be amended by the Trustees only after receipt of the consent of the Approving Entities to the proposed amendment.

CERTIFICATION


The undersigned hereby certifies that he or she is the duly-selected and Bankruptcy Court-approved Trustee for the Trust and that the foregoing is a true and correct copy of the Fourth Amended and Completely Restated Bylaws of the Trust authorized by action of the Trust.

IN WITNESS WHEREOF, the undersigned Trustee set his or her hand this \_\_ day of July, 2019

TRUSTEES:



\_\_\_\_\_  
Sandra R. Hernandez, M.D.



\_\_\_\_\_  
John F. Luikart

**CONSENT TO FOURTH AMENDMENT TO AND  
COMPLETE RESTATEMENT OF J.T. THORPE SETTLEMENT  
TRUST BYLAWS**

The Trust Advisory Committee of the J. T. Thorpe Settlement Trust hereby consents to the **FOURTH AMENDMENT TO AND COMPLETE RESTATEMENT OF J.T. THORPE SETTLEMENT TRUST BYLAWS** attached hereto.

Executed in the State of Nevada on this 14<sup>th</sup> day of July, 2019

Trust Advisory Committee of the J. T. Thorpe  
Settlement Trust

By: Al Brayton  
Al Brayton  
Its: Chair

## **EXHIBIT “C”**

J.T. THORPE, INC., A CALIFORNIA CORPORATION /  
J.T. THORPE, INC., A DISSOLVED CALIFORNIA CORPORATION  
/ THORPE HOLDING COMPANY, INC., A CALIFORNIA  
CORPORATION / THORPE TECHNOLOGIES, INC.,  
A CALIFORNIA CORPORATION  
ASBESTOS PERSONAL INJURY SETTLEMENT  
FIFTH AMENDMENT TO AND COMPLETE RESTATEMENT OF  
TRUST DISTRIBUTION PROCEDURES

J.T. THORPE, INC., A CALIFORNIA CORPORATION / J.T. THORPE, INC.,  
A DISSOLVED CALIFORNIA CORPORATION / THORPE HOLDING COMPANY, INC.,  
A CALIFORNIA CORPORATION / THORPE TECHNOLOGIES, INC.,  
A CALIFORNIA CORPORATION  
ASBESTOS PERSONAL INJURY SETTLEMENT  
FIFTH AMENDMENT TO AND COMPLETE RESTATEMENT OF  
TRUST DISTRIBUTION PROCEDURES

TABLE OF CONTENTS

SECTION I

**Introduction**..... 5  
    1.1 Purpose. .... 5  
    1.2 Interpretation. .... 5

SECTION II

**Overview** ..... 5  
    2.1 Trust Goals. .... 5  
    2.2 Trust Claim Liquidation Procedures. .... 6  
    2.3 Trust Application of the Payment Percentage. .... 7  
    2.4 Trust’s Determination of the Maximum Annual Payment. .... 8  
    2.5 Trust Claims Payment Ratio..... 8  
    2.6 Trust Indemnity and Contribution Claims. .... 11

SECTION III

**TDP Administration** ..... 11  
    3.1 Trust Advisory Committee and Futures Representative. .... 11  
    3.2 Consent and Consultation Procedures..... 12

SECTION IV

**Payment Percentage; Periodic Estimates** ..... 12  
    4.1 Uncertainty of Thorpe’s Personal Injury Asbestos Liabilities ..... 12  
    4.2 Computation of Payment Percentage..... 12  
    4.3 Applicability of the Payment Percentage..... 13

SECTION V

**Resolution of Trust Claims** ..... 14  
    5.1 Threshold Requirement for Submitting a Claim to the Trust..... 14  
    5.2 Statute of Limitations or Repose for Trust Claims..... 15  
    5.3 Ordering, Processing and Payment of Claims..... 15  
    5.4 Resolution of Pre-Confirmation Trust Claims..... 17  
    5.5 Hardship Claims. .... 18  
    5.6 Contribution Claims. .... 19  
    5.7 Claim Auditing and Review Procedures..... 20  
    5.8 Second Disease Claims..... 21  
    5.9 Arbitration..... 21  
    5.10 Litigation After Electing Non-Binding Arbitration..... 22  
    5.11 Claims Eligible for Tort System Valuation Without Having First Pursued  
        Non-Binding Arbitration..... 22

**SECTION VI**

**Claims Materials** ..... 23

**6.1 Claims Materials.**..... 23

**6.2 Content of Claims Materials.**..... 24

**6.3 Withdrawal of Claims.** ..... 27

**6.4 Inactive Claim Status.**..... 28

**6.5 Filing Fees.**..... 28

**6.6 Assignment of Direct Actions to the Trust.** ..... 28

**SECTION VII**

**General Guidelines for Liquidating and Paying Claims** ..... 28

**7.1 Discretion to Vary the Order and Amounts of Payments in Event of Limited Liquidity.** ..... 28

**7.2 Punitive Damages.**..... 29

**7.3 Suits in the Tort System.** ..... 29

**7.4 Payment of Judgments for Money Damages.** ..... 30

**7.5 Releases.** ..... 31

**7.6 Third-Party Services.**..... 31

**7.7 Trust Disclosure of Information.** ..... 31

**SECTION VIII**

**Miscellaneous**..... 32

**8.1 Amendments.**..... 32

**8.2 Severability.**..... 32

**8.3 Governing Law.**..... 32

**8.4 Attorneys' Fees.**..... 32

**8.5 Exception in California.** ..... 33



J.T. THORPE, INC., A CALIFORNIA CORPORATION/J.T. THORPE, INC.,  
A DISSOLVED CALIFORNIA CORPORATION/THORPE HOLDING COMPANY, INC.,  
A CALIFORNIA CORPORATION/THORPE TECHNOLOGIES, INC.,  
A CALIFORNIA CORPORATION  
ASBESTOS PERSONAL INJURY SETTLEMENT  
FIFTH AMENDMENT TO AND COMPLETE RESTATEMENT OF  
TRUST DISTRIBUTION PROCEDURES

The J.T. Thorpe, Inc., a California corporation/J.T. Thorpe, Inc., a dissolved California corporation/Thorpe Holding Company, Inc., a California corporation/Thorpe Technologies, Inc., a California corporation Asbestos Personal Injury Settlement Trust Distribution Procedures (“TDP”) contained herein provide for satisfying all asbestos-related personal injury and death claims caused by conduct of, and/or exposure to asbestos-containing products for which, J.T. Thorpe, Inc., a California corporation; J.T. Thorpe, Inc., a dissolved California corporation; Thorpe Holding Company, Inc., a California corporation; or Thorpe Technologies, Inc., a California corporation (collectively “Thorpe”), their predecessors, successors, and assigns have legal responsibility (hereinafter for all purposes of this TDP defined as “Trust Claims”), as provided in and required by the “First Amended Joint Plan of Reorganization, Dated August 5, 2005” (as such plan may hereinafter be further amended, revised, and/or supplemented, the “Plan”) and the J.T. Thorpe Personal Injury Settlement Trust Agreement (“Trust Agreement”). The Plan and Trust Agreement establish the J.T. Thorpe Personal Injury Settlement Trust (“Trust”). The Trustees of the Trust (“Trustees”) shall implement and administer this TDP in accordance with the Trust Agreement. Capitalized terms used herein and not otherwise defined shall have the meanings assigned to them in the Glossary, attached as Exhibit 1 to the Plan.

## SECTION I

### Introduction

**1.1 Purpose.** This TDP has been adopted pursuant to the Trust Agreement. It is designed to provide fair and equitable treatment for all Trust Claims that may presently exist or may arise in the future in substantially the same manner.

**1.2 Interpretation.** Nothing in this TDP shall be deemed to create a substantive right for any claimant.

## SECTION II

### Overview

**2.1 Trust Goals.** The goal of the Trust is to treat all claimants equitably. This TDP furthers that goal by setting forth procedures for processing and paying claims generally on an impartial, first-in-first-out (“FIFO”) basis, with the intention of paying all claimants over time as equivalent a share as possible of the value of their claims based on historical values for substantially similar claims in the tort system. To this end, the TDP establishes for unliquidated claims in the Case Valuation Matrix (“Matrix”), attached hereto as Appendix I, a schedule of five asbestos-related diseases (“Compensable Diseases”), which have presumptive medical and exposure requirements (“Medical/Exposure Criteria”), criteria for establishing liquidated values (“Matrix Values”), anticipated average values (“Average Values”), and caps on liquidated values (“Maximum Values”). The Compensable Diseases, Medical/Exposure Criteria, Matrix Values, Average Values and Maximum Values, which are set forth in the Matrix, have all been selected and derived with the intention of achieving a fair allocation of the Trust funds as among claimants suffering from different disease processes in light of the best available information, considering the settlement history of Thorpe and the rights claimants would have in the tort

system absent the bankruptcy. The TDP also provides mechanisms for the treatment and payment of Liquidated Claims.

**2.2 Trust Claim Liquidation Procedures.** Trust Claims shall be processed based on a first-in-first-out “FIFO” basis called the FIFO Processing Queue to be established pursuant to Section 5.3 below. The Trust shall liquidate all Trust Claims that meet the presumptive Medical/Exposure Criteria in accordance with the Matrix. Claims that do not meet the presumptive Medical/Exposure Criteria for the relevant Compensable Disease may undergo the Trust’s Individual Review Process described in the Matrix. In such a case, notwithstanding that the claim does not meet the presumptive Medical/Exposure Criteria for the relevant Compensable Disease, the Trust can offer the claimant an amount equal to a standard qualified claim of that Compensable Disease if the Trust is satisfied that the claimant has presented a claim that would be cognizable, valid and compensable in the tort system.

All unresolved disputes over a claimant’s medical condition, exposure history and/or the liquidated value of the claim shall be subject to binding or non-binding arbitration, at the election of the claimant, under the Arbitration Rules. Disputes with the Trust that cannot be resolved by non-binding arbitration may enter the tort system as provided in Sections 5.9 and 7.3 below. However, if and when a claimant obtains a judgment in the tort system, the judgment will be payable (subject to the Payment Percentage, Maximum Annual Payment, and Disease Category Claims Payment Ratio provisions set forth below) as provided in Section 7.4 below.

**2.3 Trust Application of the Payment Percentage.** After the liquidated value of a Trust Claim is determined, the claimant will ultimately receive a *pro-rata* share of that value based on a Payment Percentage calculated as described in Section 4.2 below. The Initial Payment Percentage shall be 50% in accordance with the “Agreement Regarding Initial Payment Percentage” between the Committee and the Futures Representative dated June 29, 2006.

The Payment Percentage may be adjusted upwards or downwards from time to time by the Trust with the consent of the Trust Advisory Committee “TAC” (as defined in Section 3.1 below) and the Futures Representative (as defined in Section 3.1 below) to reflect then-current estimates of the Trust’s assets and its liabilities, as well as the estimated value of then-pending and future claims. However, any adjustment to the Initial Payment Percentage shall be made only pursuant to Section 4.2 below. If the Payment Percentage is increased over time, claimants who have previously been paid by the Trust will receive a proportional additional payment unless the Trust with consent of the TAC and the Futures Representative concludes that the amount is so modest and the administrative costs and burdens are so great in comparison to the benefits to claimants that such additional payments shall be omitted or deferred.

To the extent that the designated legal representative of a claimant or heir (or the Trust in the case of in pro per claimants), following reasonable efforts, cannot locate a claimant or heir within one year from the approval of any additional payment pursuant to Section 4.2, the legal representatives shall return all funds, which must be held in client trust accounts, to the Trust which the Trust shall return to net claimant equity. To the extent the Trust cannot locate a claimant or heir in pro per within one year from the approval of any additional payment pursuant to Section 4.2 following reasonable efforts, the entire additional payment shall also be returned to net claimant equity.

**2.4 Trust's Determination of the Maximum Annual Payment.** The Trust shall estimate or model the amount of cash flow anticipated to be necessary over its entire life to ensure that funds will be available to treat all present and future claimants as similarly as possible. In each year, the Trust will be empowered to pay out all of the interest earned during the year, together with a portion of its principal, calculated so that the application of Trust funds over its life shall correspond with the needs created by the anticipated flow of claims (the "Maximum Annual Payment"). The Trust's distributions to claimants for that year shall not exceed the Maximum Annual Payment determined for that year.

**2.5 Trust Claims Payment Ratio.** Based upon Thorpe's claim settlement history and analysis of present and future claims, a Disease Category Claims Payment Ratio has been created based upon the category of disease claimed ("Disease Categories").

For claims paid during the year 2005, the Disease Category Claims Payment Ratio shall be 90% (the "Category A Percentage") for "Category A" claims, which consist of Trust Claims involving malignant claims that were unliquidated as of the Effective Date, and 10% for "Category B" claims (the "Category B Percentage"), which are Trust Claims involving non-malignant claims that were similarly unliquidated as of the Effective Date. For claims paid during the years 2006 through and including 2007, the Category A Percentage shall be 89% and the Category B Percentage shall be 11%. For claims paid during the years 2008 through and including 2025, the Category A Percentage shall be 90% and the Category B Percentage shall be 10%. For claims paid during the years 2026 through and including 2039, the Category A Percentage shall be 91% and the Category B Percentage shall be 9%. In each year, after the determination of the Maximum Annual Payment, the Category A Percentage of that amount will

be available to pay liquidated Category A claims and the Category B Percentage will be available to pay liquidated Category B claims that have been liquidated since the Effective Date.

In the event there are insufficient funds in any year to pay the liquidated claims against Thorpe within the Disease Categories, the available funds within the particular Disease Category shall be paid to the maximum extent to claimants in the particular Disease Category based on their place in the FIFO Payment Queue described in Section 5.3(c) below based upon the date of claim liquidation. Claims for which there are insufficient funds will be carried to the next year where they will be placed at the head of the FIFO Payment Queue. If there are excess funds in either or both Disease Category, because there was an insufficient amount of liquidated claims to exhaust the respective Maximum Annual Payment amount for that Disease Category, then the excess funds for either or both Disease Categories will be rolled over and remain dedicated to the respective Disease Category to which they were originally allocated.

The Disease Category Claims Payment Ratio shall be continued absent circumstances, such as a significant change in law or medicine, necessitating amendment to avoid a manifest injustice. The accumulation, rollover and subsequent delay of claims resulting from the application of the Disease Category Claims Payment Ratio, shall not, in and of itself, constitute such circumstances. Nor may an increase in the numbers of Disease Category B claims beyond those predicted or expected be considered as a factor in deciding whether to reduce the percentage allocated to Disease Category A. In considering whether to make any amendments to the Disease Category Claims Payment Ratio, the Trustees should also consider the reasons for which the Disease Category Claims Payment Ratio was adopted, the settlement history that gave rise to its calculation, and the foreseeability or lack of foreseeability of the reasons why there would be any need to make an amendment. In that regard, the Trustees should keep in mind the

interplay between the Payment Percentage and the Disease Category Claims Payment Ratio as it affects the net cash actually paid to claimants. In any event, no amendment to the Disease Category Claims Payment Ratio may be made without the consent of the TAC and the Futures Representative pursuant to the consent process set forth in Section 2.2(f) of the Trust Agreement. However, the Trustees may offer the option of a reduced payment percentage to either Disease Category in return for prompter payment (the "Reduced Payment Option"), after first obtaining the consent of the TAC and Futures Representative.

**Suspension of Claims Payment Ratio** Notwithstanding any other provision herein, commencing on September 1, 2020, the Trust shall cease enforcing the Disease Category Claims Payment Ratio ("Ratio") contained in the TDP subject to the ability of the Trustees, the Futures Representative and the TAC to reinstate the enforcement of the Ratio in the manner provided below. During the time that the Trust is not enforcing the Ratio, it shall continue to track and maintain records regarding the funds allocated to the Ratio and the claims paid that would have otherwise been subject to the Ratio.

Beginning on February 1, 2021, the Trust shall on July 31st (for the period January 1st to June 30th of the current year) and February 1st (for period July 1st to December 31st of the prior year) of each such period where the Ratio has been suspended provide the Trustees, the Futures Representative and the TAC a report showing: (a) the amount of the Maximum Annual Payment that would have been allocated by the Ratio for that six month period using the existing Ratio; (b) the amounts paid with respect to claims during such six month period that would have been subject to the Ratio in each category; and (c) the amounts approved for payment (but not yet paid) as of the end of such six month period with respect to claims that would have been subject to the Ratio. The Futures Representative and the TAC shall have fifteen days (15) from the

receipt of each such report to notify the Trust in writing that they are exercising their right to have the Trust begin enforcing the Ratio effective as of the end of the most recent reporting period. In addition, the Trustees may, at any time with notice to the Futures Representative and the TAC, exercise their right to reinstate the enforcement of the Ratio. If the Trustees exercise their right or if the Trustees receive a written reinstatement notice from the Futures Representative or the TAC, the Trust shall immediately begin enforcing the Ratio, effective as of the end of the most recent reporting period. If the enforcement of the Ratio is reinstated, all provisions of the TDP relating to the Ratio shall be in effect, but any deficits from prior reporting periods or years shall be ignored and any rollover amounts shall be allocated in accordance with the percentages set forth in the Ratio.

**2.6 Trust Indemnity and Contribution Claims.** As set forth in Section 5.6 below, Trust Claims for indemnity and contribution (if any) will be subject to the same categorization, evaluation, and payment provisions of this TDP as all other Trust Claims.

### **SECTION III**

#### **TDP Administration**

**3.1 Trust Advisory Committee and Futures Representative.** Pursuant to the Plan and the Trust Agreement, this TDP will be administered by the Trustees in consultation with a three-member Trust Advisory Committee (“TAC”), that represents the interests of holders of present Trust Claims, and a Legal Representative for Future Asbestos-Related Claimants (“Futures Representative”), who represents the interests of holders of Trust Claims that will be asserted in the future. The Trustees shall obtain the consent of the TAC and the Futures Representative to any amendments to these Procedures pursuant to Section 8.1 below, and to such other matters as are otherwise required below and in Section 2.2(f) of the Trust Agreement. The Trustees shall also consult with the TAC and the Futures Representative on such matters as



are provided below and in Section 2.2(e) of the Trust Agreement. The initial members of the TAC and the initial Futures Representative are identified in the Trust Agreement.

**3.2 Consent and Consultation Procedures.** In those circumstances in which consultation or consent is required, the Trustees will provide written notice to the TAC and the Futures Representative of the specific amendment or other action that is proposed. The Trustees will not implement such amendment nor take such action unless and until the parties have engaged in the consultation process described in Section 2.2(e), or the Consent Process described in Sections 5.6 and 6.6 and if necessary, 5.7 and 6.7 of the Trust Agreement.

## SECTION IV

### Payment Percentage; Periodic Estimates

**4.1 Uncertainty of Thorpe's Personal Injury Asbestos Liabilities** As discussed above, there is inherent uncertainty regarding Thorpe's total asbestos-related tort liabilities, as well as the total value of the assets available to pay such claims. Consequently, there is inherent uncertainty regarding the amounts that holders of Trust Claims will receive. To seek to ensure substantially equivalent treatment of all present and future claims, the Trustees must determine from time to time the percentage of full liquidated value that holders of Trust Claims will be likely to receive, i.e, the "Payment Percentage" described in Section 2.3 above and Section 4.2 below.

**4.2 Computation of Payment Percentage.** The Initial Payment Percentage shall be the percentage set forth in Section 2.3 of this TDP. The Payment Percentage shall be subject to change pursuant to the terms of this TDP and the Trust Agreement if the Trustees determine, with consent of the TAC and the Futures Representative, that an adjustment is required. Commencing on the first day of January, after the Plan has been Confirmed, the Trustees shall reconsider the then applicable Payment Percentage to assure that it is based on accurate current

information and may, after such reconsideration, change the Payment Percentage if necessary with the consent of the TAC and the Futures Representative. Thereafter, no less frequently than once every three years, commencing with the first day of January occurring after the Plan is consummated, the Trustees shall reconsider the then applicable Payment Percentage to assure that it is based on accurate, current information and may, after such reconsideration, change the Payment Percentage if necessary with the consent of the TAC and the Futures Representative. The Trustees shall also reconsider the then applicable Payment Percentage at shorter intervals if he or she deems such reconsideration to be appropriate or if requested to do so by the TAC or the Futures Representative. The Trustees must base his or her determination of the Payment Percentage on current estimates of the number, types, and values of present and future Trust Claims, the value and liquidity of the assets then available to the Trust for their payment, all anticipated administrative and legal expenses, and any other material matters that are reasonably likely to affect the sufficiency of funds to pay a comparable percentage of full value to all holders of Trust Claims. When making these determinations, the Trustees shall exercise common sense and flexibly evaluate all relevant factors. The Payment Percentage applicable to one category of claims may not be reduced to alleviate delays in another category claims payments caused by a backlog in that category. All claims will receive the same Payment Percentage.

**4.3 Applicability of the Payment Percentage.** No holder of a Trust Claim shall receive a payment that exceeds the Trust's determination of the Initial Payment Percentage, or the Payment Percentage in effect at the time of payment in the case of all other Trust Claims unless a Reduced Payment Option applies. If a redetermination of the Payment Percentage has been proposed in writing by the Trustees to the TAC and the Futures Representative but has not

yet been adopted, the claimant shall receive the lower of the current Payment Percentage or the proposed Payment Percentage. However, if the proposed Payment Percentage was the lower amount but is not subsequently adopted, the claimant shall thereafter receive the difference between the lower proposed amount and the higher current amount. Conversely, if the proposed Payment Percentage was the higher amount and is subsequently adopted, the claimant shall thereafter receive the difference between the lower current amount and the higher adopted amount.

## **SECTION V**

### **Resolution of Trust Claims**

**5.1 Threshold Requirement for Submitting a Claim to the Trust.** If a Claimant or Injured Person has commenced litigation seeking compensation for asbestos-related injuries or death that are the subject of a claim in a court where one or more of the Debtors liable for such claim was subject to in personam jurisdiction as of February 12, 2002, then that jurisdiction shall determine which limitations period, category, Average Value, and base case shall be used subject to the exceptions stated herein. If multiple pre-petition lawsuits in different jurisdictions naming one or more of the Debtors liable for such claim have been filed for an Injured Person or Claimant, then such Injured Person or Claimant may choose the prepetition jurisdiction (from among the different jurisdictions in which the pre-petition lawsuits naming one or more of the Debtors liable for such claim were filed for that Injured Party or Claimant, so long as in personam jurisdiction existed) in which the limitations period, category, Average Value, and base case shall be used. If a Claimant does not have a pending lawsuit against one or more of the Debtors at the time of the submission to the Trust, then in lieu of having a tort action filed for purposes of this TDP, the Claimant or Injured Person must submit a verified certification under penalty of perjury, either of counsel based upon counsel's records, or of Claimant or Injured

Person stating facts which establish in personam jurisdiction in a court where one or more of the Debtors liable for such claim was subject to in personam jurisdiction as of February 12, 2002 or incorporate a lawsuit which asserts those facts, and therefore such person can meet the jurisdictional requirements of the particular state in which the tort claim would have been timely and properly filed. The Trust shall have the right to contest any such certification. The jurisdiction so certified shall determine which limitations period, category, Average Value, and base case shall be used subject to the exceptions stated herein.

**5.2 Statute of Limitations or Repose for Trust Claims.** The statute of limitations and the choice of law determination applicable to claims against the Trust shall be determined by reference to the tort system where a claim against a Debtor was pending on the filing date of these cases, or where such a claim could have been timely and properly filed as asserted by the Claimant or Injured Person.

**5.3 Ordering, Processing and Payment of Claims.**

**5.3(a) Ordering of Claims.**

**5.3(a)(1) Establishment of the FIFO Processing Queue.** The Trust will order unliquidated claims for processing purposes on a FIFO basis except as otherwise provided herein (the “FIFO Processing Queue”). For all claims filed on or before the date six months after the Effective Date (the “Initial Claims Filing Date”), a claimant’s position in the FIFO Processing Queue shall be determined as of the earlier of (i) the date prior to February 12, 2002, “Petition Date” that the specific claim was either served or filed against Thorpe in a court in which Thorpe could properly have been sued or was actually submitted to Thorpe pursuant to an administrative processing agreement; (ii) the date before the Petition Date that a claim was filed or served against another defendant in the tort system if at the time the claim was subject to a tolling agreement with Thorpe; (iii) the date after the Petition Date but before the Effective Date

that the claim was filed or served against another defendant in a court in which Thorpe could properly have been sued; or (iv) the date after the Effective Date but on or before the Initial Claims Filing Date that the claim was served or filed with the Trust. Following the Initial Claims Filing Date, the claimant's position in the FIFO Processing Queue shall be determined by the date the claim was filed with the Trust. For all claims filed on the same date, the claimant's position in the FIFO Processing Queue shall be determined by the date of the diagnosis of the asbestos-related disease.

**5.3(a)(2) Effect of Statutes of Limitations and Repose.** All claims barred by the applicable statute of limitations or repose, as determined in Section 5.2 above, at the Petition Date shall remain barred on and after the Petition Date. All claims not so barred shall be tolled as of the Petition Date to and including October 16, 2007, without the need of the claimant to take any action whatsoever, including without limitation, filing a Proof of Claim in the Reorganization Cases.

**5.3(b) Processing of Unliquidated Trust Claims.** Within six months after the establishment of the Trust, the Trustees with the consent of the TAC and the Futures Representative shall adopt procedures for reviewing and liquidating all unliquidated Trust Claims, which shall include deadlines for processing such claims. Such procedures shall also require claimants seeking resolution of unliquidated Trust Claims to first file a Trust Claim form, together with the required supporting documentation, in accordance with the provisions of Sections 6.1 and 6.2 below. It is anticipated that the Trust shall provide an initial response to the claimant within six months of receiving the Trust Claim form. All claims filed with the Trust shall be deemed to be a claim for the highest Compensable Disease for which the claim qualifies at the time of filing, with all lower Compensable Diseases for which the claim then qualifies or

may qualify in the future subsumed into the higher Compensable Disease for both processing and payment purposes. Upon filing of a valid Trust Claim form with the required supporting documentation, the claim shall be placed in the FIFO Processing Queue in accordance with the ordering criteria described in Section 5.3(a) above.

The five Compensable Diseases covered by this TDP are set forth in detail in the Matrix. The Compensable Diseases, Matrix Values, and Medical/ Exposure Criteria shall apply to all unliquidated claims filed with the Trust.

As a general practice, the Trust will review its claims files on a regular basis and notify all claimants whose claims are likely to come up in the FIFO Processing Queue in the near future.

**5.3(c) Payment of Claims.** Trust Claims shall be paid in FIFO order based on the date their liquidation became final (the “FIFO Payment Queue”), all such payments being subject to the applicable Payment Percentage, Maximum Annual Payment, and Disease Category Claims Payment Ratio, except as otherwise provided herein. For all claims liquidated on the same date, each claimant’s position in the FIFO Payment Queue shall be determined by the date of the diagnosis of the claimant’s asbestos-related disease.

**5.4 Resolution of Pre-Confirmation Trust Claims.** As soon as practicable after the Effective Date, the Trust shall pay all Trust Claims that were liquidated by (i) a written settlement agreement entered into prior to the Petition Date for the particular claim, or (ii) the pre-confirmation claims liquidation process (collectively, the “Pre-Confirmation Liquidated Claims”). Notwithstanding the foregoing, these payments shall be subject to the limitations set forth below in this section. The liquidated value of a Pre-Confirmation Liquidated Claim shall be the amount agreed to in the binding settlement agreement, without interest, or the amount at

which the claim is liquidated pursuant to the pre-conformation claims liquidation process, as applicable. Moreover, to the extent that a claim is the subject of a written settlement agreement executed prior to the Petition Date, the holder of that claim shall have the option of (i) having the liquidated value be the amount agreed to in the binding settlement agreement, without interest, or (ii) having his or her claim re-liquidated pursuant to the pre-conformation claims liquidation process and having the liquidated value be the amount at which the claim is liquidated pursuant to the pre-conformation claims liquidation process. Notwithstanding anything to the contrary set forth in this Section 5.4, pursuant to Section 7.2 below, the liquidated value of a Pre-Confirmation Liquidated Claim shall not include any punitive or exemplary damages.

Pre-Confirmation Liquidated Claims shall be processed and paid within 90 days of the Effective Date, if feasible, or as soon thereafter as is possible. The amounts payable with respect to such claims shall not be subject to or taken into account in consideration of the Maximum Annual Payment or Disease Category Claims Payment Ratio, but shall be subject to the Payment Percentage provisions set forth in Section 4.2 above.

**5.5 Hardship Claims.** At any time the Trust may liquidate and pay certain Trust Claims that qualify as Hardship Claims. Such claims may be considered separately no matter what the order of processing otherwise would have been under this TDP. A Hardship Claim, following its liquidation, shall be placed at the head of the FIFO Liquidation Queue for purposes of payment, subject to the Maximum Annual Payment and Disease Category Claims Payment Ratio described above. A Trust Claim qualifies for payment as a Hardship Claim if the Trust, in its sole discretion, determines (a) that the claimant needs financial assistance on an immediate basis based on the claimant's expenses and all sources of available income, and (b) that there is a

causal connection between the claimant's dire financial condition and the claimant's asbestos-related disease.

**5.6 Contribution Claims.** Contribution Claims that are asserted against the Trust based upon theories of contribution or indemnification under applicable law may not be processed or paid by the Trust unless (a) such claim would not be disallowed by Section 502(e) of the Code if the Trust were a debtor in a case under the Code, and (b) the holder of such claim (the "Indirect Claimant") establishes to the satisfaction of the Trustees that (i) the Indirect Claimant has paid in full the liability and obligations of the Trust to the direct claimant to whom the Trust would otherwise have had a liability or obligation under these Procedures, (ii) the direct claimant and the Indirect Claimant have forever released the Trust from all liability to the direct claimant, and (iii) the claim is not otherwise barred by a statute of limitations or repose or by other applicable law. In no event shall any Indirect Claimant have any rights against the Trust superior to the rights of the related direct claimant against the Trust, including any rights with respect to the timing, amount or manner of payment.

The Trust shall not pay any Indirect Claimant unless and until the Indirect Claimant's aggregate liability for the direct claimant's claim has been fixed, liquidated and paid by the Indirect Claimant pursuant to final judgment and not by settlement.

The credit or offset to which a co-defendant is entitled in the tort system for settlement with the Trust is the amount of the Trust's Payment to the Claimant, which Payment amount shall be determined as: (a) the actual amount received to date by the Claimant; or (b) if no funds have yet been received, the amount of the liquidated value agreed to by the Claimant and the Trust, multiplied by the *pro rata* share in effect at the time the set-off is being applied.



Contribution Claims shall be processed in accordance with procedures to be developed and implemented by the Trustees, which procedures (a) shall determine the validity, allowability and enforceability of such claims; and (b) only then shall otherwise provide the same liquidation and payment procedures and rights to the holders of such claims as the Trust would have afforded the holders of the underlying valid Trust Claims.

**5.7 Claim Auditing and Review Procedures.**

**5.7(a) Claims Audit Program.** The Trust with consent of the TAC and Futures Representative may develop methods for auditing the reliability of evidence reasonably related to the value of the claim, including additional reading of x-rays and verification of pulmonary function tests, as well as the reliability of evidence of exposure to asbestos, including exposure to asbestos-containing products manufactured or distributed by Thorpe, and requesting from claimants or other Trusts, claims materials submitted to other Trusts. In the event that the Trust reasonably determines that any unreliable individual or entity has engaged in a pattern or practice of providing unreliable medical or other evidence to the Trust, it may decline to accept additional evidence from such provider in the future. Further, in the event that an audit reveals that fraudulent information has been provided to the Trust, the Trust may penalize any responsible claimant or claimant's attorney by disallowing the related Trust Claim or by other means including, but not limited to, requiring the claimant or attorney submitting the fraudulent information to pay the costs associated with the audit and any future related audit or audits, reordering the priority of payment of all affected claimants' Trust Claims, raising the level of scrutiny of additional information submitted from the medical facility or other source, refusing to accept additional evidence from the same, seeking the prosecution of the claimant or claimant's

attorney for presenting a fraudulent claim in violation of 18 U.S.C. §152, and seeking Rule 11 sanctions.

**5.7(b) Review by the Trust for the benefit of the TAC and Futures**

**Representative.** The Trust shall cause a review of the filed claims, paid claims, average payments and disallowed claims by Compensable Disease to be performed bi-annually or upon the request of the TAC or the Futures Representative, sufficient to allow an estimation of the adequacy of the Trust fund to compensate Claimants as compared to the current claims forecast.

**5.8 Second Disease Claims.** The holder of a claim involving a non-malignant asbestos-related disease may file a new claim for a malignant disease that is subsequently diagnosed (“Second Disease Claim”). Any payments to which such claimant may be entitled for such asbestos-related malignancy shall be reduced by the amount paid by the Trust for the non-malignant asbestos-related disease.

**5.9 Arbitration.**

**5.9(a) Establishment of Arbitration Procedures.** The Trust, with the consent of the TAC and the Futures Representative, shall institute Arbitration Rules for resolving disputes concerning the Trust’s outright rejection or denial of a claim, or concerning the claimant’s medical condition or exposure history for purposes of categorizing a claim. Binding, non-binding arbitration and tort system valuation shall also be available for resolving disputes over the liquidated value of a claim. In all arbitrations, the arbitrator shall consider the same medical and exposure evidentiary requirements that are set forth in the Matrix. In the case of an arbitration involving the liquidated value of a claim, the arbitrator shall consider the same valuation factors that are set forth in the Matrix. With respect to all claims eligible for arbitration, the claimant, but not the Trust, may elect either non-binding or binding arbitration. If

the claimant elects non-binding arbitration, claimant will be responsible for ½ of arbitrator's fees and costs. The Arbitration Rules may be modified by the Trust with the consent of the TAC and the Futures Representative. Such amendments may also include adoption of mediation procedures as well as establishment of an Extraordinary Claims Panel to review such claims pursuant to the Matrix.

**5.9(b) Claims Eligible for Arbitration.** A claim is eligible for arbitration, if it has been rejected by the Trust, or the Trust has made an offer which was rejected by the claimant. The claimant must notify the Trust of such rejection in writing.

**5.9(c) Limitations on and Payment of Arbitration Awards.** The arbitrator shall not return an award in excess of the appropriate Matrix Value for such claim based upon the facts as found by the arbitrator. For an Extraordinary Claim, the arbitrator shall not return an award greater than the Maximum Extraordinary Value for such a claim as set forth in the Matrix. A claimant who submits to arbitration and who accepts the arbitral award will receive payments in the same manner as one who accepts the Trust's original valuation of the claim.

**5.10 Litigation After Electing Non-Binding Arbitration.** A claimant who elects non-binding arbitration and then rejects the arbitral award retains the right to exit to the tort system pursuant to Sections 7.3 below. However, such a claimant shall be eligible for payment of a judgment for monetary damages obtained in the tort system from the Trust's available cash only as provided in Section 7.4 below.

**5.11 Claims Eligible for Tort System Valuation Without Having First Pursued Non-Binding Arbitration.** A claim is eligible for tort system valuation pursuant to Section 7.3 below, without having first pursued non-binding arbitration, if the Trust has made an offer and the claimant in writing has:

(a) rejected the Trust offer;

(b) counter offered to accept a partial payment of 50% of the Trust's offer;

(c) agreed both: (1) not to execute against the Trust on any judgment obtained through the tort system, and (2) not to seek any additional payments from the Trust, including without limitation not to seek any additional payments under Section 7.4 of this TDP;

(d) agreed that the provisions of Sections 3.2(d) and 9.4 of the Plan shall govern any Direct Action including any judgment obtained by Claimant;

(e) agreed that if any Direct Action is successful to the extent the net recovery to the Trust exceeds the Trust's initial offer, claimant shall be entitled to the remaining 50% of the Trust's offer plus a percentage payment of the net recovery in an amount reasonable and appropriate agreed upon by the Trustees, the Trust Advisory Committee and the Futures Representative after taking into account the result obtained and the contribution to that result by claimant which amount shall be payable upon the Trust's actual receipt of funds from the Direct Action recovery. In the event the Trustees, the Trust Advisory Committee and the Futures Representative cannot reach agreement on a reasonable and appropriate percentage payment, the claimant, the Trustees, the Trust Advisory Committee and/or the Futures Representative may request resolution of the dispute by the Bankruptcy Court; and

(f) the Trust has accepted the claimant's counter offer.

## **SECTION VI**

### **Claims Materials**

**6.1 Claims Materials.** The Trust shall prepare suitable and efficient claims materials ("Claims Materials"), and shall provide such Claims Materials upon written request. The Trust Claim form to be submitted to the Trust shall include a certification by the claimant or his or her attorney sufficient to meet the requirements of Rule 11(b) of the Federal Rules of Civil

Procedure. A copy of the Trust Claim forms to be used by the Trust for Pre-Confirmation Liquidated Claims and unliquidated Claims will be created with the consent of the TAC and the Futures Representative within three months of the establishment of the Trust. The Trust Claim forms may be changed by the Trust with the consent of the TAC and the Futures Representative. The Trust shall also establish procedures for electronic filing of claims.

**6.2 Content of Claims Materials.** The Claims Materials shall include a copy of this TDP, such instructions as the Trustees shall approve, and Trust Claim forms. The Trust Claim forms shall be submitted with supporting documentation in accordance with the relevant criteria as set forth below and in compliance with Section I of the Matrix. At a minimum, the unliquidated Trust Claim form shall require submission of sufficient information to prove, and any relevant information tending to disprove exposure, disease and damages including:

(a) All relevant information called for in the San Francisco Superior Court General Order 129 Form Interrogatories, Set 1 and Set 2 including the required complete occupational history and identification of other exposures, with the information relevant to exposure used to qualify this claim for the particular category highlighted and the pages tabbed.

(b) If the claimant was involved in any type of asbestos litigation, a complete copy of any litigation interrogatory responses created in support of that claim must be submitted to the Trust regardless of the jurisdiction in which the lawsuit was filed with any information exposures asserted in this claim highlighted and the pages tabbed (or, if applicable, noting that the interrogatories contain no reference to exposures asserted in this claim). In addition, the claimant who was involved in any type of asbestos litigation must identify all prior depositions of the claimant and produce them upon request.

(c) If the Claimant is utilizing the Trust Approved Interrogatories (set forth on the Trust Web site), portions of litigation interrogatories that were amended after the litigation was concluded or declarations to establish the Trust Claim, the responses and/or declarations must meet the following requirements:

(i) The interrogatories and/or declarations must be verified or made by a person who is competent to testify to the information stated in the interrogatories and/or declarations and the person must have personal direct knowledge of the factual information relevant to the claim and the answers and/or declarations must provide sufficient background information to explain how the person verifying the interrogatories and/or the declarant(s) acquired the personal direct knowledge of factual matters relevant to this claim, to allow the Trust to determine the credibility of the person verifying the interrogatories and/or the declarants;

(ii) Where the person lacks personal direct knowledge, the answers and/or declarations must provide sufficient information to explain how, when and from what sources the person verifying the interrogatories and/or the declarants acquired any indirect knowledge of factual matters relevant to the claim;

(iii) The interrogatory responses and/or declarant must provide specifics about the claimant's (or claimant's decedent's) exposure and not use boilerplate wording;

(iv) If the person verifying the interrogatories and/or declarants relied upon documents as the basis for the responses given in the interrogatories and/or declarations (i.e. military records, social security records, etc.), those documents must be

specifically identified and relevant portions of any such documents included in the supporting documents attached to the claim;

(v) The truth of the facts asserted in the interrogatories must be affirmed or verified under the penalty of perjury and any declarations must be made under penalty of perjury;

(vi) All declarations must be specific to the claim. In appropriate circumstances, the Trust may accept expert opinions pertaining to issues that are of general application and that are relevant to the specific claimant's claim.

(vii) The Trust shall have the right to interview by phone or in person (always with the participation or presence of claimant's counsel), anyone who verifies interrogatories, or has provided information to the person verifying the interrogatories or who submits a declaration in support of a claim submitted to the Trust.

(d) Medical records, medical reports and/or death certificates evidencing the claimed disease, with the diagnosis highlighted and the pages tabbed. For lung cancer and other cancer cases, evidence of markers or other factors which would lead to an upward adjustment under the Matrix will be highlighted and the pages tabbed. For Grade I claims, evidence of x-ray and PFT values that would lead to an increased award will be highlighted and the pages tabbed.

(e) For Serious Asbestosis claims, evidence to support this categorization will be highlighted and the pages tabbed.

(f) For an Injured Person seeking a multiplier for an economic loss in excess of the base case amount, an economic report of evidence supporting claimed wage/pension/home services loss, with total claimed loss highlighted and the page tabbed.

(g) For an Injured Person seeking a multiplier for medical expenses in excess of the base case amount, an affidavit summarizing medical expenses, or submission of medical bills to substantiate the total claimed amount.

(h) An endorsed/filed copy of the face page of the complaint or equivalent proof of commencement of litigation if applicable, or alternatively a certification under Section 5.1.

(i) Social Security records, front or identifying face page and portions relevant to facts asserted in connection with the claim of deposition transcript(s), union records, railroad records, military records (including leave records), or any other employment records all highlighted and tabbed. If such records are unavailable, the claimant or representative attorney must explain why such records are unavailable and attest that every reasonable effort has been made to obtain them.

(j) Information sufficient to establish that the claimant is not eligible nor has received Medicare benefits. Information representing that the date of last exposure to J.T. Thorpe, Inc. asbestos products or operations happened before or after December 5, 1980. Information of satisfied Medicare lien or global settlement documentation.

**6.3 Withdrawal of Claims.** A claimant may withdraw a Trust Claim at any time upon written notice to the Trust and file another claim subsequently without affecting the status of the claim for statute of limitations purposes, but any such claim filed after withdrawal shall be given a place in the FIFO Processing Queue based the date of such subsequent filing. A claim will be deemed withdrawn if the claimant neither accepts, rejects, nor initiates arbitration within six months of the Trust's offer of payment or rejection of the claim. Upon written request and good cause, the Trust may extend this period for an additional six months.



**6.4 Inactive Claim Status.**

Upon submission of a claim, claimant will have the opportunity to request that his/her claim be placed on “Inactive Claim Status”. The Trust shall suspend any claim requesting Inactive Claim Status for up to two years and continued upon written request for good cause shown. Upon written request by the Claimant, a claim may be reactivated in the FIFO Processing Queue and proceed through normal evaluation procedures as established by the Trust pursuant to Section 5.7.

**6.5 Filing Fees.** There will be a filing fee of \$250.00 for each unliquidated claim which will be refunded by the Trust if the claim is allowed. The Trust may waive the refundable filing fee if it is determined that such a fee would create undue financial hardship for the claimant. The size of the fee will be reviewed by the Trust on a yearly basis.

**6.6 Assignment of Direct Actions to the Trust.** Signature by an asbestos related claimant on his or her Compromise and Release, settling the claim, will constitute his or her assignment to the Trust of any Direct Action he or she might have against any Asbestos Insurance Company. Such signature will also authorize the Trust to act as his or her sole attorney in fact to prosecute any such Direct Action at the Trust’s sole discretion.

**SECTION VII**

**General Guidelines for Liquidating and Paying Claims**

**7.1 Discretion to Vary the Order and Amounts of Payments in Event of Limited Liquidity.** Consistent with the provisions hereof and subject to the FIFO Processing and Liquidation Queues, Maximum Annual Payment, and Disease Category Claims Payment Ratio requirements set forth above, the Trustees shall proceed with due diligence to liquidate valid Trust Claims, and shall make payments to holders of such claims in accordance with this TDP promptly as funds become available and as claims are liquidated, while maintaining sufficient

resources to pay future valid claims in substantially the same manner. Because the Trust's income over time remains uncertain, and decisions about payments must be based on estimates that cannot be done precisely, they may have to be revised in light of experiences over time, and there can be no guarantee of any specific level of payment to claimants. However, the Trustees shall use his or her best efforts to treat similar claims in substantially the same manner, consistent with his or her duties as Trustees, the purposes of the Trust, the established allocation to Categories A and B, and the practical limitations imposed by the inability to predict the future with precision. In the event that the Trust faces temporary periods of limited liquidity, the Trustees may, with the consent of the TAC and the Futures Representative, suspend the normal order of payment and may temporarily limit or suspend payments altogether, and if appropriate, at any time may offer a Reduced Payment Option.

**7.2 Punitive Damages.** In determining the value of any liquidated or unliquidated Trust Claim, punitive or exemplary damages, i.e., damages other than compensatory damages, shall not be considered or allowed, notwithstanding their availability in the tort system. Notwithstanding the foregoing, nothing in this Section 7.2 shall preclude holders of claims who opt out to the tort system pursuant to Section 5.11 of this TDP from pursuing punitive or exemplary damages in such actions, however, all payments to such claimholders on recoveries of punitive or exemplary damages shall be limited as set forth in Section 5.11.

**7.3 Suits in the Tort System.** If the holder of a disputed claim disagrees with the Trust's determination regarding the Compensable Disease of the claim, the claimant's exposure history or the liquidated value of the claim, and if the holder has either (i) first submitted the claim to non-binding arbitration as provided in Section 5.9 above and rejected the resulting arbitration award or (ii) rejected the Trust's offer and has his or her counter-offer accepted by the

Trust pursuant to Section 5.11 above, the holder may file a lawsuit in the jurisdiction where in personam jurisdiction over the Trust can be obtained. Any such lawsuit must be filed by the claimant in his or her own right and name and not as a member or representative of a class. No such lawsuit may be consolidated with any other lawsuit, with the exception of a personal injury or survival claim which may be consolidated with a wrongful death claim brought as a result of the death of the Injured Party. All defenses (including, with respect to the Trust, all defenses which could have been asserted by Thorpe) shall be available to the Trust at trial; however, the Trust may waive any defense and/or concede any issue of fact or law. If the claimant was alive at the earlier of the date on which the initial complaint was filed or the date the Trust Claim form was filed, the case will be treated as a personal injury case with all personal injury damages to be considered even if the claimant has died during the pendency of the claim.

**7.4 Payment of Judgments for Money Damages.** If and when a claimant obtains a judgment in the tort system, the claim shall be placed in the FIFO payment queue based on the date on which the judgment became final. Thereafter, the claimant shall receive from the Trust an initial payment (subject to the Payment Percentage, the Maximum Annual Payment, and Disease Category Claims Payment Ratio provisions set forth above) of an amount equal to one-hundred percent (100%) of the lesser of a) the jury award or b) the greater of (i) the Trust's last offer to the claimant or (ii) the award that the claimant declined in non-binding arbitration. The claimant shall receive the balance of the judgment, if any, in ten (10) equal installments in years six (6) through fifteen (15) following the year of the initial payment (also subject to the Payment Percentage, the Maximum Annual Payment, and Disease Category Claims Payment Ratio provisions set forth above). Under no circumstances shall interest be paid under otherwise applicable law on any judgments obtained in the tort system. The provisions of this Section 7.4

shall not apply to claim holders who pursue relief pursuant to the provisions of Section 5.11 above, as any payment to such claimholders is limited to the payment amount, if any, which such claimholders may be entitled to pursuant to Section 5.11(e).

**7.5 Releases.** The Trustees shall have the discretion, with the consent of the TAC and Futures Representative, to determine the form and substance of the releases to be provided to the Trust in order to maximize recovery for claimants against other tortfeasors without increasing the risk or amount of claims for indemnification or contribution from the Trust. The Release utilized by the Trust shall include all Personal Injury, Wrongful Death, and/or Derivative claims related to the Injured Party, with the exception of the Second Disease Claims, as described above in Section 5.8. As a condition to making any payment to a claimant, the Trust shall obtain a general, partial, limited, or other release as appropriate in accordance with the applicable state or other law. If allowed by state law, the endorsing of a check or draft for payment by or on behalf of a claimant shall constitute such a release.

**7.6 Third-Party Services.** Nothing in this TDP shall preclude the Trust from contracting with another asbestos claims resolution organization to provide services to the Trust so long as decisions about the categorization and liquidated value of Trust Claims are based on the relevant provisions of this TDP, including the Compensable Diseases, Matrix Values, Average Values, Maximum Values, and Medical/Exposure Criteria set forth in the Matrix.

**7.7 Trust Disclosure of Information.** Periodically, but not less often than once a year, the Trust shall make available to claimants and other beneficiaries, a statistical summary of the number of claims by Compensable Diseases that have been resolved by settlement, arbitration or trial by jurisdiction.

## SECTION VIII

### Miscellaneous

**8.1 Amendments.** Except as otherwise provided herein, the Trustees may amend, modify, delete, or add to any provisions of this TDP (including, without limitation, amendments to conform this TDP to advances in scientific or medical knowledge or other changes in circumstances), provided he or she first obtains the consent of the TAC and the Futures Representative pursuant to the Consent Process set forth in Sections 5.6 and 6.6 and, if necessary, Sections 5.7 and 6.7 of the Trust Agreement, except that the right to amend the Disease Category Claims Payment Ratio provisions set forth above) are governed by the restrictions in Section 2.5 above, and the right to adjust the Payment Percentage is governed by Section 4.2 above.

**8.2 Severability.** Should any provision contained in this TDP be determined to be unenforceable, such determination shall in no way limit or affect the enforceability and operative effect of any and all other provisions of this TDP. Should any provision contained in this TDP be determined to be inconsistent with or contrary to Thorpe's obligations to any insurance company providing insurance coverage to Thorpe in respect of claims for personal injury based on Thorpe Exposure, no payment shall be made by the Trust in respect of any such claim from proceeds from said insurance coverage.

**8.3 Governing Law.** This TDP shall be governed by, and construed in accordance with, the laws of the State Nevada and without regard to the conflict of laws principles of such State.

**8.4 Attorneys' Fees.** Attorneys' fees payable in connection with Trust claims paid through this TDP, whether based on hourly rates or where calculated as a percentage of recovery, shall be the lower of the fee provided in the contract between claimant and counsel or 25% of the

recovery, exclusive of costs chargeable to the claimant, which costs shall be deducted from the gross amount paid before computation of fees. This recovery shall be measured by the actual payments from the Trust to the claimant, not the liquidated value of the claim. Legal fees shall be paid as payments to claimants are made by the Trust.

**8.5 Exception in California.** The holder of an asbestos claim who is a citizen of the State of California has the option to name the Trust as a party defendant. However, the Trust shall not participate in the litigation and shall be removed from all service lists. No payment shall be made to such holder of an asbestos claim except as provided by the Matrix and the TDP. In the event a California citizen opts to name the Trust in an action commenced in a California state court, the Trust shall not consent to remove the action to any federal court and if requested to do so, shall provide a declaration that it did not consent to any removal.

## **EXHIBIT “D”**

### THIRD AMENDMENT TO AND COMPLETE RESTATEMENT OF J.T. THORPE CASE VALUATION MATRIX

The Case Valuation Matrix (“Matrix”) is designed to approximate historical settlement values in the tort system. To achieve this goal, historical settlement values were evaluated where J.T. Thorpe, Inc., a California corporation; J.T. Thorpe, Inc., a dissolved California corporation; Thorpe Holding Company, Inc., a California corporation; and Thorpe Technologies, Inc., a California corporation (collectively “Thorpe”), performed significant work and had a history of being sued and settling cases. Historical settlement values were adjusted to current settlement values using settlement data derived from other defendants who remained active in the tort system. Compensable diseases include mesothelioma, lung cancer, other cancers (as defined herein) and two grades of non-malignant asbestos-related disease. The Matrix establishes the minimum criteria which must be met in order to qualify in each disease category. Capitalized terms not defined herein shall have the meanings ascribed to them in the “J.T. Thorpe, Inc., a California corporation / J.T. Thorpe, Inc., a dissolved California corporation / Thorpe Holding Company, Inc., a California corporation / Thorpe Technologies, Inc., a California corporation Asbestos Personal Injury Settlement Trust Distribution Procedures.”

The following represents the average settlement values adjusted to current value (“Average Value”):

Mesothelioma	<u>\$ 150,000</u>
Lung Cancer	<u>\$ 40,000</u>
Other Cancer	<u>\$ 25,000</u>
Grade I Non-Malignancy	<u>\$ 10,000</u>
Grade II Non-Malignancy	<u>\$ 3,000</u>

The Matrix is designed to value cases using a base case value. This base case value is then increased and/or decreased by a series of adjustment factors that approximate factors which add or subtract value to cases in the tort system. The base case value has been set to yield (after application of the adjustment factors) average liquidation values, that are equal to the historical Average Value described above. The Base Case Values are:

Mesothelioma	<u>\$ 102,647</u>
Lung Cancer	<u>\$ 15,278</u>
Other Cancer	<u>\$ 8,496</u>
Grade I Non-Malignancy	<u>\$ 6,843</u>
Grade II Non-Malignancy	<u>\$ 2,374</u>

#### I. GENERAL CLAIM PROVISIONS

a. **Minimum and Maximum Values.** All claims after being valued at their respective base case value and any appropriate adjustments are subject to the following minimum and maximum values.

(i) **Minimum Value.** Any Injured Person who has submitted an approved claim under a Compensable Disease category and has submitted a Trust Claim form to the Trust with all required documentation as outlined in the Trust Distribution Plan and herein, will receive



a minimum of 10% of the Average Value of the claim for that disease in the controlling jurisdiction.

(ii) **Maximum Value.** Any Injured Person who has submitted an approved claim under a Compensable Disease category and has submitted a Trust Claim form to the Trust with all required documentation as outlined in the Trust Distribution Plan and herein, will receive a maximum of four times the Average Value of the claim for that disease in the controlling jurisdiction, unless it qualifies as an Extraordinary Claim as defined in Section IX of the Matrix.

b. **Medical Diagnoses.** Any diagnosis of pulmonary asbestosis shall be made by a (i) a Pathologist, who personally reviewed the Injured Person's pathology, or (ii) an Internist, Pulmonologist or Occupational Medicine Physician who actually examined the Injured Person. These findings will be contained in a detailed narrative written report of the examination. All medical diagnoses in the Matrix are required to be made by Board-Certified physicians in appropriate specialties to a level of reasonable medical probability. Specifically, medical reports that only come to a conclusion that findings are "consistent with" asbestos-related disease will not, standing alone, be sufficient to establish compliance with the medical criteria in the Matrix. Medical experts who are not Board-Certified but who meet equivalent medical experience and expertise requirements may be approved by the Trust with the consent of the Trust Advisory Committee ("TAC") and Futures Representative upon application by a Claimant.

c. **Record Review Exception.** Notwithstanding subsection (b) above, in the event that the Trust determines upon adequate showing under penalty of perjury that good cause exists to excuse either (1) personal review of Injured Person's pathology by a Pathologist; and/or (2) actual examination of the Injured Person by an Internist, Pulmonologist or Occupational Medicine Physician, the Trust in its exercise of discretion may permit those medical professionals to submit their diagnosis of pulmonary asbestosis on the basis of a review of the Injured Person's medical records ("Record Review Claim"), provided however, the Maximum Value for any such claim shall be the limit set in Section VIII for Individual Review. Examples of record review claims would be wrongful death actions where no pathology exists, or Injured Persons who are in such extremis or other circumstances exist that no such examination is practicable.

d. **Claimant's Burden to Submit Credible Reliable Claim Information.** Information submitted in support of a claim must comply with recognized medical standards (including but not limited to standards regarding equipment, testing methods, and procedures) and/or legal evidentiary and authenticity standards.

(i) While the Trust will not strictly apply rules of evidence, information provided in support of claims must be reliable and credible so that the Trust and, if needed, ADR neutrals are fully informed regarding the foundations for facts asserted in support of claims. The Trust normally will accept copies instead of authenticated copies of x-ray reports, laboratory tests, medical examinations, other medical records and reviews that otherwise comply with recognized medical and/or legal standards unless circumstances indicate that the copies of the and /or the tests, reports, or review are not authentic or are otherwise unreliable.

(ii) The Trust normally will accept copies instead of authenticated copies of deposition testimony, invoices, affidavits, business records, deck logs, military service records

(including leave records) or other credible indirect or secondary evidence in a form otherwise acceptable to the Trust that establishes an Injured Person's occupation, occupational history, business or other losses or the Injured Person's presence at a particular ship, facility, job site, building or buildings or location during a time period in which the asbestos-containing material for which Thorpe is responsible was present, unless circumstances show that the information being submitted is unreliable.

(iii) Examples of unreliable information include where the circumstances raise questions of authenticity of copies or where persons authoring or verifying facts offered in support of a claim lack direct knowledge of such facts but fail to reveal and describe what facts, and how and from what sources they learned those facts, they relied upon as the basis for their assertion of such facts. Under these circumstances, the Trust and any ADR neutrals shall apply the rules of evidence to exclude evidence where the witness or verifying party declines to provide such foundational information, e.g., on grounds that the information relied upon is privileged or confidential.

e. **Trust's Right to Require Additional Evidence.** The Trust may require the submission any other evidence to support or verify a Trust claim, including but not limited to additional exposure information, x-rays, laboratory tests, medical examinations or reviews, medical reports, or other medical evidence all of which must also meet the requirements of Section I (d) above.

f. **Conspiracy Theory Claims Prohibited.** Claims based on conspiracy theories that do not involve exposure to asbestos-containing materials installed or removed by Thorpe are not compensable under this Matrix.

## II. MESOTHELIOMA

a. **Base Case ("M").** The base case value for a Mesothelioma case is referred to in this Agreement as "M". A case will be considered a base case Mesothelioma under this Matrix when it satisfies each of the following criteria:

(i) **Diagnosis.** Injured Person diagnosed with malignant Mesothelioma by a Pathologist, Internist, Pulmonologist or Occupational Medicine Physician.

(ii) **Litigation.** Injured Person deceased at commencement of litigation or the time of filing of proof of claim, whichever is earlier;

(iii) **Age.** Injured Person was 75 years old at death;

(iv) **Dependents.** Injured Person had a spouse and no other dependents or minor children at time of death;

(v) **Economic Loss (excluding medical and funeral expenses).** Injured Person's loss of earnings, pension, social security and home services total up to \$238,825, as adjusted annually (the "Applicable Economic Loss Threshold");

(vi) **Medical and Funeral Expenses.** Injured Person's medical and funeral expenses total up to \$265,764, as adjusted annually (the "Applicable Medical Expense Threshold");

(vii) **Exposure.** Injured Person had Standard Exposure to asbestos-containing products for which Thorpe is liable at traditional jobsites including shipyards, refineries, power plants or other sites, as defined in section VII(b);

(viii) **Latency.** The Injured Person had at least a 10-year latency period between the date of the first exposure to asbestos and the date of diagnosis of the disease.

b. **Adjustments.** Certain features of a Mesothelioma case will warrant an adjustment in the liquidated value either above or below the base case Mesothelioma value, as set forth herein. The following adjustments are provided as multipliers of the base case value M. For example, an adjustment of 1.3 M for a Living 55-year-old mesothelioma Injured Person indicates that such an Injured Person would receive 1.3 times the base case Mesothelioma value. In situations where numerous adjustments are required for an Injured Person's case, all of the applicable adjustment multipliers shall be multiplied together, and times the base case value M, to determine the liquidated value of the case. For example, an Injured Person who is age 55 (1.3 M) and alive at the commencement of litigation or the time of filing of proof of claim, whichever is earlier (1.3 M), and who had exposure at what is known to be a high exposure site (1.5 M), would be eligible for a liquidated value of 1.3 times 1.3 times 1.5 or 2.535 M times the base case value.

(i) **Age.** Age shall be determined as of the commencement of litigation or the time of filing of the proof of claim, whichever is earlier. The adjustment factor for age shall be decreased .015 for every year over 75 years of age up to a maximum downward adjustment to .7 M, and shall be increased .015 for every year under 75 years of age up to a maximum upward adjustment to 1.4 M.

(ii) **Exposure.** The following adjustments are based on exposure at traditional jobsites including shipyards, refineries, power plants or other sites, as defined in section VII(b):

<b>Exposure Rating</b>	<b>Adjustment</b>
High Exposure Sites or jobtypes, as defined in Section VII(c)	2.0 M
Standard Exposure Sites, as defined in Section VII(c)	1.0 M
Low Exposure Sites, as defined in Section VII(c)	0.5 M

(iii) **Living/Deceased.** If an Injured Person is living as of the date litigation commences or the proof of claim is filed, whichever is earlier, the Injured Person's case will be adjusted by 1.3 M.

(iv) **Dependents.** If an Injured Person does not have a spouse as of the date litigation commences or the proof of claim is filed, whichever is earlier, the Injured Person's case will be adjusted by .8 M. Separately and in addition, if an Injured Person has minor children, adult disabled dependent children or dependent minor grandchildren living with the Injured Person at the time of diagnosis, the Injured Person's case will be adjusted by 1.5 M.

(v) **Total Economic Loss (excluding medical and funeral expenses).** Where the

Injured Person has or will incur economic loss for loss of earnings, pension, social security and home services in an amount greater than the Applicable Economic Loss Threshold, case value shall be adjusted upward .001 M for every \$1,194 (the Index Interval, also to be adjusted annually) of economic loss over the Applicable Economic Loss Threshold, up to a maximum adjustment to 2 M. All claimed economic loss over the Applicable Economic Loss Threshold must be supported by adequate documentation. The Applicable Economic Loss Threshold and Index Interval shall be adjusted each year in accordance with the Federal Bureau of Labor Statistics' Consumer Price Index for Urban Wage Earners and Clerical Workers published in January of each year beginning in January of 2018. The Applicable Economic Loss Threshold and Index Interval shall be the amounts in effect at the time an offer is issued by the Trust. Annual adjusted amounts will be published on the Trust's Web site each February and applied to all pending claims which do not have an outstanding offer issued.

(vi) **Medical and Funeral Expenses.** Where the Injured Person has or will incur medical and funeral expenses in an amount greater than the Applicable Medical Expense Threshold, case value shall be adjusted upward .001 M for every \$1,329 (the Index Interval, also to be adjusted annually) of medical and funeral expenses over the Applicable Medical Expense Threshold, up to a maximum adjustment to 2 M. All claimed medical and funeral expenses over the Applicable Medical Expense Threshold must be supported by adequate documentation. Standard future medical expenses are presumed to be \$99,662, as adjusted annually (the "Applicable Future Amount"). Future medical expenses exceeding the Applicable Future Amount require documentation supported by affidavit. The Applicable Medical Expense Threshold, Index Interval and Applicable Future Amount shall be adjusted each year in accordance with the Federal Bureau of Labor Statistics' Consumer Price Index for Medical Care published in January of each year beginning in January of 2018. The Applicable Medical Expense Threshold, Index Interval and Applicable Future Amount shall be the amounts in effect at the time an offer is issued by the Trust. Annual adjusted amounts will be published on the Trust's Web site each February and applied to all pending claims which do not have an outstanding offer issued.

### III. LUNG CANCER

a. **Base Case** ("LC"). The base case value for a Lung Cancer case is referred to in this Agreement as "LC". A case will be considered a base case Lung Cancer under this Matrix when it satisfies each of the following criteria:

(i) **Diagnosis.** Injured Person diagnosed with primary lung cancer by a Pathologist, Internist, Pulmonologist or Occupational Medicine Physician, and

(ii) **Litigation.** Injured Person deceased at time of commencement of litigation or the time of filing of the proof of claim, whichever is earlier;

(iii) **Age.** Injured Person was 75 years old at death;

(iv) **Dependents.** Injured Person had a spouse and no other dependents or minor children at time of death;

(v) **Economic Loss (excluding medical and funeral expenses).** Injured Person's loss of earnings, pension, social security and home services total up to \$238,825, as adjusted

annually (the “Applicable Economic Loss Threshold”);

(vi) **Medical and Funeral Expenses.** Injured Person’s medical and funeral expenses total up to \$265,764, as adjusted annually (the “Applicable Medical Expense Threshold”);

(vii) **Exposure.** Injured Person had Standard Exposure to asbestos-containing products for which Thorpe is liable at traditional jobsites including shipyards, refineries, power plants or other sites, as defined in section VII(b);

(viii) **Smoking-Pack years.** Injured Person had a 20-80 pack-year history of smoking;

(ix) **Smoking Duration.** Injured Person was still smoking at the time of diagnosis, or had quit smoking fewer than 10 years before diagnosis;

(x) **Medical Causation.** Injured Person had been not diagnosed with clinical or pathological asbestosis, but Injured Person had both:

(A) A reliable history of exposure to asbestos; and

(B) Evidence of asbestos-related anatomical changes, such as: asbestos-related pleural disease, chest X-ray abnormalities graded 1/0 or higher on the ILO scale attributed to prior asbestos exposure, or computed tomography (CT) evidence of interstitial disease attributed to prior asbestos exposure; and

(xi) **Latency.** The Injured Person had at least a 10-year latency period between the date of the first exposure to asbestos and the date of diagnosis of the disease.

b. **Adjustments.** Certain features of a Lung Cancer case will warrant an adjustment in the liquidated value either above or below the base case Lung Cancer value, as set forth herein. The following adjustments are provided as multipliers of the base case value LC. For example, an adjustment of 1.3 LC for a living 55-year-old lung cancer Injured Person **indicates that such an Injured Person would receive 1.3 times the base case Lung Cancer value.** In situations where numerous adjustments are required for an Injured Person’s case, all of the applicable adjustment multipliers shall be multiplied together, and times the base case value LC, to determine the liquidated value of the case. For example, an Injured Person who is age 55 (1.3 LC) and alive at the commencement of litigation or the time of filing of proof of claim, whichever is earlier (1.3 LC), and who had exposure at what is known to be a high exposure site (1.5 LC), would be eligible for a liquidated value of 1.3 times 1.3 times 1.5 or 2.535 LC times the base case value.

(i) **Age.** Age shall be determined as of the commencement of litigation or the time of filing of the proof of claim, whichever is earlier. The adjustment factor for age shall be decreased .015 for every year over 75 years of age up to a maximum downward adjustment to .7 LC, and shall be increased .015 for every year under 75 years of age up to a maximum upward adjustment to 1.4 LC.

(ii) **Exposure.** The following adjustments are based on exposure at traditional

jobsites including shipyards, refineries, power plants, or other sites as defined in section VII(b):

<b>Exposure Rating</b>	<b>Adjustment</b>
High Exposure Sites or jobtypes, as defined in Section VII(c)	2.0 LC
Standard Exposure Sites, as defined in Section VII(c)	1.0 LC
Low Exposure Sites, as defined in Section VII(c)	0.5 LC

(iii) **Living/Deceased.** If an Injured Person is living as of the date litigation commences or the proof of claim is filed, whichever is earlier, the Injured Person's case will be adjusted by 1.3 LC.

(iv) **Dependents.** If an Injured Person does not have a spouse as of the date litigation commences or the proof of claim is filed, whichever is earlier, the Injured Person's case will be adjusted by .8 LC. Separately and in addition, if an Injured Person has minor children, adult disabled dependent children or dependent minor grandchildren living with the Injured Person at the time of diagnosis, the Injured Person's case will be adjusted by 1.5 LC.

(v) **Total Economic Loss (excluding medical and funeral expenses).** Where the Injured Person has or will incur economic loss for loss of earnings, pension, social security and home services in an amount greater than the Applicable Economic Loss Threshold, case value shall be adjusted upward .001 LC for every \$1,194 (the Index Interval, also to be adjusted annually) of economic loss over the Applicable Economic Loss Threshold, up to a maximum adjustment to 2 LC. All claimed economic loss over the Applicable Economic Loss Threshold must be supported by adequate documentation. The Applicable Economic Loss Threshold and Index Interval shall be adjusted each year in accordance with the Federal Bureau of Labor Statistics' Consumer Price Index for Urban Wage Earners and Clerical Workers published in January of each year beginning in January of 2018. The Applicable Economic Loss Threshold and Index Interval shall be the amounts in effect at the time an offer is issued by the Trust. Annual adjusted amounts will be published on the Trust's Web site each February and applied to all pending claims which do not have an outstanding offer issued.

(vi) **Medical and Funeral Expenses.** Where the Injured Person has or will incur medical and funeral expenses in an amount greater than the Applicable Medical Expense Threshold, case value shall be adjusted upward .001 LC for every \$1,329 (the Index Interval, also to be adjusted annually) of medical and funeral expenses over the Applicable Medical Expense Threshold, up to a maximum adjustment to 2 LC. All claimed medical and funeral expenses over the Applicable Medical Expense Threshold must be supported by adequate documentation. Standard future medical expenses are presumed to be \$99,662, as adjusted annually (the "Applicable Future Amount"). Future medical expenses exceeding the Applicable Future Amount require documentation supported by affidavit. The Applicable Medical Expense Threshold, Index Interval and Applicable Future Amount shall be adjusted each year in accordance with the Federal Bureau of Labor Statistics' Consumer Price Index for Medical Care published in January of each year beginning in January of 2018. The Applicable Medical Expense Threshold, Index Interval and Applicable Future Amount shall be the amounts in effect at the time an offer is issued by the

Trust. Annual adjusted amounts will be published on the Trust’s Web site each February and applied to all pending claims which do not have an outstanding offer issued.

(vii) **Medical Causation.** The following adjustments apply to Injured Persons who have different smoking histories and/or medical findings from those described for the base Lung Cancer case. In no event can any of the adjustments listed below be combined for an overall causation adjustment in excess of 3.0 LC.

<b>Causation Information</b>	<b>Adjustment</b>
Pathological diagnosis of asbestosis, or occupational levels of asbestos bodies or asbestos fibers in lung tissue	2.0 LC
Clinical diagnosis of asbestosis (in absence of pathological diagnosis)	1.5 LC
 <b>Causation Information</b>	
<b>Adjustment</b>	
No radiographic evidence of asbestos exposure and no increased fiber burden as a marker of asbestos exposure (Applicable to smokers only)	0.5 LC
Lifetime non-smoker	2.0 LC
1-20 pack-years of smoking	1.2 LC
Over 80 pack-years of smoking	0.6 LC
Diagnosis over 10 years since Injured Person quit smoking	1.2 LC
Diagnosis over 15 years since Injured Person quit smoking	1.5 LC

#### **IV. OTHER CANCER**

a. **Base Case** (“OCA”). The base case value for an Other Cancer case is referred to in this Agreement as “OCA”. A case will be considered a base case Other Cancer under this Matrix when it satisfies each of the following criteria:

(i) **Diagnosis.** Injured Person diagnosed with laryngeal, esophageal, kidney, colorectal cancer, non-Hodgkin’s lymphoma or chronic lymphocytic leukemia by a Pathologist, Internist, Pulmonologist or Occupational Medicine Physician.

(ii) **Litigation.** Injured Person deceased at commencement of litigation or the time of filing of proof of claim, whichever is earlier;

(iii) **Age.** Injured Person was 75 years old at death;

(iv) **Dependents.** Injured Person had a spouse and no other dependents or minor children at time of death;

(v) **Economic Loss (excluding medial and funeral expenses).** Injured Person's loss of earnings, pension, social security and home services total up to \$238,825, as adjusted annually (the "Applicable Economic Loss Threshold");

(vi) **Medical and Funeral Expenses.** Injured Person's medical and funeral expenses total up to \$265,764, as adjusted annually (the "Applicable Medical Expense Threshold");

(vii) **Exposure.** Injured Person had Standard Exposure to asbestos-containing products for which Thorpe is liable at traditional jobsites including shipyards, refineries, power plants or other sites, as defined in section VII(b);

(viii) **Smoking-Pack years.** Injured Person had a 20-80 pack-year history of smoking;

(ix) **Smoking Duration.** Injured Person was still smoking at the time of diagnosis, or had quit smoking fewer than 10 years before diagnosis;

(x) **Medical Causation.** Injured Person not diagnosed with clinical or pathological asbestosis, but Injured Person had both:

(A) A reliable history of exposure to asbestos, and

(B) Evidence of asbestos-related anatomical changes, such as: asbestos-related pleural disease chest X-ray abnormalities graded 1/0 or higher attributed to prior asbestos exposure on the ILO scale, or computed tomography (CT) evidence of interstitial disease attributed to prior asbestos exposure; and

(xi) **Latency.** The Injured Person had at least a 10-year latency period between the date of the first exposure to asbestos and the date of manifestation of the disease.

b. **Adjustments.** Certain features of an Other Cancer case will warrant an adjustment in the liquidated value either above or below the base case Other Cancer value, as set forth herein. The following adjustments are provided as multipliers of the base case value OCA. For example, an adjustment of 1.3 OCA for a living 55-year-old other cancer Injured Person indicates that such an Injured Person would receive 1.3 times the base case Other Cancer value. In situations where numerous adjustments are required for an Injured Person's case, all of the applicable adjustment multipliers shall be multiplied together and times the base case value OCA, to determine the liquidated value of the case. For example, an Injured Person who is age 55 (1.3 OCA) and alive at the commencement of litigation or the time of filing of proof of claim, whichever is earlier (1.3 OCA), and who had exposure at what is known to be a high exposure site (1.5 OCA), would be eligible for a liquidated value of 1.3 times 1.3 times 1.5 or 2.535 OCA times the base case value.

(i) **Age.** Age shall be determined as of the commencement of litigation or the time of filing of the proof of claim, whichever is earlier. The adjustment factor for age shall be decreased .015 for every year over 75 years of age up to a maximum downward adjustment to .7 OCA, and shall be increased .015 for every year under 75 years of age up to a maximum upward



adjustment to 1.4 OCA.

(ii) **Exposure.** The following adjustments are based on exposure at traditional jobsites including shipyards, refineries, power plants or other sites, as defined in section VII(b):

<b>Exposure Rating</b>	<b>Adjustment</b>
High Exposure Sites or jobtypes, as defined in Section VII(c)	2.0 OCA
Standard Exposure Sites, as defined in Section VII(c)	1.0 OCA
Low Exposure Sites, as defined in Section VII(c)	0.5 OCA

(iii) **Living/Deceased.** If an Injured Person is living as of the date litigation commences or the proof of claim is filed, whichever is earlier, the Injured Person's case will be adjusted by 1.3 OCA.

(iv) **Dependents.** If an Injured Person does not have a spouse as of the date litigation commences or the proof of claim is filed, whichever is earlier, the Injured Person's case will be adjusted by .8 OCA. Separately and in addition, if an Injured Person has minor children, adult disabled dependent children or dependent minor grandchildren living with the Injured Person at the time of diagnosis, the Injured Person's case will be adjusted by 1.5 OCA.

(v) **Total Economic Loss (excluding medical and funeral expenses).** Where the Injured Person has or will incur economic loss for loss of earnings, pension, social security and home services in an amount greater than the Applicable Economic Loss Threshold, case value shall be adjusted upward .001 OCA for every \$1,194 (the Index Interval, also to be adjusted annually) of economic loss over the Applicable Economic Loss Threshold, up to a maximum adjustment to 2 OCA. All claimed economic loss over the Applicable Economic Loss Threshold must be supported by adequate documentation. The Applicable Economic Loss Threshold and Index Interval shall be adjusted each year in accordance with the Federal Bureau of Labor Statistics' Consumer Price Index for Urban Wage Earners and Clerical Workers published in January of each year beginning in January of 2018. The Applicable Economic Loss Threshold and Index Interval shall be the amounts in effect at the time an offer is issued by the Trust. Annual adjusted amounts will be published on the Trust's Web site each February and applied to all pending claims which do not have an outstanding offer issued.

(vi) **Medical and Funeral Expenses.** Where the Injured Person has or will incur medical and funeral expenses in an amount greater than the Applicable Medical Expense Threshold, case value shall be adjusted upward .001 OCA for every \$1,329 (the Index Interval, also to be adjusted annually) of medical and funeral expenses over the Applicable Medical Expense Threshold, up to a maximum adjustment to 2 OCA. All claimed medical and funeral expenses over the Applicable Medical Expense Threshold must be supported by adequate documentation. Standard future medical expenses are presumed to be \$99,662, as adjusted annually (the "Applicable Future Amount"). Future medical expenses exceeding the Applicable Future Amount require documentation supported by affidavit. The Applicable Medical Expense Threshold, Index

Interval and Applicable Future Amount shall be adjusted each year in accordance with the Federal Bureau of Labor Statistics’ Consumer Price Index for Medical Care published in January of each year beginning in January of 2018. The Applicable Medical Expense Threshold, Index Interval and Applicable Future Amount shall be the amounts in effect at the time an offer is issued by the Trust. Annual adjusted amounts will be published on the Trust’s Web site each February and applied to all pending claims which do not have an outstanding offer issued.

(vii) **Medical Causation.** The following adjustments apply to Injured Persons who have different smoking histories and/or medical findings from those described for the base Other Cancer case. In no event can any of the adjustments listed below be combined for an overall causation adjustment in excess of 3.0 OCA.

<b>Causation Information</b>	<b>Adjustment</b>
Pathological diagnosis of asbestosis, or occupational levels of asbestos bodies or asbestos fibers in lung tissue	2.0 OCA
Clinical diagnosis of asbestosis (in absence of pathological diagnosis)	1.5 OCA
No radiographic evidence of asbestos exposure and no increased fiber burden as a marker of asbestos exposure	0.25 OCA
Lifetime non-smoker	2.0 OCA
1-20 pack-years of smoking	1.2 OCA
Over 80 pack-years of smoking	0.6 OCA
<b>Causation Information</b>	<b>Adjustment</b>
Diagnosis over 10 years since Injured Person quit smoking	1.2 OCA
Diagnosis over 15 years since Injured Person quit smoking	1.5 OCA

(viii) **Other Organ Cancers.** An Injured Person who has not been diagnosed with cancers of the organs described for the base Other Cancer case (i.e., laryngeal, esophageal, kidney, colo-rectal cancers, non-Hodgkin’s lymphoma and chronic lymphocytic leukemia) may still obtain compensation under this Matrix, if the Injured Person has been diagnosed with a primary cancer of a different organ and a Board-Certified specialist in an appropriate specialty or a Board-Certified occupational medicine physician at the time of the report attributes the malignancy to prior asbestos exposure. An Injured Person’s case which meets the criteria set forth above, subject to the Trust’s consent, shall be classified as an "Other Organ Cancer" and will be adjusted by .5 OCA.

## V. GRADE I NON-MALIGNANCY

a. **Base Case (“I”).** The base case value for an Grade I Non-malignancy case is referred to in this Matrix as “I”. A case will be considered a base case Grade I Non-malignancy under this Matrix when it satisfies each of the following criteria:

(i) **Age.** Injured Person is 75 years old;

(ii) **Dependents.** Injured Person has a spouse and no other dependents or minor children;

(iii) **Economic Loss (excluding medical and funeral expenses).** Injured Person's loss of earnings, pension, social security and home services total up to \$238,825, as adjusted annually (the "Applicable Economic Loss Threshold");

(iv) **Medical and Funeral Expenses.** Injured Person's medical and funeral expenses total up to \$265,764, as adjusted annually (the "Applicable Medical Expense Threshold");

(v) **Exposure.** Injured Person had Standard Exposure to asbestos-containing products at traditional jobsites including shipyards, refineries, power plants or other sites, as defined in section VII(b);

(vi) **Medical Causation.** Injured Person satisfies all the following criteria of interstitial lung disease with impairment of lung function:

1. The Injured Person must establish at least a 10-year latency period between the date of the first exposure to asbestos and the date of diagnosis of the disease, and clinical evidence of asbestosis defined in subsection 2;

2. Clinical Evidence of Asbestosis. A diagnosis of pulmonary asbestosis by a Pulmonologist, Internist or Occupational Medicine Physician who actually examined the Injured Person based on the following minimum objective criteria:

(a) Chest X-rays which, in the opinion of a Certified B-reader, show small irregular opacities of ILO Grade 1/0 or greater, or a report from a Pulmonologist, Internist or Occupational Medicine Physician that the Injured Person has evidence of asbestos-related interstitial fibrosis on high resolution CT scan; and

(b) Pulmonary Function Testing results demonstrating either:

1)  $FVC < 80\%$  of Predicted Value with  $FEV-1/FVC \geq 65\%$  (actual value) if the individual tested is at least 70 years old at the date of testing,  $\geq 70\%$  (actual value) if the individual tested is at least 60 years old but less than 70 years old at the date of testing, and  $\geq 75\%$  (actual value) if the individual tested is less than 60 years old at the date of testing; or

2)  $TLC < 80\%$  of Predicted Value; or

3)  $DLCO < 75\%$  of Predicted Value with  $FEV-1/FVC \geq 65\%$  (actual value) if the individual tested is at least 70 years old at the date of testing,  $\geq 70\%$  (actual value) if the individual tested is at least 60 years old but less than 70 years old at the date of testing, and  $\geq 75\%$  (actual value) if the individual tested is less than 60 years old at the date

of testing and a statement by a Pulmonologist or an Occupational Medicine Physician stating that the asbestos-related lung disease is the probable explanation for the test result.

3. Those claims wherein the Injured Person suffers from extensive disabling asbestos-related pleural disease may be submitted to the Individual Review process, as described in Section VIII of this Matrix, provided however such a claim shall not be limited to Average Value and may be awarded up to the Maximum Value for Grade I.

b. **Adjustments.** Certain features of a Grade I Non-malignancy Case will warrant an adjustment in the liquidated value either above or below the base case Grade I Non-malignancy value, as set forth herein. The following adjustments are provided as multipliers of the base case value I. For example, an adjustment of 1.3 I for a 55-year-old Grade I non-malignancy Injured Person indicates that such an Injured Person would receive 1.3 times the base case Grade I Non-malignancy value. In situations where numerous adjustments are required for an Injured Person's case, all of the applicable adjustment multipliers shall be multiplied together and times the base case value I, to determine the liquidated value of the case. For example, an Injured Person who is age 55 (1.3 I) and determined to be an Enhanced Grade I non-malignancy Injured Person as defined in section (vi) herein (1.5 I) and who had exposure at what is known to be a high exposure site (1.5 I), would be eligible for a liquidated value of 1.3 times 1.5 times 1.5, or 2.925 I, times the base case value.

(i) **Age.** Age shall be determined as of the commencement of litigation or the time of filing of the proof of claim, whichever is earlier. The adjustment factor for age shall be decreased .015 for every year over 75 years of age up to a maximum downward adjustment to .7 I, and shall be increased .015 for every year under 75 years of age up to a maximum upward adjustment to 1.4 I.

(ii) **Exposure.** The following adjustments are based on exposure at traditional jobsites including shipyards, refineries, power plants or other sites, as defined in section VII(b):

<b>Exposure Rating</b>	<b>Adjustment</b>
High Exposure Sites or jobtypes, as defined in Section VII(c)	2.0 I
Standard Exposure Sites, as defined in Section VII(c)	1.0 I
Low Exposure Sites, as defined in Section VII(c)	0.5 I

(iii) **Dependents.** If an Injured Person does not have a spouse as of the date litigation commences or the proof of claim is filed, whichever is earlier, the Injured Person's case will be adjusted by .8 I. Separately and in addition, if an Injured Person has minor children, adult disabled dependent children or dependent minor grandchildren living with the Injured Person at the time of diagnosis, the Injured Person's case will be adjusted by 1.5 I.

(iv) **Total Economic Loss (excluding medical and funeral expenses).** Where the Injured Person has or will incur economic loss for loss of earnings, pension, social security and home services in an amount greater than the Applicable Economic Loss Threshold, case value

shall be adjusted upward .001 I for every \$1,194 (the Index Interval, also to be adjusted annually) of economic loss over the Applicable Economic Loss Threshold, up to a maximum adjustment to 2 I. All claimed economic loss over the Applicable Economic Loss Threshold must be supported by adequate documentation. The Applicable Economic Loss Threshold and Index Interval shall be adjusted each year in accordance with the Federal Bureau of Labor Statistics' Consumer Price Index for Urban Wage Earners and Clerical Workers published in January of each year beginning in January of 2018. The Applicable Economic Loss Threshold and Index Interval shall be the amounts in effect at the time an offer is issued by the Trust. Annual adjusted amounts will be published on the Trust's Web site each February and applied to all pending claims which do not have an outstanding offer issued.

(v) **Medical and Funeral Expenses.** Where the Injured Person has or will incur medical and funeral expenses in an amount greater than the Applicable Medical Expense Threshold, case value shall be adjusted upward .001 I for every \$1,329 (the Index Interval, also to be adjusted annually) of medical and funeral expenses over the Applicable Medical Expense Threshold, up to a maximum adjustment to 2 I. All claimed medical and funeral expenses over the Applicable Medical Expense Threshold must be supported by adequate documentation. Standard future medical expenses are presumed to be \$99,662, as adjusted annually (the "Applicable Future Amount"). Future medical expenses exceeding the Applicable Future Amount require documentation supported by affidavit. The Applicable Medical Expense Threshold, Index Interval and Applicable Future Amount shall be adjusted each year in accordance with the Federal Bureau of Labor Statistics' Consumer Price Index for Medical Care published in January of each year beginning in January of 2018. The Applicable Medical Expense Threshold, Index Interval and Applicable Future Amount shall be the amounts in effect at the time an offer is issued by the Trust. Annual adjusted amounts will be published on the Trust's Web site each February and applied to all pending claims which do not have an outstanding offer issued.

(vi) **Enhanced Grade I Non-Malignancy.** If an Injured Person has evidence of asbestosis of a severity exceeding the following criteria, the liquidated value of that Injured Person's case will be adjusted by 1.5 I.

1. The Injured Person must establish at least a 10-year latency period between the date of first exposure to asbestos and the date of manifestation of the disease, and either clinical or pathological evidence of asbestosis as defined in subsection 2 or 3;

2. Clinical Evidence of Asbestosis. A diagnosis of pulmonary asbestosis by an Internist, Pulmonologist or an Occupational Medicine Physician who actually examined the Injured Person based on the following minimum objective criteria:

Chest X-rays which, in the opinion of a Certified B-reader, show small irregular opacities of ILO Grade 1/1 or greater, or an asbestos-related interstitial fibrosis on high resolution CT scan; and Pulmonary Function Testing results demonstrating either:

a)  $FVC < 60\%$  of Predicted Value with  $FEV-1/FVC \geq 65\%$  9 (actual value) if the individual tested is at least 70 years old at the date of testing,  $\geq 70\%$  (actual value) if the individual tested is at least 60 years old but less than 70 years old at the date of testing, and  $\geq 75\%$  (actual value) if the individual tested is less than 60 years old at the date of testing; or

b) TLC<70% of Predicted Value; or

c) DLCO<60% of Predicted Value with FEV-1/FVC $\geq$ 65% (actual value) if the individual tested is at least 70 years old at the date of testing,  $\geq$ 70% (actual value) if the individual tested is at least 60 years old but less than 70 years old at the date of testing, and  $\geq$ 75% (actual value) if the individual tested is less than 60 years old at the date of testing and a statement by a Pulmonologist or an Occupational Medicine Physician stating that the asbestos-related lung disease is the probable explanation for the test result.; or,

d) VO MAX<20mL (kg•min) or<5.7 METS with FEV-1/FVC $\geq$ 65% (actual value) if the individual tested is at least 70 years old at the date of testing,  $\geq$ 70% (actual value) if the individual tested is at least 60 years old but less than 70 years old at the date of testing, and  $\geq$ 75% (actual value) if the individual tested is less than 60 years old at the date of testing and a statement by a Pulmonologist or an Occupational Medicine Physician stating that the asbestos-related lung disease is the probable explanation for the test result.

3. Pathological Evidence of Asbestosis. A statement by a Pathologist, Pulmonologist or an Occupational Medicine Physician that a representative section of lung tissue demonstrates asbestosis as defined by the 1982 report of the Pneumoconiosis Committee of the College of American Pathologists and the National Institute for Occupational Safety and Health including the "demonstration of discrete foci of fibrosis in the walls of respiratory bronchioles associated with accumulations of asbestos bodies", and also that there is no more probable explanation for the presence of the fibrosis than prior asbestos exposure.

(vii) **“Serious asbestosis”** is

1. Asbestosis with ILO 2/2 or greater and AMA Class IV Impairment.

Or

2. Where the Injured Person is “On Oxygen” and otherwise meets the requirements of subsections i, ii, or iii, below.

i. Injured Person has a diagnosis of asbestosis, has pulmonary function test results qualifying as Grade I, and a Pulmonologist or Occupational Medicine physician states that a contributing cause for the use of oxygen is asbestosis. Claim will be valued as a matrix claim even if there are other contributing causes listed for the need for oxygen.

ii. Injured Person has a diagnosis of asbestosis, but does not have pulmonary function test results qualifying as Grade I. Even though a Pulmonologist or Occupational Medicine physician states that the predominant cause or contributing cause for use of oxygen is asbestosis, claim a) will be valued under Individual Review and subject to the Individual Review process as described in Section VIII of the Matrix and b) if there are other contributing causes, the Trust will give equal weight to each cause for the need to be on oxygen.

- iii. Injured Person has diagnosis of asbestosis, treating physician board certified in pulmonology or occupational medicine prescribes oxygen to the Injured Party, and the treating physician states the predominant need for oxygen is asbestosis. Regardless of the existence of other contributing causes for the need to be on oxygen, claim will be valued as a matrix claim.

“On Oxygen” means oxygen needed to perform activities of daily life, e.g., not oxygen that is prescribed only for comfort care, at night, for surgery, or on occasion.

Or

3. Asbestosis death” is where asbestosis is listed as the cause or a significant contributing cause of death on the death certificate, or where a report from a Pathologist, Pulmonologist, or and Occupational Medicine Physician states that asbestosis was a significant contributing cause of death. If and Injured Person has evidence of serious asbestosis or asbestosis death, and exposure to (debtor) products or conduct was a substantial contributing cause of the serious asbestosis or asbestosis death, then the valuation criteria for lung cancer, including the base Lung Cancer case, as defined in (II)(a), shall be utilized to determine the value of the claims.

## VI. GRADE II NON-MALIGNANCY

a. **Base Case** (“II”). The base case value for a Grade II Non-malignancy case is referred to in this Matrix as “II”. A case will be considered a base case Grade II Non-malignancy under this Matrix when it satisfies each of the following criteria:

(i) **Age.** Injured Person is 75 years old;

(ii) **Exposure.** Injured Person had Standard Exposure to asbestos for which Thorpe is liable at traditional jobsites including shipyards, refineries, power plants or other sites, as defined in section VII(b);

(iii) **Medical Causation.** Injured Person satisfies the following criteria for asbestos-related disease:

1. The Injured Person must establish at least a 10-year latency period between the date of the first exposure to asbestos and the date of diagnosis of the disease; and

2. The Injured Person must establish evidence of an asbestos-related disease including:

- a) Clinical Evidence of Asbestosis. A diagnosis of pulmonary asbestosis by an Internist, Pulmonologist or qualified Occupational Medicine Physician who actually examined the Injured Person based on the following minimum objective criteria:

1) Chest X-rays which, in the opinion of a Certified B-reader, show small irregular opacities of ILO Grade 1/0 or greater, or

2) Asbestos-related interstitial fibrosis on high resolution CT scan or appropriate diagnostic imaging procedure; or

b) Clinical Evidence of Asbestos-Related Pleural Disease. A diagnosis of asbestos-related pleural disease by an Internist, Pulmonologist or Occupational Medicine Physician.

b. **Adjustments.** Certain features of a Grade II Non-malignancy case will warrant an adjustment in the liquidated value either above or below the base Grade II Non-malignancy value, as set forth herein. The following adjustments are provided as multipliers of the base case value II. For example, an adjustment of 1.3 II for a 55-year-old Grade II non-malignancy Injured Person indicates that such an Injured Person would receive 1.3 times the base case Grade II Non-malignancy value. In situations where numerous adjustments are required for an Injured Person's case, all of the applicable adjustment multipliers shall be multiplied together and times the base case value II, to determine the liquidated value of the case. For example, an Injured Person who is age 55 (1.3 II) and who had exposure at what is known to be a high exposure site (1.5 II), would be eligible for a liquidated value of 1.3 times 1.5, or 1.95 II, times the base case value.

(i) **Age.** Age shall be determined as of the commencement of litigation or the time of filing of the proof of claim, whichever is earlier. The adjustment factor for age shall be decreased .015 for every year over 75 years of age up to a maximum downward adjustment to .7 II, and shall be increased .015 for every year under 75 years of age up to a maximum upward adjustment to 1.4 II.

(ii) **Exposure.** The following adjustments are based on exposure at traditional jobsites including shipyards, refineries, power plants or other sites, as defined in section VII(b):

<b>Exposure Rating</b>	<b>Adjustment</b>
High Exposure Sites or jobtypes, as defined in Section VII(c)	2.0 II
Standard Exposure Sites, as defined in Section VII(c)	1.0 II
Low Exposure Sites, as defined in Section VII(c)	0.5 II

## VII. EXPOSURE REQUIREMENTS

a. **Standard Exposure Criteria.** Subject to Section 6.2 of the Trust Distribution Procedures, exposure to asbestos-containing material for which Thorpe is responsible can be established by evidence described in Section I (d) and (e) above. Claimant must demonstrate the Injured Party had reasonable proximity to work performed by Thorpe. The Trust shall have the right to consider all other appropriate evidence of exposure and may establish appropriate alternative exposure criteria after consultation with the TAC and the Futures Representative. The burden shall be on the Claimant or Injured Person to establish exposure to Thorpe products by



credible reliable evidence.

b. **Site List/Traditional jobsites.** The Trust in consultation with the TAC will compile a list of the ships, facilities and other locations where Thorpe performed installation or removal of asbestos-containing materials for which Thorpe is liable. The Trust may use this list to establish and to characterize exposure and to create a list of sites where exposure is accepted. The Trust with consent of the TAC and Futures Representative may modify the list in light of additional evidence or experience with claims processing. Any Injured Person may submit additional evidence to establish Thorpe's presence at a site, or in support of a higher exposure categorization of a particular site.

c. **Exposure Site Rating and High Exposure Jobtypes.**

1. **High Exposure Sites.** Sites rated "High" include exposures to asbestos at shipyards, refineries, power plants and other industrial and commercial sites where Thorpe was determined by the Trust to have performed 50 or more distinct contracts or jobs installing or removing asbestos-containing material for which Thorpe is responsible.

2. **Standard Exposure Sites.** Sites rated "Standard" include exposures to asbestos at shipyards, refineries, power plants and other industrial and commercial sites where Thorpe was determined by the Trust to have performed more than 3 and fewer than 50 distinct contracts or jobs installing or removing asbestos-containing material for which Thorpe is responsible.

3. **Low Exposure Sites.** Sites rated "Low" include exposures to asbestos at shipyards, refineries, power plants and other industrial and commercial sites where Thorpe was determined by the Trust to have performed 3 or fewer distinct contracts or jobs installing or removing asbestos-containing material for which Thorpe is responsible.

4. **High Exposure Jobtypes.** Certain jobtypes, known as "High Exposure Jobtypes" including boilermakers, insulators, pipefitters, steamfitters, stationary engineers, boilertenders, and Thorpe employees will receive an upward adjustment of 2 times the base case value of the particular Compensable Diseases, if they worked these jobs at High Exposure, Standard Exposure or Low Exposure Thorpe jobsites. Individuals with these jobtypes will be presumptively considered to qualify for the upward adjustment notwithstanding the site exposure rating. Other individuals who claim boiler exposure at Thorpe jobsites will be evaluated on a case-by-case basis for this upward adjustment. The maximum adjustment based upon High Exposure Jobtypes will be 2 times the base case value of the particular Compensable Disease, even if it occurs at a High Exposure Site. The Trust, with consent of the TAC, may review the list of qualifying High Exposure Jobtypes and modify the list in light of additional evidence or experience with claims processing.

d. **Minimum Exposure Criteria.**

1. To meet the minimum exposure requirements, an Injured Person filing a claim as a Mesothelioma case must establish that the Injured Person's asbestos exposure at approved Thorpe sites totals at least three months or at least 10% of the Injured Person's total asbestos exposure. Notwithstanding the foregoing, an Injured Person filing Thorpe sites totals at least

one month (but less than three months) exposure shall be entitled to a reduced liquidated claim value.

2. An Injured person filing in any other Compensable Disease category must establish that the Injured Person's asbestos exposure at approved Thorpe sites totals at least one year or at least 25% of the Injured Person's total asbestos exposure. Notwithstanding the forgoing, an Injured Person filing in any other Compensable Disease category who can establish that the Injured Person's exposure at approved Thorpe sites totals at least three months (but less than one year) exposure shall be entitled to a reduced liquidated claim value.

3. If no one site is sufficient to establish the duration necessary, an Injured Person may aggregate exposure at multiple sites to meet the minimum exposure requirements. The Trust will use a blending formula to give credit for exposure time beginning with the highest rated site and job type.

4. If the Injured Person has exposure at multiple sites, but there is no evidence supporting actual length of time at any of the sites, for purposes of applying the provisions of 2, above, the Trust will allocate exposure based upon an even distribution of the total length of exposure among all sites claimed. The Injured Person's attorney and the Injured Person or Personal Representative must provide declarations stating that the work sites listed include all work sites where the Injured Person worked, and that there is no other information available to demonstrate actual work time at each site. In addition, the interrogatories accompanying the claim must contain the Injured Person's entire work history.

Nothing in sub-paragraphs 3 and 4, above, shall diminish the obligation of a claimant to offer evidence of exposure that meets the minimum required exposure at approved Thorpe Sites set forth in paragraph c. above to qualify for a Matrix Claim.

**e. Specific Exposure Types.**

1. **Ship Exposure.** Evaluation of shipboard exposure shall be as follows:

a) Claims of shipboard exposure will require evidence that Thorpe actually performed installation or removal of asbestos-containing products on the ship, and that the Injured Person can demonstrate presence in an area of the ship that would constitute an exposure to Thorpe's operations at that ship or an exposure to these products.

b) Exposure on board a ship at a shipyard during a repair or overhaul will constitute an exposure at that shipyard if the Injured Person remained on board during the repair or overhaul, subject to meeting the duration of exposure requirements herein.

c) Evidence that an Injured Person was subsequently present on a ship that was repaired or overhauled at a shipyard where Thorpe installed or removed asbestos-containing material is not sufficient to constitute exposure. See Dumin v. Owens Corning Fiberglas Corp., 28 Cal. App. 4<sup>th</sup> 650 (1994).

d) It shall not be sufficient for an Injured Person to show that Thorpe

generally performed installation or removal at a shipyard where a particular ship that the Injured Person worked on was repaired. Specific identification of Thorpe installation and/or removal of asbestos-containing products on board the ship and meeting the duration of exposure requirements on the ship are both required. See Dumin v. Owens Corning Fiberglas Corp., 28 Cal. App. 4<sup>th</sup> 650 (1994).

2. **Derivative Exposure.** An Injured Person exposed to asbestos-containing products for which Thorpe is liable solely from exposure to an occupationally exposed person, such as a family member, will have his or her claims valued by the Trust as follows:

a) The Injured Person must establish that the occupationally exposed person would have met the exposure requirements under the Matrix that would have been applicable had that person filed a direct claim with the Trust.

b) The Injured Person must establish that he or she is suffering from one of the Compensable Diseases and that his or her own exposure to the occupationally exposed person occurred within the same time frame as the occupationally exposed person experienced Thorpe exposure as defined herein and that such exposure was the cause of the claimed disease. All other liquidation and payment rights and limitations under this Matrix shall be applicable to such claims.

3. **Longshore Exposure.** A Longshoreman with Thorpe exposure will be treated as a Standard exposure.

f. **Remote Exposures.** The following adjustment shall be made to the liquidated value of claims based upon the length of time that has passed between the time that Thorpe last performed operations at the jobsite and the time the Injured Person was exposed at the jobsite: (1) if Thorpe last performed operations at the jobsite five years or less before the Injured Person was exposed at the jobsite – no adjustment is made to the liquidated value of the claim; (2) if Thorpe last performed operations at the jobsite more than five years, but less than ten years, before the Injured Person was exposed at the jobsite - the liquidated value of the claim shall be reduced by 50%; (3) if Thorpe last performed operations at the jobsite more than ten years, but less than twenty years, before the Injured Person was exposed at the jobsite - the liquidated value of the claim shall be reduced by 75%; and (4) if Thorpe last performed operations at the jobsite more than twenty years before the Injured Person was exposed at the jobsite - the claim shall be disallowed in its entirety unless the Claimant or Injured Party can demonstrate actual exposure by the Injured Party to asbestos containing products used by Thorpe in its operations at that jobsite.

## VIII. INDIVIDUAL REVIEW

Any Claimant or Injured Person whose claim does not meet the medical or exposure criteria for any Compensable Disease shall have the opportunity for individual consideration and evaluation of his or her claim. In such a case, the Trust shall either deny the claim or the Trust can offer the Injured Person a liquidated value amount up to the average settlement value for that Compensable Disease, unless the claim qualifies as an Extraordinary Claim as defined in IX below, in which case its liquidated value cannot exceed the maximum value specified for such a claim.

## IX. EXTRAORDINARY CLAIMS PROVISION

a. **Extraordinary Claims.** In extraordinary situations such as where an Injured Person was exposed only to Thorpe, or where Thorpe exposure constituted over 80% of the Injured Person's asbestos exposure, where extraordinary present or future medical expenses are incurred, or where special damages are exceptionally large, the Trust may individually evaluate and liquidate a claim for an amount that exceeds the Maximum Value for the particular Compensable Disease asserted by the Injured Person. Any dispute as to Extraordinary Claim status shall be submitted to arbitration by a special Extraordinary Claims panel established by the Trust. Under no circumstances shall an Extraordinary Claim be valued at more than 8 times the Average Value for the particular Compensable Disease.

## **EXHIBIT “E”**



Financial Statements  
December 31, 2024 and 2023  
**J.T. Thorpe Settlement Trust**

J.T. Thorpe Settlement Trust

Table of Contents

December 31, 2024 and 2023

---

Independent Auditor’s Report .....	1
Financial Statements	
Statements of Net Claimants’ Equity .....	4
Statements of Changes in Net Claimants’ Equity .....	5
Statements of Cash Flows .....	6
Notes to Financial Statements .....	7
Supplementary Information	
Schedule of Operating Expenses.....	16



CPAs & BUSINESS ADVISORS

## Independent Auditor's Report

To the Trustees  
J.T. Thorpe Settlement Trust  
Reno, Nevada

### Opinion

We have audited the financial statements of J.T. Thorpe Settlement Trust (the "Trust"), which comprise the statements of net claimants' equity of the Trust as of December 31, 2024 and 2023, and the related statements of changes in net claimants' equity and cash flows for the years then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the net claimants' equity of the Trust as of December 31, 2024 and 2023, and its changes in net claimants' equity and its cash flows for the years then ended in accordance with the Trust's other basis of accounting, as described in Note 1 to the financial statements.

### Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Trust and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### Emphasis of a Matter - Basis of Accounting

We draw attention to Note 1 to the financial statements, which describes the basis of accounting used in the preparation of the financial statements. The financial statements are prepared on the Trust's other basis of accounting, which is a basis of accounting other than accounting principles generally accepted in the United States of America. Our opinion is not modified with respect to this matter.

### Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with the Trust's other basis of accounting described in Note 1 to the financial statements; this includes determining that the Trust's other basis of accounting is an acceptable basis for the preparation of the financial statements in the circumstances. Management is also responsible for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.



In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Trust's ability to continue as a going concern for one year after the date that the financial statements are available to be issued.

### **Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Trust's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Trust's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

### **Report on Supplementary Information**

Our audits were conducted for the purpose of forming an opinion on the financial statements as a whole. The schedule of operating expenses for the years ended December 31, 2024 and 2023 on page 16 is presented for purposes of additional analysis and is not a required part of the financial statements. Such supplementary information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audits of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial

statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the supplementary information is fairly stated, in all material respects, in relation to the financial statements as a whole.

**Restriction on Use**

Our report is intended solely for the information and use of the management of the Trust and Trustees, the beneficiaries of the Trust, the Futures Representative, the Futures Counsel, the members of and counsel to the Trust Advisory Committee, and the United States Bankruptcy Court for the Central District of California, Los Angeles Division and is not intended to be and should not be used by anyone other than these specified parties.

*Eide Bailly LLP*

Reno, Nevada  
April 1, 2025

J.T. Thorpe Settlement Trust  
Statements of Net Claimants' Equity  
December 31, 2024 and 2023

	2024	2023
<b>Assets</b>		
Cash, cash equivalents and investments		
Restricted	\$ 5,000,000	\$ 5,000,000
Unrestricted	119,919,364	120,484,773
Total cash, cash equivalents, and investments	124,919,364	125,484,773
Accrued interest and dividend receivables	999,607	1,050,011
Prepaid insurance	141,920	70,108
Prepaid federal income tax	221,599	185,495
Total assets	126,282,490	126,790,387
<b>Liabilities</b>		
Accrued expenses	145,825	113,009
Claim processing deposits	136,250	157,750
Unpaid claims		
Trust outstanding offers	1,713,628	2,001,295
Pre-petition liquidated claims	38,594	37,543
Deferred tax liability	9,334,049	7,986,560
Facility and staff sharing agreement payable	322,800	290,400
Total liabilities	11,691,146	10,586,557
Net Claimants' Equity	\$ 114,591,344	\$ 116,203,830

J.T. Thorpe Settlement Trust  
Statements of Changes in Net Claimants' Equity  
Years Ended December 31, 2024 and 2023

	2024	2023
Net Claimants' Equity, Beginning of Year	\$ 116,203,830	\$ 114,976,520
Additions to Net Claimants' Equity		
Investment income, net of investment expenses of \$341,206 and \$348,591, respectively	3,153,374	2,524,236
Claims processing deposits retained	36,750	37,000
Net decrease in deferred facility and staff sharing agreement	-	85,199
Net decrease in outstanding claim offers	286,616	-
Net realized and unrealized gains	4,678,185	8,367,912
Total additions	8,154,925	11,014,347
Deductions from Net Claimants' Equity		
Operating expenses	792,023	929,173
Provision for income taxes, current	813,896	1,559,384
Provision for income taxes, deferred	1,347,489	1,826,860
Net increase in facility and staff sharing agreement	32,400	-
Claims settled	6,781,603	3,981,603
Net increase in outstanding claim offers	-	1,490,017
Total deductions	9,767,411	9,787,037
Net Claimants' Equity, End of Year	\$ 114,591,344	\$ 116,203,830

J.T. Thorpe Settlement Trust  
Statements of Cash Flows  
Years Ended December 31, 2024 and 2023

	2024	2023
Cash Inflows		
Investment income receipts	\$ 3,203,778	\$ 2,409,576
Increase in claim processing deposits	-	3,500
Claims processing deposits retained	36,750	37,000
Net realized gains	980,866	3,437,631
Total cash inflows	4,221,394	5,887,707
Cash Outflows		
Claims settled	6,781,603	3,981,603
Disbursements for prepaid insurance	71,812	-
Decrease in claim processing deposits	21,500	-
Disbursements for Trust operating expenses	759,207	879,392
Disbursements for Trust income taxes	850,000	1,400,000
Total cash outflows	8,484,122	6,260,995
Net Cash Outflows	(4,262,728)	(373,288)
Non-Cash Changes		
Use of prepaid insurance	-	76,481
Net unrealized gains (losses)	3,697,319	4,930,281
Net Change in Cash, Cash Equivalents, and Investments	(565,409)	4,633,474
Cash, Cash Equivalents and Investments, Beginning of Year	125,484,773	120,851,299
Cash, Cash Equivalents and Investments, End of Year	\$ 124,919,364	\$ 125,484,773

## **Note 1 - Summary of Accounting Policies**

### **Description of Trust**

The J.T. Thorpe Settlement Trust (the "Trust"), organized pursuant to the laws of the state of Nevada with its office in Reno, Nevada, was established pursuant to the J. T. Thorpe, Inc. ("J. T. Thorpe"), Dissolved J. T. Thorpe, Inc. ("Dissolved Thorpe"), Thorpe Technologies, Inc., and Thorpe Holding Company, Inc., (collectively the "Debtors"), First Amended Joint Plan of Reorganization (the "Plan"), dated August 5, 2005. The Trust was formed to assume the Debtors' liabilities resulting from pending and potential litigation involving individuals exposed to asbestos who have manifested asbestos-related diseases or conditions for which the Debtors are legally responsible; liquidate, resolve, pay and satisfy all valid asbestos-related claims in accordance with the Plan; preserve, hold, manage and maximize the Trust assets for use in paying and satisfying allowed asbestos-related claims; prosecute, settle and manage the disposition of the asbestos in-place insurance coverage; and prosecute, settle and manage asbestos insurance coverage actions. Upon approval of the Plan, the Trust assumed liability for existing and future asbestos health claims against the Debtors. The Trust was created effective June 29, 2006.

The Trust was initially funded with insurance settlement proceeds, Dissolved Thorpe securities, cash and a note receivable. Since the Trust's creation, the note receivable has been collected. The Trust's funding is dedicated solely to the settlement of asbestos health claims and the related costs thereto, as defined in the Plan.

The Trust processes and pays all asbestos-related claims in accordance with the J. T. Thorpe Settlement Trust Agreement, as amended and restated, the Case Valuation Matrix, as amended and restated (the "Matrix"), and the Trust Distribution Procedures, as amended and restated (the "TDP") (collectively, the "Trust Documents").

### **Special-Purpose Accounting Methods**

The Trust's financial statements are prepared using special-purpose accounting methods that differ from accounting principles generally accepted in the United States. The special-purpose accounting methods were adopted in order to present the amount of equity available for payment of current and future claims. These special-purpose accounting methods are as follows:

- The financial statements are prepared using the accrual basis of accounting, as modified below.
- The funding received from J. T. Thorpe, Dissolved Thorpe, Thorpe Technologies, Inc., Thorpe Holding Company, Inc. and their insurers is recorded directly to net claimants' equity. These funds do not represent income of the Trust. Offers for asbestos health claims are reported as deductions from net claimants' equity and do not represent expenses of the Trust.
- Costs of fixed assets, which will be exhausted during the life of the Trusts and are not available for satisfying claims, are expensed when incurred. These costs include acquisition costs of computer hardware, software, software development, office furniture, and leasehold improvements.
- Future fixed liabilities and contractual obligations entered into by the Trust are recorded directly against net claimants' equity. Accordingly, the future minimum commitments outstanding at period end for non-cancelable obligations have been recorded as deductions from net claimants' equity.

## J.T. Thorpe Settlement Trust

Notes to Financial Statements

December 31, 2024 and 2023

---

- The liability for unpaid claims reflected in the statement of net claimants' equity represents settled but unpaid claims and outstanding offers. A claims liability is recorded once an offer is made to the claimant at the amount equal to the expected pro rata payment. No liability is recorded for future claim filings and filed claims on which no offer has been made. Net claimants' equity represents funding available to pay present and future claims on which no fixed liability has been recorded.
- Investments are recorded at fair value. All interest and dividend income is included in investment income on the statement of changes in net claimants' equity. Net realized and unrealized gains and losses are recorded as a separate component on the statement of changes in net claimants' equity. The fair value hierarchy of investments is reported.
- Realized gains/losses are recorded based on the security's amortized cost. At the time a security is sold, all previously recorded unrealized gains/losses are reversed and recorded net, as a component of net realized and unrealized gains/losses in the accompanying statement of changes in net claimants' equity.

### **Cash and Cash Equivalents**

Cash and cash equivalents include demand deposit accounts and cash invested in money market funds and AAA-rated US Treasury Bills with an original maturity of three months or less. Cash and cash equivalents are combined with investments in the statement of cash flows in conjunction with the Trust's special purpose accounting method and in accordance with the measurement focus of the Trust to present changes in the amount of assets available for payment of current and future claims.

### **Fair Value Measurements**

Fair value measurements are determined through the use of an independent, nationally recognized pricing service. For securities that have quoted prices in active markets, market quotations are provided. For securities that do not trade on a daily basis, the pricing service provides fair value estimates using a variety of inputs including, but not limited to, benchmark yields, reported trades, broker/dealer quotes, issuer spreads, bids, offers, reference data, prepayment spreads and measures of volatility. The Trust reviews on an ongoing basis the reasonableness of the methodologies used by the pricing service, as well as determines the aggregate portfolio price performance and reviews it against applicable indices.

### **Deposits**

Claims processing deposits represent filing fees collected for each unliquidated claim, for which fees are refunded by the Trust if the claim is paid.

### **Use of Estimates**

The preparation of financial statements in conformity with the special-purpose accounting methods described above requires the Trust to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of additions and deductions to net claimants' equity during the reporting period. Actual results could differ from those estimates.

J.T. Thorpe Settlement Trust

Notes to Financial Statements

December 31, 2024 and 2023

---

### **Concentration of Risk**

The Trust maintains all cash and investments at one financial institution. Financial instruments that potentially subject the Trust to concentrations of risk consist of cash, cash equivalents and investments. Cash equivalents consist of money market funds and Treasury Bills. The Trust did not have uninsured cash balances in excess of Federal Deposit Insurance Corporation limits of \$250,000 at December 31, 2024 and 2023. Investments are in excess of Securities Investor Protection Corporation limits of \$500,000.

The Trust utilizes risk controls to meet investment objectives authorized by its Trustees. Such risk controls include the use of outside investment advisors meeting predetermined criteria, and third-party quantitative and qualitative risk measurement evaluation tools. The Trust believes its risk control practices are appropriate to meet investment objectives.

Investment securities, in general, are exposed to various risks, such as interest rates, credit, and overall market volatility. Due to the level of risk associated with certain investment securities, it is reasonably possible that changes in the values of investment securities will occur in the near term and that such change could materially affect the amounts reported in the financial statements.

### **Income Taxes**

The Trust's policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. As of December 31, 2024, the Trust did not have any accrued interest or penalties associated with any unrecognized tax benefits, nor did it incur any interest and penalties expense with any unrecognized tax benefits for the year then ended. The Trust is unaware of information concerning any tax positions for which a material change in the unrecognized tax benefit or liability is reasonably possible within the next twelve months. The Trust files income tax returns in the United States. Although the Trust owes no tax to the State of California, it files an annual tax return in California reporting no taxable income or tax owed. The Trust is no longer subject to United States federal tax examinations for years before 2021 and state examinations for years before 2020.

### **Subsequent Events**

The Trust evaluated subsequent events through April 1, 2025, the date the financial statements were available to be issued.



J.T. Thorpe Settlement Trust

Notes to Financial Statements

December 31, 2024 and 2023

**Note 2 - Cash, Cash Equivalents and Investments**

The Trust has recorded cash, cash equivalents, and investments at estimated fair value as follows:

	<u>December 31, 2024</u>	
	<u>Cost</u>	<u>Fair Value</u>
Restricted		
Cash equivalents	\$ 275,492	\$ 275,492
U.S. Government obligations	2,931,206	2,883,808
Municipal bonds	30,000	30,447
Asset-backed debt	83,914	84,031
Corporate debt	<u>1,749,547</u>	<u>1,726,222</u>
Total restricted	<u>5,070,159</u>	<u>5,000,000</u>
Unrestricted		
Cash demand deposits	23,010	23,010
Cash equivalents	3,686,829	3,699,910
Equity securities	11,193,330	37,545,058
U.S. Government obligations	15,452,383	15,234,226
Municipal bonds	54,357,017	53,678,027
Asset-backed debt	475,250	478,142
Corporate debt	<u>9,321,736</u>	<u>9,260,991</u>
Total unrestricted	<u>94,509,555</u>	<u>119,919,364</u>
Total Funds	<u>\$ 99,579,714</u>	<u>\$ 124,919,364</u>
	<u>December 31, 2023</u>	
	<u>Cost</u>	<u>Fair Value</u>
Restricted		
Cash equivalents	\$ 184,218	\$ 184,218
U.S. Government obligations	1,372,294	1,338,985
Municipal bonds	351,008	346,345
Asset-backed debt	141,402	138,927
Corporate debt	<u>3,039,636</u>	<u>2,991,525</u>
Total restricted	<u>5,088,558</u>	<u>5,000,000</u>
Unrestricted		
Cash demand deposits	14	14
Cash equivalents	4,712,681	4,714,761
Equity securities	13,152,427	35,480,121
U.S. Government obligations	7,825,781	7,797,271
Municipal bonds	56,490,228	55,873,064
Asset-backed debt	620,238	617,882
Corporate debt	<u>15,965,597</u>	<u>16,001,660</u>
Total unrestricted	<u>98,766,966</u>	<u>120,484,773</u>
Total Funds	<u>\$ 103,855,524</u>	<u>\$ 125,484,773</u>

J.T. Thorpe Settlement Trust

Notes to Financial Statements

December 31, 2024 and 2023

The Trust accounts for investments according to a fair value hierarchy that distinguishes between assumptions based on market data (observable inputs) and the Trust's assumptions (unobservable inputs). The hierarchy consists of three broad levels as follows:

- Level 1 Quoted market prices in active markets for identical assets or liabilities.
- Level 2 Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, or valuations based on models where significant inputs are observable or can be corroborated by observable market data.
- Level 3 Valuations based on models where significant inputs are not observable, and for which the determination of fair value requires significant management judgment or estimation. The Trust does not hold any Level 3 investments as of December 31, 2024 and 2023.

Assets measured at fair value on a recurring basis, including financial instruments for which the Trust accounts, were as follows at:

	December 31, 2024		
	Level 1	Level 2	Total
<b>Assets</b>			
Cash demand deposits	\$ 23,010	\$ -	\$ 23,010
Cash equivalents	3,975,402	-	3,975,402
Equity securities	37,545,058	-	37,545,058
U.S. Government obligations	6,898,864	11,219,170	18,118,034
Municipal bonds	-	53,708,474	53,708,474
Asset-backed debt	-	562,173	562,173
Corporate debt and other	10,987,213	-	10,987,213
	<u>\$ 59,429,547</u>	<u>\$ 65,489,817</u>	<u>\$ 124,919,364</u>
<b>December 31, 2023</b>			
	Level 1	Level 2	Total
<b>Assets</b>			
Cash demand deposits	\$ 14	\$ -	\$ 14
Cash equivalents	4,898,979	-	4,898,979
Equity securities	35,480,121	-	35,480,121
U.S. Government obligations	7,771,428	1,364,828	9,136,256
Municipal bonds	-	56,219,409	56,219,409
Asset-backed debt	-	756,809	756,809
Corporate debt and other	18,993,185	-	18,993,185
	<u>\$ 67,143,727</u>	<u>\$ 58,341,046</u>	<u>\$ 125,484,773</u>

The Trust experiences transfers in and out of levels within the fair value hierarchy primarily due to the market activity of the underlying security. The Trust's policy is to recognize transfers in and out at the actual date the event or change in circumstance caused the transfer.

J.T. Thorpe Settlement Trust

Notes to Financial Statements

December 31, 2024 and 2023

The maturities of the Trust’s investments at market value (excluding cash equivalents) are as follows as of December 31, 2024:

	<u>Less than 1 Year</u>	<u>After 1 Year Through 5 Years</u>	<u>After 5 Year Through 10 Years</u>	<u>After 10 Years</u>	<u>Total</u>
U.S. Government obligations	\$ 309,325	\$ 2,578,371	\$ 4,690,940	\$ 10,539,398	\$ 18,118,034
Municipal bonds	4,794,684	26,140,627	5,581,369	17,191,794	53,708,474
Asset-backed debt	-	428,002	134,171	-	562,173
Corporate debt	<u>927,743</u>	<u>5,529,425</u>	<u>4,422,269</u>	<u>107,776</u>	<u>10,987,213</u>
	<u>\$ 6,031,752</u>	<u>\$ 34,676,425</u>	<u>\$ 14,828,749</u>	<u>\$ 27,838,968</u>	<u>\$ 83,375,894</u>

**Note 3 - Fixed Assets**

The cost of non-income producing assets that will be exhausted during the life of the Trust and are not available for satisfying claims are expensed as incurred. Since inception, the cost of fixed assets expensed, net of disposals, includes:

Acquisition of computer hardware and software	<u>\$ 178,106</u>
---	-------------------

These items have not been recorded as assets, but rather as operating expenses and direct deductions from net claimants’ equity in the accompanying financial statements. The cost of fixed assets that were expensed during each of the years ended December 31, 2024 and 2023 were \$62,500 and \$0, respectively.

Total depreciation expense related to asset acquisition using accounting principles generally accepted in the United States would have been \$7,042 and \$7,337 for the years ended December 31, 2024 and 2023, respectively.

**Note 4 - Claim Liabilities**

The Trust distinguishes between claims that were resolved prior to the establishment of the Trust (“Pre-petition Liquidated Claims”) and claims received and processed using the Trust Procedures after the creation of the Trust (“Trust Claims”).

The cases underlying the Pre-petition Liquidated Claims were stayed by the court until the Plan was approved. The Trust approved procedures and immediately arranged to pay, subject to receiving a claimant release, the approved Payment Percentage of the liquidated value of each Pre-petition Liquidated Claim.

J.T. Thorpe Settlement Trust

Notes to Financial Statements

December 31, 2024 and 2023

---

For Trust Claims, a liability for unpaid claims is recorded at the time the offer is extended to the firm of record or claimant. Funds are mailed after the approved release is signed, received, and approved by the Trust. Unpaid claims liabilities remain on the Trust's books until the offer is accepted, rejected, withdrawn or expired after six months. Offers may be extended an additional six months upon written request and good cause. As of the years ended December 31, 2024 and 2023, there were no expired offers.

All claimants are entitled to the full liquidated value of their claim. Under the TDP, claimants receive an initial pro rata payment equal to the approved Payment Percentage of the claim's liquidated value. The remaining obligation for the unpaid portion of the liquidated amount is not recorded and is not a liability of the Trust, unless the Payment Percentage is increased. In that instance, the Trust is currently obligated to retroactively pay the increased percentage to all previously paid claimants (see Note 6).

In the interest of treating all claimants equitably in accordance with the Plan, the Trustees have recommended that all payments made during each calendar year ended December 31, 2008 through December 31, 2024 include a Cost of Living Adjustment for inflation based on the Federal Bureau of Labor Statistics' *Consumer Price Index for Urban Wage Earners and Clerical Workers* (CPI-W). Claims liabilities at year end are adjusted for any approved Inflation Adjustment. Inflation Adjustments are cumulative. Cumulative Inflation Adjustments of 56.82% and 52.55% are included in outstanding claims liabilities as of December 31, 2024 and 2023, respectively.

The Trust approved \$6,490,885 and \$5,437,599 of Trust Claims during the years ended December 31, 2024 and 2023, respectively.

**Note 5 - Facility and Staff Sharing Agreement**

The Trust has entered into a facilities and staff sharing agreement with the Western Asbestos Settlement Trust, (the "Western Trust"). The two Trusts are related through common trustees. Under the agreement, and in exchange for advance monthly payments, the Western Trust provides use of its facilities and services relating to administration and claims processing. The monthly payment in 2024 was \$24,200. The monthly payment in 2023 was \$31,300. Agreement provisions allow for automatic renewals for additional one-year periods unless either party provides written notice. The amounts of advance monthly payments are agreed upon between the Trusts from time to time. The equitable amount agreed upon is based on the required written calendar year reconciliation of annual services that is performed by the Western Trust. Any excess of costs over payments or payments over cost is required to be repaid by the benefited party with interest. The reconciliations for 2024 and 2023 were performed and recorded in the respective periods. The reconciliation performed for the years ended December 31, 2024 and 2023 resulted in a payable to the Western Trust of \$20,502 and \$20,591, respectively. The monthly payment for 2025 will change to \$26,900. The future payments under this agreement have been recorded as a liability on the accompanying statement of net claimants' equity.

#### **Note 6 - Net Claimants' Equity**

The Trust was created pursuant to the Plan approved by the United States Bankruptcy Court for the Central District of California, Los Angeles Division. The TDP was adopted pursuant to the Plan and concurrently with the Trust Agreement. It is designed to provide fair and equitable treatment for all Trust claims that may presently exist or may arise in the future. The TDP prescribes certain procedures for distributing the Trust's limited assets, including pro rata payments and initial determination of claim value based on compensable diseases, and individual factual information concerning each claimant as set forth in the Trust Documents.

Under the TDP, the Trust forecasts its anticipated annual sources and uses of cash until the last projected future claim has been paid. A pro rata Payment Percentage is calculated such that the Trust will have no remaining assets or liabilities after the last future claimant receives his/her pro rata share.

Based on research and testimony presented during the bankruptcy, the Court approved an initial Payment Percentage to claimants to be applied to the liquidated value of then current and estimated future claims. The TDP provided that the Trust Advisory Committee ("TAC") and the Futures Representative may agree on a different Initial Payment Percentage prior to the Effective Date if another party became a Settling Asbestos Insurance Company. Pursuant to an agreement between the TAC and the Futures Representative dated June 29, 2006, the Initial Payment Percentage to be used was 50% of the total liquidated value. The TDP gives the Trustees, with the consent of the TAC and the Futures Representative, the power to periodically update its estimate of the Payment Percentage based on updated assumptions regarding its future assets and liabilities and, if appropriate, propose additional changes in the Payment Percentage. In December 2008, the Payment Percentage was temporarily decreased from 50% to 40%. The decrease had no impact on previously paid claims. In November 2010, after evaluating assumptions regarding the Trust's future assets and liabilities, the Trustees approved an adjustment in the Payment Percentage from 40% to 45%. In May 2018, after evaluating assumptions regarding the Trust's future assets and liabilities, the Trustees approved an adjustment in the Payment Percentage from 45% to 50%. The adjustment was retroactive for all claims previously paid at the 45% Payment Percentage. These changes were made with the consent of the TAC and Futures Representative.

#### **Note 7 - Restricted Cash, Cash Equivalents and Investments**

To avoid the high costs of director and officer liability insurance, and pursuant to the Trust Agreement, the Trust has elected to be partially self-insured and has established a segregated security fund of \$5,000,000. These funds are devoted exclusively to securing the obligations of the Trust to indemnify the former and current Trustees, employees, agents and representatives of the Trust. The funds are held in a separate Trust bank account, and interest income accrues to the benefit of the Trust.

As of December 31, 2024 and 2023, cash, cash equivalents and investments of \$5,000,000 were restricted for this purpose.

In addition, the Trust initially purchased a \$5,000,000 Directors and Officers/Errors and Omissions policy in 2018 and a \$5,000,000 Directors and Officers/Errors and Omissions DIC policy in 2019. The Trust has continued to renew the policies every two years.

J.T. Thorpe Settlement Trust  
Notes to Financial Statements  
December 31, 2024 and 2023

---

In November 2022, the Trust purchased additional coverage, increasing the Directors and Officers/Errors and Omissions policy and Directors and Officers/Errors and Omissions DIC policy, to \$10,000,000 each.

**Note 8 - Income Taxes**

For federal income tax purposes, the Trust is taxed as a Qualified Settlement Fund (QSF). Income and expenses associated with the Trust are taxed in accordance with Section 468B of the Internal Revenue Code. The statutory income tax rate for the Trust is 37.0% for the years ended December 31, 2024 and 2023.

The Trust records deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the book and tax basis of assets and liabilities.

The provision for income taxes consists of the following for the years ended December 31:

	2024	2023
Income tax – current expense	\$ 813,896	\$ 1,559,384
Deferred income tax expense	1,347,489	1,826,860
	\$ 2,161,385	\$ 3,386,244

The components of the deferred income tax liability, as presented in the statements of net claimants' equity consisted of the following at December 31:

	2024	2023
<u>Deferred tax asset (liability)</u>		
Unrealized investment gains	\$ (9,370,831)	\$ (8,002,822)
Depreciation and amortization	36,782	16,262
	\$ (9,334,049)	\$ (7,986,560)

On December 22, 2017, the United States enacted tax reform legislation commonly known as H.R.1, referred to as the "Tax Cuts and Jobs Act" (the "Act"), resulting in significant changes to U.S. tax law. Among other provisions, the Act temporarily reduces the tax rate from 39.6% to 37% until 2026.



Supplementary Information  
December 31, 2024 and 2023

## J.T. Thorpe Settlement Trust

J.T. Thorpe Settlement Trust  
Schedule of Operating Expenses  
Years Ended December 31, 2024 and 2023

---

	<u>2024</u>	<u>2023</u>
Accounting	\$ 42,233	\$ 41,918
Claims processing	162,793	98,045
Futures representative	36,039	52,254
Information technology support	22,188	22,057
Insurance	80,291	81,568
Legal fees	16,745	43,969
Trust advisory committee	10,776	11,453
Trust facility and staff sharing expense	310,902	396,191
Trustee fees	81,657	108,836
Trustees professional	28,399	72,882
	<u>\$ 792,023</u>	<u>\$ 929,173</u>



## **EXHIBIT “F”**

**EXHIBIT “F”**

**J.T. Thorpe Settlement Trust  
Claim Report  
as of December 31, 2024**

This report is submitted pursuant to Section 2.2 (c)(ii) of the Fifteenth Amendment to and Complete Restatement of J.T. Thorpe Settlement Trust Agreement, which requires the Trust to file with the Bankruptcy Court a summary of the number and type of claims disposed of during the period covered by the financial statements (“Accounting Period”). This report summarizes the Trust’s processing of claims received since the Effective Date of the Trust (“Trust Claims”).

**Trust Claims**

Claims received and disposed of from January 1, 2024, through December 31, 2024 in accordance with the Third Amendment to and Complete Restatement of J.T. Thorpe Case Valuation Matrix (“Matrix”) and the J.T. Thorpe, Inc., a California corporation/J.T. Thorpe, Inc., a dissolved California corporation/Thorpe Holding Company, Inc., a California corporation/Thorpe Technologies, Inc., a California corporation Asbestos Personal Injury Settlement Fifth Amendment to and Complete Restatement of Trust Distribution Procedures (“TDP”) are as set forth below.

The value of each compensable disease is determined by the Matrix and TDP. Claim compensation is adjusted for individual claimants based upon tort related individual characteristics, including, but not limited to: age, marital status, dependents, medical loss, economic loss, exposure location, and whether living at the time of commencement of litigation or filing the claim with the Trust. Each valid claim is awarded a total liquidated value. As of December 31, 2024, Trust Claims were paid at the approved Payment Percentage of 50%. Payments made on Trust Claims in 2024 included an additional 52.55% to account for cumulative inflation based upon the CPI-W.

During the Accounting Period, 261 claims were received. In addition, offers were issued to 135 claimants. Further, 134 claims were paid.

Below is a summary of the number and type of claims disposed of (paid) in 2024.

Compensable Disease	Number of Claims
Grade II Non-Malignant	7
Grade I Non-Malignant and Enhanced Asbestosis	34
Grade I Non-Malignant Serious Asbestosis	9
Other Cancer	9
Lung Cancer	20
Mesothelioma	55
<b>Totals</b>	<b>134</b>

## **EXHIBIT “G”**

# **Investment Policy Statement**

## **J.T. Thorpe Settlement Trust**

**February, 2025**  
Prepared by Callan LLC

## Table of Contents

<b>EXECUTIVE SUMMARY .....</b>	<b>2</b>
<b>LONG-RANGE ASSET ALLOCATION TARGET .....</b>	<b>3</b>
<b>MAINTENANCE OF THE STRATEGIC ASSET ALLOCATION .....</b>	<b>3</b>
<b>PORTFOLIO EVALUATION BENCHMARK .....</b>	<b>4</b>
<b>MANAGER EVALUATION .....</b>	<b>4</b>
<b>REVIEW OF INVESTMENTS .....</b>	<b>5</b>
<b>INVESTMENT PRACTICES .....</b>	<b>5</b>
A. EQUITY .....	6
B. U.S. FIXED-INCOME .....	7
C. DERIVATIVES POLICY .....	9
D. OTHER INVESTMENTS .....	9
<b>PROXY VOTING GUIDELINES.....</b>	<b>9</b>
<b>GUIDELINES FOR MANAGER SELECTION .....</b>	<b>9</b>
<b>TRUSTEES .....</b>	<b>10</b>

## Executive Summary

<b>Type of Plan</b>	Taxable Trust
<b>Investment Planning Time Horizon</b>	5 years
<b>Expected Annualized After-Tax Return and Risk<sup>1</sup></b>	Return = 1.7 Risk = 5.9

### **Primary Goal**

The J.T. Thorpe Settlement Trust (the “Trust”) is organized pursuant to the laws of the state of Nevada with its office in Reno, Nevada. It was established pursuant to the J.T. Thorpe, Inc., J.T. Thorpe, Inc., a dissolved California corporation; Thorpe Technologies, Inc.; Thorpe Holding Company, Inc.; (collectively the “Debtors”) First Amended Joint Plan of Reorganization, dated August 5, 2005, as amended, modified or supplemented from time to time (the “Plan”). The Trust was formed to assume the Debtors’ liabilities resulting from pending and potential litigation involving individuals exposed to asbestos who have manifested asbestos-related diseases or conditions; liquidate, resolve, pay and satisfy all asbestos-related claims in accordance with the Plan. As well the Trust must preserve, hold, manage and maximize the Trust assets for use in paying and satisfying current and future allowed asbestos-related claims.

As set forth in the Trust Distribution Procedures, Section 2.4, the Trust shall estimate or model the amount of cash flow anticipated as necessary over its entire life to ensure that funds will be available to treat all present and futures claimants as similarly as possible. In order to pay the anticipated claims, the Trust relied upon an expert report filed with the U.S. Bankruptcy Court which calculated a reasonable real after tax discount rate to use in calculating the present value of the future claims to be assumed by the Trust. These estimates provided the Trust with an assumption that the assets should earn an after-tax real rate of return of approximately 1% per annum. While additional assets may be made available, the Trust will operate on the assumption that there will be no additional contributions. As such, protection of principal will be a primary goal.

The expected annualized after-tax return and risk, asset allocations, target index and portfolio benchmarks identified herein may be adjusted from time to time as agreed upon by the Trust’s Trustees (“Trustees”) and as reflected in the minutes of the Trustees’ meeting following such agreement.

---

<sup>1</sup> Represents expected after-tax (25%) geometric return and risk using Callan’s 2025 Capital Market assumptions applied to the Portfolio Evaluation Benchmark described below.

## **Long-range Asset Allocation Target**

The Trust will have the following long-term asset allocation target.

Fixed Income	70%
Equity	30%

The long-range asset allocation target will be applicable to the long-term investable assets net of any set-asides and liquidity reserves. This asset allocation was established through quantitative and qualitative assessments of the returns and risks available in the capital markets over long-term periods as well as the diversification available from using multiple asset classes. While an investment program consisting entirely of fixed income would demonstrate the least volatility of any asset allocation considered, a quantitative study performed by the Trust's investment consultant demonstrated that the probability of exhausting Trust assets in advance of paying claims as planned was minimized by introducing an equity allocation into the portfolio. Allocations to each of the asset classes will be further diversified and tailored to reflect the tax-status of the Trust as described in the "Investment Practices" section of this policy.

## **Maintenance of the Strategic Asset Allocation**

### **Target Mix With Ranges**

	<b>Low</b>	<b>Target</b>	<b>High</b>
Fixed Income	<b>55%</b>	<b>70%</b>	<b>85%</b>
Equity	<b>15%</b>	<b>30%</b>	<b>45%</b>

The Trust will from time to time adjust the asset allocation and the index components within the designated range based upon the changing cash flow needs of the Trust, claims submitted and projections of future claims. The Trust will deviate from targets over short and intermediate periods in response to liquidity needs, market performance, and the cost of asset allocation adjustments including transactions costs and the taxation of transactions. Deviations from the target allocation beyond the low or high allocations defined in the table above represent significant deviations from the return and risk characteristics of the target allocations and will prompt the Trustees to consider moving the allocations back to toward the target allocation.

The Strategic Allocation and Target Index are to be reviewed at least annually for presentation to the Trustees and the Trust's Executive Director ("Executive Director"), for reasonableness relative to significant economic and market changes, or to changes in the Trust's long-term goals and objectives. A formal asset allocation study should be conducted at least every three years to verify or amend the targets.

## **Portfolio Evaluation Benchmark – Target Index**

A special target index was constructed to monitor the performance of the total fund. This target index serves as a minimum performance objective for the Trust. It is expected that in most market environments the Trust's actual asset allocation will approximately resemble the allocation expressed in the target index. The Trust will deviate from the target index over short and intermediate periods in response to liquidity needs, market performance, market outlook, and the cost of asset allocation adjustments including transactions costs and the taxation of transactions.

Target Index:

- ◆ 12.5% S&P 500 Index
- ◆ 5.0% S&P 500 Value Index
- ◆ 5.0% Russell 2500 Index
- ◆ 7.5% MSCI ACWI ex US Index
- ◆ 49.0% Bloomberg Municipal 1-15 Year Bond Index
- ◆ 14.0% Bloomberg Intermediate Aggregate Bond Index
- ◆ 7.0% 3-Month Treasury Bills

With the possible exception of the short duration enhanced cash portfolio, individual investment managers will be retained to manage the sub-components of the Target Index. Individual investment managers will be measured against each sub-component index and not against this total fund objective. However, it is expected that the sum of their efforts will exceed the trust objective over time.

## **Manager Evaluation**

Investment managers will be measured relative to an appropriate market index. A market index is assigned to each Manager and is intended as a guide for the investment manager to understand the risk/reward posture of their portfolio. Managers have full discretion to manage the risk posture of their portfolios relative to their designated market index and may, with conviction and appropriate expertise, execute security strategies not reflected by their market index as long as they conform to the investment guidelines.

Trustees or Executive Director may, at either's discretion, also evaluate the investment managers relative to peer groups of managers with similar investment styles. These evaluations will take into account the exceptional nature of the Trust investment manager mandates including but not limited to custom benchmarks and the unique tax situation of the Trust.

## **Review of Investments**

There shall be a continual review of the investments under management by Callan LLC ("Consultant"). The Trustees, consultant and/or the Executive Director shall confer with the investment managers regarding investment performance, market environment and other issues as required. Each investment manager shall report pertinent data to Trust and



custodian at least monthly. All legal, organizational and personnel related developments will be reported to the client and consultant as soon as practicable.

Consultant will meet with the Trustees, Executive Director, and other Trust representatives as requested by the Trustees, to review performance of the Trust and individual managers quarterly. These reviews will be conducted in the context of these guidelines.

### **Investment Practices**

Investments will be prudent and consistent with the best investment practices, and in compliance with Trust documents including but not limited to Article 3 of the J.T. Thorpe Settlement Trust Agreement as amended.

- No more than 45% at cost or 50% at market value of total Trust assets may be invested in equities with the balance invested in Fixed Income securities or cash equivalents.
- 10% of the Trust's assets may be invested in debt securities that are non-rated or below investment grade as long as those securities are in a diversified and managed portfolio of bonds and/or stock.
- The percentage of the Trust assets (debt and equity) invested in any one company is limited to 5% at market with the exception of debt securities or other instruments issued or fully guaranteed as to principal and interest by the United States of America or any agency or instrumentality thereof. The Trust does not include cash equivalents in the calculation of maximums allowed for certain types of securities.
- Cash flow, other than an automatic withdrawal of the income on a monthly basis, may be required to maintain the long-range asset allocation target and to satisfy claim liabilities.
- The Trust seeks to limit exposure to securities issued by companies who produce tobacco products as well as companies who are, or may become, exposed to significant asbestos related claims. For this reason, the investment in debt or equity securities of companies who produce tobacco products is prohibited. In addition, the investment in equity and debt securities issued by Johnson & Johnson, Bayer, and Monsanto is prohibited.

#### ***A. Equity***

Excluding any securities issued by the Debtors, the Trust shall not acquire or hold, directly or indirectly, any common or preferred stock, convertible securities, REITS, or Royalty Trusts ("Stock") unless such stock is included in a diversified and managed portfolio or portfolios which include various industry sectors.

##### **1. S&P 500 Index Strategy**

- The objective of the S&P 500 index strategy is to tax-efficiently track the **S&P 500 Index**, with a tracking error (defined as annualized standard deviation of the portfolio's monthly returns relative to the S&P 500) of 100 basis points or less. The percent ownership of any company shall not

exceed the greater of 5% of the portfolio's market value or 0.50% more than the weight of the company in the **S&P 500 Index** at any time.

## 2. **S&P 500 Value Index Strategy**

- The objective of the S&P 500 Value index strategy is to track the **S&P 500 Value Index**, with a tracking error (defined as annualized standard deviation of the portfolio's monthly returns relative to the S&P 500) of 25 basis points or less.

## 3. **Small/Mid Cap Core Strategy**

- The objective of the small/mid cap strategy is to provide an additional source of long-term growth and after-tax returns to the Trust and exceed the **Russell 2500 Index** over a full market cycle.
- The actively managed small/mid cap equity portfolio must be diversified by industry and security. The percent ownership of any company within this portfolio is limited to 5% of the portfolio's market value.
- 

## 4. **International Equity Strategy**

- The objective of the international equity strategy is to provide an additional source of long-term growth and after-tax returns to the Trust and exceed the **MSCI ACWI ex-US Index** over a full market cycle.
- The actively managed international equity portfolio must be diversified by country, region, industry and security. The percent ownership of any company within this portfolio is limited to 5% of the portfolio's market value. In addition exposure to Emerging Markets and Frontier Markets is limited to 35% of market value.

### ***B. U.S. Fixed-Income***

#### **Allowable securities are as follows:**

- U.S. Treasury and agency securities
- Agency and non-agency mortgage-backed securities backed by loans secured by residential, multifamily and commercial properties including but not limited to pass-throughs, CMOs, REMICs, CMBS, project loans, construction loans and adjustable rate mortgages
- Obligations of domestic and foreign corporations
- Asset backed securities
- Municipal bonds, both taxable and tax-exempt
- Municipal pre-refunded bonds backed by U.S. Treasury or Agency Securities
- Municipal inflation protected securities (MIPS)
- Preferred stock, including non-convertible preferred stock such as bank trust preferreds
- Money market instruments rated A-1 or P-1 or better at time of purchase

- Repurchase obligations as long as, in the opinion of the Trustees and asset manager, they are adequately collateralized
- Obligations of foreign governments and supra-national organizations
- Obligations of domestic and foreign commercial banks
- 144A securities including issues in the corporate, mortgage and asset-backed sectors
- CDs may be held as long as all of the publicly held long-term debt securities, if any, of the issuing entity are rated investment grade (see credit criteria below) or above.
- Non-investment grade bonds subject to an overall limit of 10% of Trust's assets and within a managed and diversified portfolio.

### **Credit Criteria**

- To be deemed investment grade, securities must be rated investment grade or better at the time of purchase by a nationally recognized rating agency (Moody's, Standard & Poors and Fitch). Split rated securities shall be assumed to have the higher credit grade.
- If a portfolio holding is downgraded to below investment grade and the holding is in a portfolio which is not permitted to purchase below investment grade securities, manager shall promptly notify the Trust and provide an evaluation and recommended plan of action.

#### **1. Municipal Bond Portfolio**

- The portfolio's investment objective is to provide an after-tax total rate of return that exceeds the after-tax total return of the Bloomberg **Municipal 1-15 Year Index**.
- The portfolio will have a targeted duration of approximately +/-40% around the benchmark (calculated using the Treasury risk basis).
- With the exception of Treasury, Agency debentures, pass-throughs or REMICs, no more than 5% of the portfolio may be invested in securities of a single issuer.
- 15% maximum in BBB rated securities.
- Securities must be rated investment grade at time of purchase. Non-rated, pre-refunded bonds fully backed by U.S. Treasury and Agency Securities are exempt from this restriction.

#### **2. Taxable Fixed Income Portfolio**

- The portfolio's objective is to invest in the intermediate portion of the yield curve and to outperform the target benchmark
- The portfolio's benchmark is the **Bloomberg Intermediate US Aggregate Index**.
- The portfolio will have a targeted duration of approximately +/-25% around the benchmark.

- No more than 5% of the portfolio may be invested in securities of a single issuer, with the exception of the U.S. Treasury, agency and agency mortgage issues.
- The weighted average credit quality of the portfolio shall be maintained at a minimum of A1 by Moody's and/or A+ by Standard and Poor's or Fitch.
- Securities must be rated investment grade at time of purchase.

### **3. Short Duration Enhanced Cash Portfolio**

- The portfolio's objective is to provide a high level of liquidity and preserve principal. Adding incremental yield is a secondary objective.
- Benchmark is the **3-Month Treasury Bills**.
- No more than 5% of the portfolio may be invested in securities of a single issuer, with the exception of the U.S. Treasury and U.S. Agency debt.
- The portfolio's duration will not exceed 300% of the index's duration.
- Portfolio's weighted average credit quality must be at least Aa2 by Moody's and/or AA by Standard and Poor's or Fitch.
- All securities must be rated investment grade and have a final maturity less than or equal to 5 years from time of purchase. No more than 15% of the portfolio can be rated less than A-, or its equivalent.
- Portfolio level spread duration cannot exceed 2 years.

### ***C. Derivatives Policy***

Derivatives shall be held for the purposes of hedging, cost reduction and liquidity enhancement only. Derivatives shall not be used for speculative purposes.

- No leverage shall be introduced through the use of derivatives
- The Trust shall not acquire or hold any options

### ***D. Other Investments***

Pursuant to Section 3.2 of the Trust Agreement as Amended, in order to achieve the overall after tax real rate of return Trust Investment objective and to meet other Trust objectives, the Trust may under conditions and terms satisfactory to the Trustees, acquire securities or other instruments issued by any person not otherwise defined in this Investment Policy ("Other Investments"), provided however that the aggregate market value of all such Other Investments after acquisition do not exceed two percent of the aggregate value of the Trust Estate.

### **Proxy Voting Guidelines**

Investment managers employed by the Trust are required to vote proxies with the primary objective of maintaining and advancing the economic value of the Trust. Investment

managers should work with the Trust custodian to ensure timely receipt of proxies. Investment managers should have specific guidelines and institute a regular review process for voting proxies.

### **Guidelines for Manager Selection**

The Trustees and Executive Director, with the assistance of the Futures Representative and Chair of the TAC, if desired by the Trustees, will select appropriate investment managers to manage the Trust's assets. This selection process shall include the establishment of specific search criteria, and documentation of analysis and due diligence on potential candidates. All manager candidates must meet the following minimum criteria:

- (1) Be a bank, insurance company, investment management company, or investment adviser as defined by the Registered Investment Advisers Act of 1940.
- (2) Provide historical quarterly performance numbers calculated on a time-weighted basis, based on a composite of all fully discretionary accounts of similar investment style.
- (3) Provide performance evaluation reports prepared by an objective third party that illustrate the risk/return profile of the manager relative to other managers of like investment style.
- (4) Provide detailed information on the history of the firm, key personnel, key clients, fee schedule, and support personnel and demonstrate financial and professional staff stability.
- (5) Clearly articulate the investment strategy that will be followed and document that the strategy has been successfully adhered to over time.
- (6) All investment manager candidates are expected to comply with all laws, regulations, and standards of ethical conduct.

### **Trustees**

#### **Fiduciary and Investment Responsibilities of the Trustees:**

- Maintain overall responsibility for financial management of the Trust including the investment of Trust assets consistent with all Trust documents
- Determine the asset allocation of Trust assets through the Investment Policy Statement and investment manager guidelines
- Use "prudent experts" to assist in making investment decisions
- Control investment expenses
- In recognition of their fiduciary duties, the Trustees must act in good faith and not allow their personal interests to prevail over that of the Trust

## PROOF OF SERVICE OF DOCUMENT

1 I am over the age of 18 and not a party to this bankruptcy case or adversary proceeding. My business  
2 address is 2818 La Cienega Avenue, Los Angeles, California 90034.

3 A true and correct copy of the foregoing document entitled **NINETEENTH ANNUAL REPORT AND**  
4 **ACCOUNTING, AUDITED FINANCIAL STATEMENTS, AND CLAIM REPORT** will be served or was  
served (a) on the judge in chambers in the form and manner required by LBR 5005-2(d); and (b) in the  
manner stated below:

5 **1. TO BE SERVED BY THE COURT VIA NOTICE OF ELECTRONIC FILING (NEF):** Pursuant to  
controlling General Orders and LBR, the foregoing document will be served by the court via NEF and  
6 hyperlink to the document. On **April 29, 2025**, I checked the CM/ECF docket for this bankruptcy case or  
adversary proceeding and determined that the following persons are on the Electronic Mail Notice List to  
7 receive NEF transmission at the email addresses stated below:

- 8 • Michael H Ahrens mahrens@sheppardmullin.com
- 9 • Daniel J Bussel dbussel@ktbslaw.com
- 10 • Christopher Celentino christopher.celentino@dinsmore.com,  
caron.burke@dinsmore.com
- 11 • David N Chandler , courtdocsdncpc@gmail.com
- 12 • Brian L. Davidoff bdavidoff@greenbergglusker.com,  
calendar@greenbergglusker.com;jking@greenbergglusker.com;cmillerwatkins@greenber  
13 glusker.com
- 14 • Asheley G Dean asheley.dean@hoganlovells.com
- 15 • Richard W Esterkin richard.esterkin@morganlewis.com
- 16 • Gary S Fergus gfergus@ferguslegal.com
- 17 • Gary S Fergus gfergus@ferguslegal.com
- 18 • Ellen A Friedman efriedman@friedmanspring.com, khollander@friedmanspring.com
- 19 • Gabriel I Glazer gglazer@pszjlaw.com
- 20 • Valerie B Greenberg valerie.greenberg@akerman.com, debra.atkinson@akerman.com
- 21 • Gail S Greenwood ggreenwood@pszjlaw.com, rrosales@pszjlaw.com
- 22 • Gregory K Jones gjones@stradlinglaw.com,  
smjohnson@sycr.com;smjohnson@stradlinglaw.com
- 23 • Eve H. Karasik ehk@lnbyb.com
- 24 • David S Kupetz david.kupetz@troutman.com, mylene.ruiz@troutman.com
- 25 • Mette H Kurth mette.kurth@pierferd.com, mette-kurth-7580@ecf.pacerpro.com
- 26 • Jeffrey S Kwong jsk@lnbyg.com, jsk@ecf.inforuptcy.com
- 27 • Michael J Mandelbrot mandelbrot@asbestoslegalcenter.org,  
mjmandelbrot@yahoo.com
- 28 • Merle Meyers mmeyers@mlg-pc.com
- Keith C Owens kowens@foxrothschild.com, khoang@foxrothschild.com
- Danielle A Pham dpham@gordonsilver.com
- Marcy Railsback marcy@bovinorailsback.com, marcyrailsback@hotmail.com
- Steven B Sacks ssacks@sackslawoffice.com, ksieckman@srclaw.com
- John P Sande - SUSPENDED - jps@jonesvargas.com
- David Samuel Shevitz David.S.Shevitz@usdoj.gov
- Matthew J. Shier mshier@shierkatz.com, mterry@shierkatz.com
- United States Trustee (LA) ustpreion16.la.ecf@usdoj.gov
- Jeanne C Wanlass jcwanlass@yahoo.com
- Jeanne C Wanlass jcwanlass@yahoo.com
- Michael R Weiss michael.weiss@akerman.com,  
andrea.ordonez@akerman.com,rob.diwa@akerman.com,masterdocketlit@akerman.com

1 **2. SERVED BY UNITED STATES MAIL:** On **April 29, 2025**, I served the following persons and/or  
2 entities at the last known addresses in this bankruptcy case or adversary proceeding by placing a true  
3 and correct copy thereof in a sealed envelope in the United States mail, first class, postage prepaid, and  
addressed as follows. Listing the judge here constitutes a declaration that mailing to the judge will be  
completed no later than 24 hours after the document is filed.

4 The Honorable Sheri Bluebond  
5 United States Bankruptcy Court  
6 255 E. Temple Street, Suite 1534  
7 Los Angeles, CA 90012

Service information continued on attached page

8 **3. SERVED BY PERSONAL DELIVERY, OVERNIGHT MAIL, FACSIMILE TRANSMISSION OR**  
**EMAIL** (state method for each person or entity served): Pursuant to F.R.Civ.P. 5 and/or controlling LBR,  
9 on **April 29, 2025**, I served the following persons and/or entities by personal delivery, overnight mail  
10 service, or (for those who consented in writing to such service method), by facsimile transmission and/or  
email as follows. Listing the judge here constitutes a declaration that personal delivery on, or overnight  
mail to, the judge will be completed no later than 24 hours after the document is filed.

11 I declare under penalty of perjury under the laws of the United States of America that the foregoing is  
12 true and correct.

13 <b>April 29, 2025</b>	Lisa Masse	/s/ Lisa Masse
<i>Date</i>	<i>Type Name</i>	<i>Signature</i>

14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

Russell Clementson  
Office of the United States Trustee  
915 Wilshire Boulevard, Suite 1850  
Los Angeles, CA 90017

John E. Allen, President  
J.T. Thorpe, Inc.  
449 West Allen Avenue  
Suite 119  
San Dimas, CA 91773

Alan Brayton  
Brayton Purcell  
222 Rush Landing Road  
Novato, CA 94945

Sander Esserman, Counsel for  
Futures Representative David F. Levi  
Stutzman Bromberg Esserman & Plifka  
2323 Bryan Street, Suite 2200  
Dallas, TX 75201-2689

The Honorable David F. Levi  
Futures Representative  
Box 1168  
Corrales, NM 87048

The Hon. Sheri Bluebond  
United States Bankruptcy Court  
255 E. Temple Street, Suite 1534  
Los Angeles, CA 90012